



(11) **EP 2 453 012 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
16.05.2012 Bulletin 2012/20

(51) Int Cl.:
C12N 9/02^(2006.01) C12N 15/82^(2006.01)

(21) Application number: **10190629.5**

(22) Date of filing: **10.11.2010**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(71) Applicant: **Bayer CropScience AG**
40789 Monheim (DE)

(72) Inventors:
• **Lange, Gudrun, Dr.**
65779 Kelkheim (DE)
• **Poree, Fabien, Dr.**
65936 Frankfurt (DE)
• **Laber, Bernd, Dr.**
65510 Idstein (DE)
• **Freigang, Jörg, Dr.**
40764 Langenfeld (DE)
• **Schulz, Arno, Dr.**
65817 Eppstein (DE)

(54) **HPPD variants and methods of use**

(57) The present invention relates to an isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from certain amino acids at specific positions important for conferring an increased HPPD inhibitor tolerance. The present invention also re-

lates to proteins encoded by the nucleic acid of the invention, to chimeric genes, plant cells comprising the nucleic acid of the invention operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region, plants essentially consisting of the plant cells of the invention and methods of obtaining transgenic plants.

EP 2 453 012 A1

Description

[0001] The present invention relates to an isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from certain amino acids at specific positions important for conferring an increased HPPD inhibitor tolerance. The present invention also relates to proteins encoded by the nucleic acid of the invention, to chimeric genes, plant cells comprising the nucleic acid of the invention operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region, plants essentially consisting of the plant cells of the invention and methods of obtaining transgenic plants.

[0002] In this specification, a number of documents including patent applications and manufacturer's manuals are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

[0003] HPPD (hydroxyphenylpyruvate dioxygenase) proteins are enzymes which catalyse the reaction in which para-hydroxyphenylpyruvate (abbreviated herein as HPP), a tyrosine degradation product, is transformed into homogentisate (abbreviated herein as HG), the precursor in plants of tocopherol and plastoquinone (Crouch N.P. et al. (1997) Tetrahedron, 53, 20, 6993-7010, Fritze et al., (2004), Plant Physiology 134:1388-1400). Tocopherol acts as a membrane-associated antioxidant. Plastoquinone, firstly acts as an electron carrier between PSII and the cytochrome b6/f complex and secondly, is a redox cofactor for phytoene desaturase, which is involved in the biosynthesis of carotenoids.

[0004] Up to now, more than 700 nucleic acid sequences from various organisms present in NCBI database were annotated as coding for a putative protein having an HPPD domain. But for most of these sequences, it has not been proven that the protein would have an HPPD enzymatic activity either in an *in vitro* assay or an *in planta* approach, nor that such HPPD protein can confer herbicide tolerance to HPPD inhibitor herbicides when expressed in a plant. Several HPPD proteins and their primary sequences have been described in the state of the art, in particular the HPPDs of bacteria such as *Pseudomonas* (Rüetschi et al Eur. J. Biochem., 205, 459-466, 1992, WO 96/38567), of plants such as *Arabidopsis* (WO 96/38567, Genebank AF047834), carrot (WO 96/38567, Genebank 87257), *Avena sativa* (WO 02/046387), wheat (WO 02/046387), *Brachiaria platyphylla* (WO 02/046387), *Cenchrus echinatus* (WO 02/046387), *Lolium rigidum* (WO 02/046387), *Festuca arundinacea* (WO 02/046387), *Setaria faberi* (WO 02/046387), *Eleusine indica* (WO 02/046387), *Sorghum* (WO 02/046387), *Coccicoidea* (Genebank COITRP), of *Coptis japonica* (WO 06/132270), *Chlamydomonas reinhardtii* (ES 2275365), or of mammals such as mouse or pig.

[0005] Most plants synthesize tyrosine via arrogenate (Abou-Zeid et al. (1995), Applied Env Microb 41: 1298-1302; Bonner et al., (1995), Plant Cells Physiol. 36, 1013-1022; Byng et al., (1981), Phytochemistry 6: 1289-1292; Connely and Conn (1986), Z. Naturforsch 41 c: 69-78; Gaines et al., (1982), Plants 156: 233-240). In these plants, the HPP is derived only from the degradation of tyrosine. On the other hand, in organisms such as the yeast *Sacharomyces cerevisiae* or the bacterium *Escherichia coli*, HPP is a tyrosine precursor, and it is synthesized by the action of an enzyme, prephenate dehydrogenase (hereinafter referred to as PDH), which converts prephenate to HPP (Lingens et al., (1967) European J. Biochem 1: 363-374; Sampathkumar and Morrisson (1982), Bioch Biophys Acta 701: 204-211). In these organisms, the production of HPP is therefore directly connected to the aromatic amino acid biosynthetic pathway (shikimate pathway), and not to the tyrosine degradation pathway.

[0006] Inhibition of HPPD leads to uncoupling of photosynthesis, deficiency in accessory light-harvesting pigments and, most importantly, to destruction of chlorophyll by UV-radiation and reactive oxygen species (bleaching) due to the lack of photo protection normally provided by carotenoids (Norris et al. (1995), Plant Cell 7: 2139-2149). Bleaching of photosynthetically active tissues leads to growth inhibition and plant death.

[0007] At present, most commercially available HPPD inhibitor herbicides belong to one of these four chemical families:

1) the triketones, e.g. sulcotrione [i.e. 2-[2-chloro-4-(methylsulfonyl)benzoyl]-1,3-cyclohexanedione], mesotrione [i.e. 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione]; tembotrione [i.e. 2-[2-chloro-4-(methylsulfonyl)-3-[(2,2,2,-trifluoroethoxy)methyl] benzoyl]-1,3-cyclohexanedione]; tefuryltrione [i.e. 2-[2-chloro-4-(methylsulfonyl)-3-[[tetrahydro-2-furanyl)methoxy]methyl]benzoyl]-1,3 cyclohexanedione]; bicyclopyrone [i.e. 4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]bicyclo[3.2.1]oct-3-en-2-one]; Benzobicyclon [i.e. 3-(2-chloro-4-mesylbenzoyl)-2-phenylthiobicyclo[3.2.1]oct-2-en-4-one]

2) The diketonitriles, e.g. 2-cyano-3-cyclopropyl-1-(2-methylsulphonyl-4-trifluoromethylphenyl)-propane-1,3-dione and 2-cyano-1-[4-(methylsulphonyl)-2-trifluoromethylphenyl]-3-(1-methylcyclopropyl)propane-1,3-dione;

3) the isoxazoles, e.g. isoxaflutole [i.e. (5-cyclopropyl-4-isoxazolyl)[2-(methylsulfonyl)-4-(trifluoromethyl)phenyl]methanone]. In plants, the isoxaflutole is rapidly metabolized in DKN, a diketonitrile compound which exhibits the

HPPD inhibitor property; and

4) the pyrazolines, e.g. topramezone [i.e. [3-(4,5-dihydro-3-isoxazolyl)-2-methyl-4-(methylsulfonyl) phenyl](5-hydroxy-1-methyl-1H-pyrazol-4-yl)methanone], and pyrasulfotole [(5-hydroxy-1,3-dimethylpyrazol-4-yl)(2-mesy-4-trifluoromethylphenyl)methanone]; pyrazofen [2-[4-(2,4-dichlorobenzoyl)-1,3-dimethylpyrazol-5-yloxy]acetophenone].

[0008] These HPPD-inhibiting herbicides can be used against grass and/or broad leaf weeds in crop plants that display metabolic tolerance, such as maize (*Zea mays*) in which they are rapidly degraded (Schulz et al., (1993). FEBS letters, 318, 162-166; Mitchell et al., (2001) Pest Management Science, Vol 57, 120-128; Garcia et al., (2000) Biochem., 39, 7501-7507; Pallett et al., (2001) Pest Management Science, Vol 57, 133-142). In order to extend the scope of these HPPD-inhibiting herbicides, several efforts have been developed in order to confer to plants, particularly plants without or with an underperforming metabolic tolerance, a tolerance level acceptable under agronomic field conditions.

[0009] Besides the attempt of by-passing HPPD-mediated production of homogentisate (US 6,812,010), overexpressing the sensitive enzyme so as to produce quantities of the target enzyme in the plant which are sufficient in relation to the herbicide has been performed (WO96/38567). Overexpression of HPPD resulted in better pre-emergence tolerance to the diketonitrile derivative (DKN) of isoxaflutole (IFT), but tolerance was not sufficient for tolerance to post-emergence treatment (Matringe et al., (2005), Pest Management Science 61: 269-276).

[0010] In WO 04/024928, the inventors have sought to increase the prenylquinone biosynthesis (e.g., synthesis of plastoquinones, tocopherols) in the cells of plants by increasing the flux of the HPP precursor into the cells of these plants. This has been done by connecting the synthesis of said precursor to the "shikimate" pathway by overexpression of a PDH enzyme. They have also noted that the transformation of plants with a gene encoding a PDH enzyme makes it possible to increase the tolerance of said plants to HPPD inhibitors.

[0011] Another strategy was to mutate the HPPD in order to obtain a target enzyme which, while retaining its properties of catalysing the transformation of HPP into homogentisate, is less sensitive to HPPD inhibitors than is the native HPPD before mutation.

[0012] This strategy has been successfully applied for the production of plants tolerant to 2-cyano-3-cyclopropyl-1-(2-methylsulphonyl-4-trifluoromethylphenyl)-propane-1,3-dione and to 2-cyano-1-[4-(methylsulphonyl)-2-trifluoromethylphenyl]-3-(1-methylcyclopropyl)propane-1,3-dione (EP496630), two HPPD-inhibiting herbicides belonging to the diketonitriles family (WO 99/24585). Pro215Leu, Gly336Glu, Gly336Ile, and more particularly Gly336Trp (positions of the mutated amino acid are indicated with reference to the *Pseudomonas* HPPD) were identified as mutations which are responsible for an increased tolerance to pre-emergence treatment with these diketonitrile herbicides without causing an alteration of the activity of the enzyme.

[0013] More recently, introduction of a *Pseudomonas* HPPD gene into the plastid genome of tobacco and soybean has shown to be more effective than nuclear transformation, conferring even tolerance to post-emergence application of isoxaflutole (Dufourmantel et al., 2007, Plant Biotechnol J.5(1):118-33).

[0014] In the patent application WO 2009/144079, a nucleic acid sequence encoding a mutated hydroxyphenylpyruvate dioxygenase (HPPD) at position 336 of the *Pseudomonas fluorescens* HPPD protein and its use for obtaining plants which are tolerant to HPPD inhibitor herbicides is disclosed.

[0015] In WO 2002/046387, several domains of HPPD proteins originated from plants have been identified that may be relevant to confer tolerance to various HPPD inhibitor herbicides but no *in planta* nor biochemical data have been shown to confirm the impact of the as described domain functions.

[0016] In WO 2008/150473, the combination of two distinct tolerance mechanisms - a modified *Avena sativa* gene coding for a mutant HPPD enzyme and a CYP450 Maize monooxygenase (nsf1 gene) - was exemplified in order to obtain an improved tolerance to HPPD inhibitor herbicides, but no data have been disclosed demonstrating the synergistic effects based on the combination of both proteins.

[0017] US 2010/0197503 suggests a number of mutations at different positions within or close to the active site of the HPPD taken from *Avena sativa* and examined some of them for their inhibition by certain HPPD inhibitors such as sulcotrione *in vitro* and *in planta*.

[0018] Despite these successes obtained for the development of plants showing tolerance to several HPPD inhibitors herbicides described above, it is still necessary to develop and/or improve the tolerance of plants to newer or to several different HPPD inhibitors, particularly HPPD inhibitors belonging to the classes of the triketones (e.g. sulcotrione, mesotrione, tembotrione, benzobicyclon and bicyclopyrone) and the pyrazolines (e.g., topramezone and pyrasulfotole).

[0019] Accordingly, the present invention relates to an isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from:

EP 2 453 012 A1

- a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
- b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr" at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 2;
- 5 c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No.;
- d) Ala, Phe, His, Gln, Val, Trp, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;
- 10 e) Leu, Val, or Met at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;
- f) Leu, Gln, Arg, Val, Tyr, Ala, Ile, Lys or Met at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID No. 2;
- g) Ala, Thr or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;
- 15 h) Ala, Ile, Asn, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- i) Leu, Gln, Val, Ala, Phe, Gly, Met, Arg or Ser at a position in an HPPD protein, said position corresponding to position 293 of the amino acid sequence of SEQ ID No. 2;
- 20 j) Ile, Met, Ala, Pro, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 294 of the amino acid sequence of SEQ ID No. 2;
- k) Gln, His or Asn at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;
- l) Ile, Met, Asn or Leu at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- 25 m) Leu or Met at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- n) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 381 of the amino acid sequence of SEQ ID No. 2;
- o) Phe or Ser at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;
- 30 p) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 419 of the amino acid sequence of SEQ ID No. 2;
- q) Asp, Lys, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- 35 r) Ala, Gly, Met, Pro or Thr at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- s) Ala, Phe, Ile or Val at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 2;
- t) Ile, Pro, Arg, Ser, Ala, Gly, Lys, Asn or Gln at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2;
- 40 u) Glu, Phe, Thr, Val, Ala, Gln or Ser at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;
- v) Ile, Met, Gln, Val, Phe or Leu at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2; and
- 45 w) at least one amino acid deletion or replacement at any one of positions 228, 248, 270, 271, 379 and/or 427.

[0020] Unless indicated otherwise, the specific definitions or specific features of certain embodiments can be introduced into any other embodiment of the present invention.

50 **[0021]** According to the present invention, a "nucleic acid" is understood as being a nucleotide sequence which can be of the DNA or RNA type, preferably of the DNA type, and in particular double-stranded, whether it be of natural or synthetic origin, in particular a DNA sequence in which the codons which encode the HPPD according to the invention have been optimized in accordance with the host organism in which it is to be expressed (e.g., by replacing codons with those codons more preferred or most preferred in codon usage tables of such host organism or the group to which such host organism belongs, compared to the original or source organism).

55 **[0022]** An "isolated nucleic acid/DNA/protein", as used in the present application, refers to a nucleic acid/DNA/protein which is not naturally-occurring (such as an artificial or synthetic DNA with a different nucleotide sequence than the naturally-occurring DNA, or a modified protein) or which is no longer in the natural environment wherein it was originally present, e.g., a DNA coding sequence associated with a heterologous regulatory element (such as a bacterial coding

sequence operably-linked to a plant-expressible promoter) in a chimeric gene, a DNA transferred into another host cell, such as a transgenic plant cell.

[0023] The terminology relating to nucleic acid or protein "comprising" a certain nucleotide sequence or amino acid sequence, as used throughout the text, refers to a nucleic acid or protein including or containing at least the described sequence, so that other nucleotide or amino acid sequences can be included at the 5' (or N-terminal) and/or 3' (or C-terminal) end, e.g. (the nucleotide sequence of) a selectable marker protein, (the nucleotide sequence of) a transit peptide, and/or a 5' leader sequence or a 3' trailer sequence. Similarly, use of the term "comprise", "comprising" or "comprises" throughout the text and the claims of this application should be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The term "comprising" also includes the term "consisting of".

[0024] In accordance with the present invention, the term "mutated HPPD protein" which is interchangeably used with the term "mutant HPPD protein" denotes an HPPD protein having an amino acid sequence which does not occur in nature. As opposed to the term "isolated" referred to above, the term "mutated" cannot refer to the environment of the (amino acid or protein) sequence in question, such as it being isolated from its natural environment or being coupled to a heterologous (amino acid or protein) sequence, but only refers to the amino acid sequence defining said mutated HPPD protein which cannot be found anywhere in nature but arose from a unmutated or wild-type starting amino acid sequence. In other words, in arriving at the nucleic acid of the present invention encoding a mutated HPPD protein, a starting amino acid sequence of a naturally existing protein has to be taken and to be modified by man by replacing at least one amino acid as defined in the present application.

[0025] The sequence which encodes an original unmutated HPPD which will be mutated according to the invention can be of any origin. In particular, it can be of bacterial, plant or animal origin. Advantageous examples which may be cited are bacteria of the *Pseudomonas* sp. type, for example *Pseudomonas fluorescens*, or otherwise cyanobacteria of the *Synechocystis* genus. The sequence can also be of plant origin, in particular derived from dicotyledonous plants, umbelliferous plants, or otherwise monocotyledonous plants. Advantageous examples which may be cited are plants such as tobacco, *Arabidopsis*, *Daucus carotta*, *Zea mays* (corn), wheat, barley, *Avena sativa*, wheat, *Brachiaria platyphylla*, *Cenchrus echinatus*, *Lolium rigidum*, *Festuca arundinacea*, *Setaria faberi*, *Eleusine indica*, and *Sorghum*. The coding sequences, and the way of isolating and cloning them, are described in the previously cited references. In a particular embodiment of the invention, the HPPD is from a bacterial origin, particularly from *Pseudomonas* sp., more particularly from *Pseudomonas fluorescens*, *Rhodococcus* sp., *Blepharisma japonicum*, *Synechococcus* sp., *Picrophilus torridus*, *Kordia algicida* or from a plant origin, particularly from *Arabidopsis thaliana* or *Avena sativa*. The HPPD to make the mutation (s) in for the purpose of the invention, can be any naturally-occurring HPPD, or any active fragment thereof or any variant thereof wherein some amino acids (1 to 10 amino acids) have been replaced, added or deleted for cloning purposes, to make a transit peptide fusion, and the like, which retains HPPD activity, i.e. the property of catalysing the conversion of para-hydroxyphenylpyruvate to homogentisate.

[0026] The mutated HPPD protein according to the present invention has HPPD activity, i. e., as described above, catalyses the reaction in which para-hydroxyphenylpyruvate is transformed into homogentisate. Preferentially, the catalytic activity of the isolated mutated HPPD of the present invention, when tested in vitro, does not differ from that of the unmutated reference HPPD protein by more than 70%, preferably more than 50%, more preferably more than 30%, even more preferably more than 20% when assayed under identical conditions and in the absence of the HPPD inhibitor herbicides described above. The catalytic activity of an HPPD enzyme may be defined by various methods well-known in the art. WO 2009/144079 describes various suitable screening methods.

[0027] Initial screens may be performed with the nucleic acid encoding the mutated HPPD protein of the invention being expressed in bacteria.

[0028] Colorimetric Screening Test for Active HPPD Enzymes:

A YT-broth-type culture medium with 1% agarose, 5mM L-Tyrosine and 42mM Succinate, which contains the selection agent for the vector pSE420 (Invitrogen, Karlsruhe, Germany) is poured into deep well plates. *E.coli* culture in the exponential growth phase which contains the vector pSE420-HPPDx (HPPDx means any gene coding for a putative HPPD enzyme/protein) is applied to each well.

After 16 hours at 37°C, the wells which do not contain the culture medium, those which have been seeded with an *E. coli* culture containing the empty vector pSE420 are transparent, or those which have been seeded with an *E. coli* culture containing a vector pSE420-HPPDx containing a gene coding for an inactive HPPD are transparent, while the wells seeded with an *E. coli* culture containing the vector pSE420-HPPDx coding for an active HPPD are brown. It has been previously demonstrated that this test reflects the HPPD activity, whatever the origin of this activity is, and allows the identification of HPPD activities (US 6,768,044), i.e. at a qualitative level.

[0029] Further and more elaborate screens may be carried out in plant cells or plants expressing the mutated HPPD protein of the invention.

[0030] The same screenings may also be used when examining of whether a mutated HPPD protein is capable of modulating, such as decreasing or increasing, the tolerance of a plant to at least one HPPD herbicide inhibitor which will be referred to further below, with the difference that at least one of such an HPPD inhibitor is added. Examples of HPPD inhibitors to be used in those screenings include tembotrione, mesotrione, pyrasulfotole, bicyclopyrone, topram-
 5 ezone and sulcotrione. A screening method which is simple to implement is to determine the dose of HPPD inhibitor which fully inhibits the original unmutated HPPD, and which is lethal for the cells which express this unmutated HPPD, and to subject the mutated cells to this predetermined dose, and thereafter to isolate the mutated cells which have withstood this lethal dose, and then to isolate and to clone the gene which encodes the mutated HPPD.

[0031] Alternatively, at the quantitative level data like pl_{50} (pl_{50} -value means the log value of the concentration of inhibitor necessary to inhibit 50% of the enzyme activity in molar concentration) can be obtained by employing the isolated and purified HPPD polypeptide, i.e. the mutated vs. the unmutated HPPD polypeptide and in presence or
 10 absence of the any respective HPPD inhibitor herbicide.

[0032] The terms "tolerance", "tolerant" or "less sensitive" denotes the lack of susceptibility of a plant expressing the mutated HPPD protein of the present invention to substances, particularly herbicides, which inhibit HPPD proteins,
 15 optionally in comparison with the plant's own HPPD protein or with any known HPPD protein. More specifically, said terms mean the relative levels of inherent tolerance of the HPPD screened according to a visible indicator phenotype of the strain or plant transformed with a nucleic acid comprising the gene coding for the respective HPPD protein in the presence of different concentrations of the various HPPD inhibitors. Dose responses and relative shifts in dose responses associated with these indicator phenotypes (formation of brown colour, growth inhibition, bleaching, herbicidal effect
 20 etc) are conveniently expressed in terms, for example, of GR50 (concentration for 50% reduction of growth) or MIC (minimum inhibitory concentration) values where increases in values correspond to increases in inherent tolerance of the expressed HPPD, in the normal manner based upon plant damage, meristematic bleaching symptoms etc. at a range of different concentrations of herbicides. These data can be expressed in terms of, for example, GR50 values derived from dose/response curves having "dose" plotted on the x-axis and "percentage kill", "herbicidal effect", "numbers
 25 of emerging green plants" etc. plotted on the y-axis where increased GR50 values correspond to increased levels of inherent tolerance of the expressed HPPD. Herbicides can suitably be applied pre-emergence or post emergence.

[0033] Likewise, tolerance level of the nucleic acid or gene encoding an HPPD protein according to the invention, or the mutated HPPD protein of the invention is screened via transgenesis, regeneration, breeding and spray testing of a
 30 test plant such as tobacco, or a crop plant such as soybean or cotton. In line with the results obtained by such screening, such plants are at least 2-4 times more tolerant to HPPD inhibitors like tembotrione, mesotrione, diketonitrile, and/or bicyclopyrone, pyrasulfotole, than plants that do not contain any exogenous gene encoding an HPPD protein, or than plants that contain a gene comprising an *Arabidopsis thaliana* HPPD-encoding DNA, under control of the same promoter as the nucleic acid encoding the mutated HPPD protein of the invention. Accordingly, the term "capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD" denotes a tolerance increased in a plant by at least
 35 the factor of 2, alternatively at least the factor of 3 or 4 or even 5 or 6 as compared to a plant only expressing its endogenous HPPD or a plant expressing an *Arabidopsis thaliana* HPPD. In this regard, the term "herbicide acting on HPPD" is not limited to substances which are known and/or used as herbicides but to any substances which inhibits the catalytic activity of HPPD proteins.

[0034] In an alternative embodiment of the nucleic acid encoding a mutated HPPD polypeptide comprising at least
 40 one of the mutations as defined above, the HPPD protein comprises

- a) a His at a position in an HPPD protein, said position corresponding to position 226 of the amino acid sequence of SEQ ID No. 2;
- b) a Ser at a position in an HPPD protein, said position corresponding to position 267 of the amino acid sequence
 45 of SEQ ID No. 2;
- c) an Asn at a position in an HPPD protein, said position corresponding to position 282 of the amino acid sequence of SEQ ID No. 2;
- d) a His at a position in an HPPD protein, said position corresponding to position 308 of the amino acid sequence of SEQ ID No. 2;
- e) a Tyr at a position in an HPPD protein, said position corresponding to position 342 of the amino acid sequence
 50 of SEQ ID No. 2;
- f) a Glu at a position in an HPPD protein, said position corresponding to position 394 of the amino acid sequence of SEQ ID No. 2;
- g) a Gly at a position in an HPPD protein, said position corresponding to position 420 of the amino acid sequence
 55 of SEQ ID No. 2; and
- h) an Asn at a position in an HPPD protein, said position corresponding to position 423 of the amino acid sequence of SEQ ID No. 2

[0035] In the mutated HPPD protein encoded by the nucleic acid of the invention at least one amino acid has been deleted or replaced as defined above.

[0036] The replacement or deletion can be effected in the nucleic acid sequence which encodes the original unmutated, i. e. naturally occurring HPPD as defined above by any means which is appropriate for replacing, in the said sequence, the codon which encodes the amino acid to be replaced with the codon which corresponds to the amino acid which is to replace it, or by deleting a codon, with the said codons being widely described in the literature and well known to the skilled person. Several molecular biological methods can be used to achieve this replacement or deletion. A preferred method for preparing a mutated nucleic acid sequence according to the invention and the corresponding protein comprises carrying out site-directed mutagenesis on codons encoding one or more amino acids which are selected in advance. The methods for obtaining these site-directed mutations are well known to the skilled person and widely described in the literature (in particular: Directed Mutagenesis: A Practical Approach, 1991, Edited by M.J. McPHERSON, IRL PRESS), or are methods for which it is possible to employ commercial kits (for example the U. S. E. mutagenesis kit from PHARMACIA). After the site-directed mutagenesis, it is useful to select the cells which contain a mutated HPPD which is less sensitive to an HPPD inhibitor by using an appropriate screening aid. Appropriate screening methods to achieve this have been described above.

[0037] In accordance with the present invention, the term "said position corresponding to position X", X being any number to be found in the respective context in the present application, does not only include the respective position in the SEQ ID No. referred to afterwards but also includes any sequence encoding an HPPD protein, where, after alignment with the reference SEQ ID No., the respective position might have a different number but corresponds to that indicated for the reference SEQ ID No. Whereas HPPD sequences may be very diverse and may only show a low sequence identity of about 30%, HPPD proteins are characterized by a common three dimensional consensus structure which is achieved despite a low sequence identity. Due to specific positions being conserved within HPPD proteins, alignment of HPPD proteins can be effected by applying various alignment tools in a senseful manner. Methods of aligning nucleic acid or amino acid sequences and, accordingly, determining the sequence identity of two or more sequences, are well-known in the art. They include performing mathematical algorithms such as the algorithm of Myers and Miller (1988) CABIOS 4:11-17 or the local alignment algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482-489; the global alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453; the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci USA 87:2264 and that of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)).

[0038] Such algorithms can be implemented in computer programs including but not limited to CLUSTALX, ALIGN, GAP, BESTFIT, BLAST, FASTDB and FASTA.

[0039] For example, when using BESTFIT (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

[0040] The identity between a first sequence and a second sequence, also referred to as a global sequence alignment, is determined using the FASTDB computer program based on the algorithm of Brutlag and colleagues (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

[0041] The present invention is based on the results of a combination of a comparison of the amino acid sequences of HPPD proteins from various organisms and the analysis of the substrate binding and inhibitor binding site of selected HPPD proteins using X-ray crystallography. Using this combined approach, it was possible to determine key positions in HPPD proteins, where an amino acid can be replaced with one of a defined set of other amino acids in order to modulate HPPD catalytic activity and the affinity to at least one HPPD herbicide inhibitor to a plant expressing the mutated HPPD protein.

[0042] Superposition of the 3D structure of HPPD from *Arabidopsis thaliana* (1TFZ) (Yang et al., 2004, Biochemistry 43, 10414-10423) with the 3D structures of HPPD from other species such as *Pseudomonas fluorescens* (1CJX) (Serre et al., 1999, Structure Fold Des. 7, 977-988), *Streptomyces avermitilis* (1T47) (Brownlee et al., 2004, Biochemistry 43, 6370-6377), *Homo sapiens* (3ISQ) (PDB ID: 3isq Pilka et al., Structural Genomics Consortium (SGC). Crystal structure of human 4-Hydroxyphenylpyruvate dioxygenase), *Rattus norvegicus* (1SQI) (Yang et al., 2004, Biochemistry 43, 10414-10423) shows that they have the same folding and corresponding amino acids are at equivalent position in the 3D structure of the protein. Since the species with known 3D structures are very diverse in their amino acid sequence, it can be assumed that all HPPD sequences have the same basic folding even though the overall sequence identity is low. The sequence and the 3D structure of *Arabidopsis thaliana* has been used as reference structure in the present invention. Figure 1 shows the superposition of the structure of *A.thaliana* HPPD with the structure of (a) *Pseudomonas*

EP 2 453 012 A1

fluorescens, (b) *Streptomyces avermitilis*, (c) *Homo sapiens* and (d) *Rattus norvegicus*. In order to define the binding site of the substrate and/or inhibitors, amino acids were selected which play a role in catalysis or inhibitor binding. This includes amino acids in the active site and amino acids from the C-terminal helix. The 3D arrangement is demonstrated in Figure 2 which displays the amino acids defined as binding site in case of (a) *Arabidopsis thaliana*, (b) *Pseudomonas fluorescens*, (c) *Streptomyces avermitilis*, (d) *Homo sapiens* and (e) *Rattus norvegicus*. The amino acid numbering of the *Pseudomonas Fluorescens structure* (1 cjx) was changed into the numbering according to SEQ ID No. 10. The 36 amino acids defining the binding site including their position are listed in Table 1 for (a) *Arabidopsis thaliana*, (b) *Pseudomonas fluorescens*, (c) *Streptomyces avermitilis*, (d) *Homo sapiens* and (e) *Rattus norvegicus*.

Table 1: Amino acids forming the binding site in A.thaliana, P.fluorescens, S.avermitilis, H.sapiens, R. norvegicus

<i>Arabidopsis thaliana</i>		<i>Pseudomonas fluorescens</i>		<i>Streptomyces avermitilis</i>		<i>Homo sapiens</i>		<i>Rattus norvegicus</i>	
Position	Amino Acid	Position	Amino Acid	Position	Amino Acid	Position	Amino Acid	Position	Amino Acid
226	H	162	H	187	H	183	H	183	H
228	V	164	T	189	V	185	V	185	V
248	H	186	R	211	T	207	H	207	H
250	F	188	A	213	M	209	F	209	F
251	A	189	R	214	K	210	W	210	W
252	E	190	Y	215	E	211	S	211	S
253	F	191	F	216	F	212	V	212	V
265	L	200	L	228	L	224	L	224	L
267	S	202	S	230	S	226	S	226	S
268	A	203	K	231	K	227	I	227	I
269	V	204	A	232	V	228	V	228	V
270	L	205	M	233	V	229	V	229	V
271	A	206	S	234	A	230	A	230	A
280	P	215	P	243	P	239	P	239	P
282	N	217	N	245	N	241	N	241	N
293	Q	226	Q	255	Q	251	Q	251	Q
294	I	227	I	256	I	252	I	252	I
307	Q	240	Q	269	Q	265	Q	265	Q
308	H	241	H	270	H	266	H	266	H
335	M	264	M	293	L	289	L	289	L
342	Y	271	Y	299	Y	295	Y	295	Y
368	L	295	L	323	L	323	L	323	L
379	Q	310	Q	334	Q	334	Q	334	Q
381	F	312	F	336	F	336	F	336	F
392	F	321	F	347	F	347	F	347	F
394	E	323	E	349	E	349	E	349	E
419	F	333	F	359	F	359	F	359	F
420	G	334	G	360	G	360	G	360	G
421	K	335	E	361	K	361	A	361	A
422	G	336	G	362	G	362	G	362	G
423	N	337	N	363	N	363	N	363	N
424	F	338	F	364	F	364	F	364	F
425	S	339	K	365	K	365	N	365	N
426	E	340	A	366	A	366	S	366	S
427	L	341	L	367	L	367	L	367	L
431	I	345	I	371	I	371	F	371	F

[0043] An exemplary alignment of HPPD proteins is given in Table 2a for the HPPD proteins with known 3D structures.

EP 2 453 012 A1

Table 2a gives the numbering of the amino acids of the Arabidopsis sequence and also the amino acids which are common within these HPPD sequences, with these amino acids being designated by an asterisk. On the basis of such an alignment and from the definition of the Arabidopsis amino acid by its position and its nature, it is easy to identify the position of the corresponding amino acid in another HPPD sequence. Figure 2 shows that this can be done with the alignment of sequences of different plant, mammalian and bacterial origin, demonstrating that this method of alignment, which is well known to a skilled person, can be generalized to any other sequence. An alignment of different HPPD sequences is also described in Patent Application WO 97/49816.

Table 2a: Alignment of HPPD sequences with known crystal structures i.e. A.thaliana, P.fluorescens, S.avermitilis, H.sapiens, R. norvegicus

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid
1	M		-		-		-			
2	G		-		-		-			
3	H		-		-		-			
4	Q		-		-		-			
5	N		-		-		-			
6	A		-		-		-			
7	A		-		-		-			
8	V		-		-		-			
9	S		-		-		-			
10	E		-		-		-			
11	N		-		-		-			
12	Q		-		-		-			
13	N		-		-		-			
14	H		-	1	M		-			
15	D		-	2	T		-			
16	D		-	3	Q		-			
17	G		-	4	T		-			
18	A		-	5	T		-			
19	A		-	6	H	8	G	8	G	
20	S		-	7	H	9	A	9	P	
21	S		-	8	T	10	K	10	K	
22	P		-	9	P	11	P	11	P	
23	G		-		-		-			
24	F		-		-		-			
25	K		-		-		-			
26	L		-		-		-			
27	V		-		-		-			
28	G		-		-		-			
29	F		-		-		-			

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana		P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus	amino acid	
5	30	S	-		-		-				
	31	K	-		-		-				
10	32	F	-		-		-				
	33	V	-		-		-				
	34	R	-	10	D	12	E	12	E		
	35	K	2	A	11	T	13	R	13	R	
15	36	N	3	D	12	A	14	G	14	G	
	37	P	4	L	13	R	15	R	15	R	
	38	K	5	Y	14	Q	16	F	16	F	
20	39	S	6	E	15	A	17	L	17	L	
	40	D	7	N	16	D	18	H	18	H	
	41	K	8	P	17	P	-				
	42	F	9	M	18	F	-				
25	43	K	10	G	19	P	-				
	44	V	11	L	20	V	-				
	45	K	12	M	21	K	-				
30	46	R	13	G	22	G	-				
	47	F	14	F	23	M	19	F	19	F	
	48	H	15	E	24	D	20	H	20	H	
	49	H	16	F	25	A	21	S	21	S	
35	50	I	17	I	26	V	22	V	22	V	
	51	E	18	E	27	V	23	T	23	T	
	52	F	19	F	28	F	24	F	24	F	X
40	53	W	20	A	29	A	25	W	25	W	
	54	C	21	S	30	V	26	V	26	V	
	55	G	22	P	31	G	27	G	27	G	
	56	D	23	T	32	N	28	N	28	N	
45	57	A	24	P	33	A	29	A	29	A	
	58	T	25	G	34	K	30	K	30	K	
	59	N	26	T	35	Q	31	Q	31	Q	
50	60	V	27	L	36	A	32	A	32	A	
	61	A	28	E	37	A	33	A	33	A	
	62	R	29	P	38	H	34	S	34	S	
	63	R	30	I	39	Y	35	F	35	F	
55	64	F	31	F	40	Y	36	Y	36	Y	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	65	S	32	E	41	S	37	C	37	C	
	66	W	33	I	42	T	38	S	38	N	
10	67	G	34	M	43	A	39	K	39	K	
	68	L	35	G	44	F	40	M	40	M	
	69	G	36	F	45	G	41	G	41	G	
	70	M	37	T	46	M	42	F	42	F	
15	71	R	38	K	47	Q	43	E	43	E	
	72	F	39	V	48	L	44	P	44	P	
	73	S	40	A	49	V	45	L	45	L	
20	74	A	41	T	50	A	46	A	46	A	
	75	K	42	H	51	Y	47	Y	47	Y	
	76	S	43	R	52	S	48	R	48	K	
	77	D	44	S	53	G	49	G	49	G	
25	78	L	45	K	54	P	50	L	50	L	
	79	S	46	N	55	E	51	E	51	E	
	80	T		-	56	N	52	T	52	T	
30	81	G		-	57	G	53	G	53	G	
	82	N		-	58	S	54	S	54	S	
	83	M		-	59	R	55	R	55	R	
	84	V		-	60	E	56	E	56	E	
35	85	H		-	61	T	57	V	57	V	
	86	A		-	62	A	58	V	58	V	
	87	S	47	V	63	S	59	S	59	S	
40	88	Y	48	H	64	Y	60	H	60	H	
	89	L	49	L	65	V	61	V	61	V	
	90	L	50	Y	66	L	62	I	62	I	
	91	T	51	R	67	T	63	K	63	K	
45	92	S	52	Q	68	N	64	Q	64	Q	
	93	G	53	G	69	G	65	G	65	G	X
	94	D	54	E	70	S	66	K	66	K	
50	95	L	55	I	71	A	67	I	67	I	
	96	R	56	N	72	R	68	V	68	V	
	97	F	57	L	73	F	69	F	69	F	
	98	L	58	I	74	V	70	V	70	V	
55	99	F	59	L	75	L	71	L	71	L	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid
5	100	T	60	N	76	T	72	S	72	C
	101	A	61	N	77	S	73	S	73	S
10	102	P	62	E	78	V	74	A	74	A
	103	Y	63	P	79	I	75	L	75	L
	104	S	64	N	80	K	76	N	76	N
	105	P	65	S	81	P		-		
15	106	S	66	I	82	A		-		
	107	L	67	A	83	T		-		
	108	S	68	S	84	P	77	P	77	P
20	109	A		-	85	W	78	W	78	W
	110	G		-	86	G	79	N	79	N
	111	E		-	87	H	80	K	80	K
	112	I		-	88	F	81	E	81	E
25	113	K		-	89	L	82	M	82	M
	114	P		-	90	A	83	G	83	G
	115	T		-		-		-		
30	116	T		-		-		-		
	117	T		-		-		-		
	118	A		-		-		-		
	119	S		-		-		-		
35	120	I		-		-		-		
	121	P		-		-		-		
	122	S		-		-		-		
40	123	F		-		-		-		
	124	D		-		-		-		
	125	H		-		-		-		
	126	G		-		-		-		
45	127	S		-		-		-		
	128	C		-		-		-		
	129	R		-		-		-		
50	130	S	69	Y	91	D	84	D	84	D
	131	F	70	F	92	H	85	H	85	H
	132	F	71	A	93	V	86	L	86	L
	133	S	72	A	94	A	87	V	87	V
55	134	S	73	E	95	E	88	K	88	K

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	135	H	74	H	96	H	89	H	89	H	X
	136	G	75	G	97	G	90	G	90	G	X
10	137	L	76	P	98	D	91	D	91	D	
	138	G	77	S	99	G	92	G	92	G	
	139	V	78	V	100	V	93	V	93	V	X
	140	R	79	C	101	V	94	K	94	K	
15	141	A	80	G	102	D	95	D	95	D	
	142	V	81	M	103	L	96	I	96	I	
	143	A	82	A	104	A	97	A	97	A	X
20	144	I	83	F	105	I	98	F	98	F	
	145	E	84	R	106	E	99	E	99	E	
	146	V	85	V	107	V	100	V	100	V	X
	147	E	86	K	108	P	101	E	101	E	
25	148	D	87	D	109	D	102	D	102	D	X
	149	A	88	S	110	A	103	C	103	C	
	150	E	89	Q	111	R	104	D	104	E	
30	151	S	90	K	112	A	105	Y	105	H	
	152	A	91	A	113	A	106	I	106	I	
	153	F	92	Y	114	H	107	V	107	V	
	154	S	93	N	115	A	108	Q	108	Q	
35	155	I	94	R	116	Y	109	K	109	K	
	156	S	95	A	117	A	110	A	110	A	
	157	V	96	L	118	I	111	R	111	R	
40	158	A	97	E	119	E	112	E	112	E	
	159	N	98	L	120	H	113	R	113	R	
	160	G	99	G	121	G	114	G	114	G	X
	161	A	100	A	122	A	115	A	115	A	
45	162	I	101	Q	123	R	116	K	116	K	
	163	P		-	124	S	117	I	117	I	
	164	S		-	125	V	118	M	118	V	
50	165	S		-	126	A	119	R	119	R	
	166	P		-	127	E	120	E	120	E	
	167	P	102	P	128	P	121	P	121	P	X
	168	I	103	I	129	Y	122	W	122	W	
55	169	V	104	H	130	E	123	V	123	V	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	170	L	105	I	131	L	124	E	124	E	
	171	N	106	D	132	K	125	Q	125	E	
10	172	E	107	T	133	D	126	D	126	D	
	173	A	108	G	134	E	127	K	127	K	
	174	V	109	P	135	H	128	F	128	F	
	175	T	110	M	136	G	129	G	129	G	
15	176	I	111	E	137	T	130	K	130	K	
	177	A	112	L	138	V	131	V	131	V	
	178	E	113	N	139	V	132	K	132	K	
20	179	V	114	L	140	L	133	F	133	F	
	180	K	115	P	141	A	134	A	134	A	
	181	L	116	A	142	A	135	V	135	V	
	182	Y	117	I	143	I	136	L	136	L	
25	183	G	118	K	144	A	137	Q	137	Q	
	184	D	119	G	145	T	138	T	138	T	
	185	V	120	I	146	Y	139	Y	139	Y	
30	186	V	121	G	147	G	140	G	140	G	
	187	L	122	G	148	K	141	D	141	D	
	188	R	123	A	149	T	142	T	142	T	
	189	Y	124	P	150	R	143	T	143	T	
35	190	V	125	L	151	H	144	H	144	H	
	191	S	126	Y	152	T	145	T	145	T	
	192	Y	127	L	153	L	146	L	146	L	
40	193	K	128	I	154	V	147	V	147	V	
	194	A	129	D	155	D	148	E	148	E	
	195	E	130	R	156	R	149	K	149	K	
	196	D	131	F	157	T	150	M	150	I	
45	197	T	132	G	158	G	151	N	151	N	
	198	E	133	E	159	Y	152	Y	152	Y	
		-	134	G		-		-			
50	199	K	135	S	160	D	153	I	153	T	
	200	S	136	S	161	G	154	G	154	G	
	201	E	137	I	162	P	155	Q	155	R	
	202	F	138	Y	163	Y	156	F	156	F	
55	203	L	139	D	164	L	157	L	157	L	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	204	P	140	I	165	P	158	P	158	P	
	205	G	141	D	166	G	159	G	159	G	
10	206	F	142	F	167	Y	160	Y	160	F	
	207	E	143	V	168	V	161	E	161	E	
	208	R	144	Y	169	A	162	A	162	A	
	209	V	145	L	170	A	163	P	163	P	
15	210	E	146	E	171	A	164	A	164	T	
	211	D	147	G		-	165	F	165	Y	
		-		-		-	166	M	166	K	
20		-		-		-	167	D	167	D	
		-		-	172	P	168	P	168	T	
	212	A	148	V	173	I	169	L	169	L	
	213	S	149	E	174	V	170	L	170	L	
25	214	S	150	R	175	E	171	P	171	P	
	215	F	151	N	176	P	172	K	172	K	
	216	P	152	P	177	P	173	L	173	L	
30	217	L	153	V	178	A	174	P	174	P	
	218	D	154	G	179	H	175	K	175	S	
	219	Y	155	A	180	R	176	C	176	C	
	220	G	156	G	181	T	177	S	177	N	
35	221	I	157	L	182	F	178	L	178	L	
	222	R	158	K	183	Q	179	E	179	E	
	223	R	159	V	184	A	180	M	180	I	
40	224	L	160	I	185	I	181	I	181	I	
	225	D	161	D	186	D	182	D	182	D	X
	226	H	162	H	187	H	183	H	183	H	X
	227	A	163	L	188	C	184	I	184	I	
45	228	V	164	T	189	V	185	V	185	V	
	229	G	165	H	190	G	186	G	186	G	
	230	N	166	N	191	N	187	N	187	N	X
50	231	V	167	V	192	V	188	Q	188	Q	
	232	P	168	Y	193	E	189	P	189	P	
		-	169	R	194	L	190	D	190	D	
		-	170	G	195	G	191	Q	191	Q	
55	233	E	171	R	196	R	192	E	192	E	

EP 2 453 012 A1

(continued)

	Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common
5		A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid
	234	L	172	M	197	M	193	M	193	M	
	235	G	173	V	198	N	194	V	194	E	
10	236	P	174	Y	199	E	195	S	195	S	
	237	A	175	W	200	W	196	A	196	A	
	238	L	176	A	201	V	197	S	197	S	
	239	T	177	N	202	G	198	E	198	E	
15	240	Y	178	F	203	F	199	W	199	W	
	241	V	179	Y	204	Y	200	Y	200	Y	
	242	A	180	E	205	N	201	L	201	L	
20	243	G	181	K	206	K	202	K	202	K	
	244	F	182	L	207	V	203	N	203	N	
	245	T	183	F	208	M	204	L	204	L	
	246	G	184	N	209	G	205	Q	205	Q	
25	247	F	185	F	210	F	206	F	206	F	X
	248	H	186	R	211	T	207	H	207	H	
	249	Q	187	E	212	N	208	R	208	R	
30	250	F	188	A	213	M	209	F	209	F	
	251	A	189	R	214	K	210	W	210	W	
	252	E	190	Y	215	E	211	S	211	S	
	253	F	191	F	216	F	212	V	212	V	
35	254	T	192	D	217	V	213	D	213	D	
	255	A	193	I	218	G	214	D	214	D	
	256	D	194	K	219	D	215	T	215	T	
40	257	D	195	G	220	D	216	Q	216	Q	
	258	V	196	E	221	I	217	V	217	V	
	259	G		-	222	A	218	H	218	H	
	260	T		-	223	T	219	T	219	T	
45	261	A		-	224	E	220	E	220	E	
	262	E	197	Y	225	Y	221	Y	221	Y	
	263	S	198	T	226	S	222	S	222	S	
50	264	G	199	G	227	A	223	S	223	S	
	265	L	200	L	228	L	224	L	224	L	X
	266	N	201	T	229	M	225	R	225	R	
	267	S	202	S	230	S	226	S	226	S	X
55	268	A	203	K	231	K	227	I	227	I	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	269	V	204	A	232	V	228	V	228	V	
	270	L	205	M	233	V	229	V	229	V	
10	271	A	206	S	234	A	230	A	230	A	X
	272	S	207	A	235	D	231	N	231	N	
	273	N	208	P	236	G	232	Y	232	Y	
	274	D	209	D	237	T	233	E	233	E	
15	275	E	210	G	238	L	234	E	234	E	
	276	M	211	M	239	K	235	S	235	S	
	277	V	212	I	240	V	236	I	236	I	
20	278	L	213	R	241	K	237	K	237	K	
	279	L	214	I	242	F	238	M	238	M	
	280	P	215	P	243	P	239	P	239	P	X
	281	I	216	L	244	I	240	I	240	I	
25	282	N	217	N	245	N	241	N	241	N	X
	283	E	218	E	246	E	242	E	242	E	X
	284	P	219	E	247	P	243	P	243	P	
30	285	V	220	S	248	A	244	A	244	A	
	286	H		-	249	L	245	P	245	P	
	287	G		-	250	A	246	G	246	G	
	288	T	221	S	251	K	247	K	247	R	
35	289	K	222	K	252	K	248	K	248	K	X
	290	R	223	G		-		-			
	291	K	224	A	253	K	249	K	249	K	
40	292	S	225	G	254	S	250	S	250	S	
	293	Q	226	Q	255	Q	251	Q	251	Q	X
	294	I	227	I	256	I	252	I	252	I	X
	295	Q	228	E	257	D	253	Q	253	Q	
45	296	T	229	E	258	E	254	E	254	E	
	297	Y	230	F	259	Y	255	Y	255	Y	
	298	L	231	L	260	L	256	V	256	V	
50	299	E	232	M	261	E	257	D	257	D	
	300	H	233	Q	262	F	258	Y	258	Y	
	301	N	234	F	263	Y	259	N	259	N	
	302	E	235	N	264	G	260	G	260	G	
55	303	G	236	G	265	G	261	G	261	G	X

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	304	A	237	E	266	A	262	A	262	A	
	305	G	238	G	267	G	263	G	263	G	X
10	306	L	239	I	268	V	264	V	264	V	
	307	Q	240	Q	269	Q	265	Q	265	Q	X
	308	H	241	H	270	H	266	H	266	H	X
	309	L	242	V	271	I	267	I	267	I	
15	310	A	243	A	272	A	268	A	268	A	X
	311	L	244	F	273	L	269	L	269	L	
	312	M	245	L	274	N	270	K	270	R	
20	313	S	246	T	275	T	271	T	271	T	
	314	E	247	D	276	G	272	E	272	E	
	315	D	248	D	277	D	273	D	273	D	X
	316	I	249	L	278	I	274	I	274	I	
25	317	F	250	V	279	V	275	I	275	I	
	318	R	251	K	280	E	276	T	276	T	
	319	T	252	T	281	T	277	A	277	T	
30	320	L	253	W	282	V	278	I	278	I	
	321	R	254	D	283	R	279	R	279	R	
	322	E	255	A	284	T	280	H	280	H	
	323	M	256	L	285	M	281	L	281	L	
35	324	R	257	K	286	R	282	R	282	R	
	325	K	258	K	287	A	283	E	283	E	
	326	R	259	I	288	A	284	R	284	R	
40	327	S		-		-		-			
	328	S		-		-		-			
	329	I		-		-		-			
	330	G		-		-		-			
45	331	G	260	G	289	G	285	G	285	G	X
	332	F	261	M	290	V	286	L	286	M	
	333	D	262	R	291	Q	287	E	287	E	
50	334	F	263	F	292	F	288	F	288	F	X
	335	M	264	M	293	L	289	L	289	L	
	336	P	265	T	294	D	290	S	290	A	
	337	S	266	A	295	T	291	V	291	V	
55	338	P	267	P	296	P	292	P	292	P	X

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid
5	339	P	268	P	-	-	-	-	-	
	340	P	269	D	297	D	293	S	293	S
10	341	T	270	T	298	S	294	T	294	S
	342	Y	271	Y	299	Y	295	Y	295	Y
	343	Y	272	Y	300	Y	296	Y	296	Y
	344	Q	273	E	301	D	297	K	297	R
15	345	N	274	M	302	T	298	Q	298	L
	346	L	275	L	303	L	299	L	299	L
	347	K	276	E	304	G	300	R	300	R
20	348	K	277	G	305	E	301	E	301	E
	349	R	278	R	306	W	302	K	302	N
	350	V	279	L	307	V	303	L	303	L
	351	G	280	P	308	G	304	K	304	K
25	352	D	281	D	309	D	305	T	305	T
	353	V	282	H	310	T	306	A	306	S
	354	L	283	G	311	R	307	K	307	K
30	355	S	284	E	312	V	308	I	308	I
	356	D	285	P	313	P	309	K	309	Q
	357	D	286	V	314	V	310	V	310	V
	358	Q	287	D	-	-	311	K	311	K
35		-	288	Q	-	-	312	E	312	E
		-	289	L	-	-	313	N	313	N
	359	I	290	Q	-	-	314	I	314	M
40	360	K	291	A	315	D	315	D	315	D
	361	E	292	R	316	T	316	A	316	V
	362	C	293	G	317	L	317	L	317	L
	363	E	294	I	318	R	318	E	318	E
45	364	E	295	L	319	E	319	E	319	E
	365	L	296	L	320	L	320	L	320	L
	366	G	297	D	321	K	321	K	321	K
50	367	I	298	G	322	I	322	I	322	I
	368	L	299	S	323	L	323	L	323	L
	369	V	300	S	324	A	324	V	324	V
	370	D	301	V	325	D	325	D	325	D
55	371	R	302	E	326	R	326	Y	326	Y

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid	
5	372	D	303	G	327	D	327	D	327	D	
	373	D	304	D	328	E	328	E	328	E	
10	374	Q	305	K	329	D	329	K	329	K	
	375	G	306	R	330	G	330	G	330	G	
	376	T	307	L	331	Y	331	Y	331	Y	
	377	L	308	L	332	L	332	L	332	L	X
15	378	L	309	L	333	L	333	L	333	L	X
	379	Q	310	Q	334	Q	334	Q	334	Q	X
	380	I	311	I	335	I	335	I	335	I	X
20	381	F	312	F	336	F	336	F	336	F	X
	382	T	313	S	337	T	337	T	337	T	
	383	K	314	E	338	K	338	K	338	K	
	384	P	315	T	339	P	339	P	339	P	
25	385	L	316	L	340	V	340	V	340	M	
	386	G	317	M	341	Q	341	Q	341	Q	
	387	D	318	G	342	D	342	D	342	D	
30	388	R		-	343	R	343	R	343	R	
	389	P		-	344	P	344	P	344	P	
	390	T	319	P	345	T	345	T	345	T	
	391	I	320	V	346	V	346	L	346	L	
35	392	F	321	F	347	F	347	F	347	F	X
	393	I	322	F	348	F	348	L	348	L	
	394	E	323	E	349	E	349	E	349	E	X
40	395	I	324	F	350	I	350	V	350	V	
	396	I	325	I	351	I	351	I	351	I	X
	397	Q	326	Q	352	E	352	Q	352	Q	
	398	R	327	R	353	R	353	R	353	R	X
45	399	V	328	K	354	H	354	H	354	H	
	400	G		-		-		-			
	401	C		-		-		-			
50	402	M		-		-		-			
	403	M		-		-		-			
	404	K		-		-		-			
	405	D		-		-		-			
55	406	E		-		-		-			

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common	
	A. thaliana		P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus	amino acid	
5	407	E	-		-		-				
	408	G	-		-		-				
10	409	K	-		-		-				
	410	A	-		-		-				
	411	Y	-		-		-				
	412	Q	-		-		-				
15	413	S	-		-		-				
	414	G	-		-		-				
	415	G	329	G	355	G	355	N	355	N	
20	416	C	330	D	356	S	356	H	356	H	
	417	G	331	D	357	M	357	Q	357	Q	
	418	G	332	G	358	G	358	G	358	G	X
	419	F	333	F	359	F	359	F	359	F	X
25	420	G	334	G	360	G	360	G	360	G	X
	421	K	335	E	361	K	361	A	361	A	
	422	G	336	G	362	G	362	G	362	G	X
30	423	N	337	N	363	N	363	N	363	N	X
	424	F	338	F	364	F	364	F	364	F	X
	425	S	339	K	365	K	365	N	365	N	
	426	E	340	A	366	A	366	S	366	S	
35	427	L	341	L	367	L	367	L	367	L	X
	428	F	342	F	368	F	368	F	368	F	X
	429	K	343	E	369	E	369	K	369	K	
40	430	S	344	S	370	A	370	A	370	A	
	431	I	345	I	371	I	371	F	371	F	
	432	E	346	E	372	E	372	E	372	E	X
	433	E	347	R	373	R	373	E	373	E	
45	434	Y	348	D	374	E	374	E	374	E	
	435	E	349	Q	375	Q	375	Q	375	Q	
	436	K	350	V	376	E	376	N	376	A	
50	437	T	351	R	377	K	377	L	377	L	
	438	L	352	R	378	R	378	R	378	R	
	439	E	353	G	379	G	379	G	379	G	
	440	A	354	V	380	N	380	N	380	N	
55	441	K	355	L	381	L	381	L	381	L	

EP 2 453 012 A1

(continued)

Pos.	1TFZ	Pos.	1 CJX	Pos.	1T47	Pos.	31SQ	Pos.	1SQI	Common
	A. thaliana	P. fluorescens		S. avermitilis		H. Sapiens		R. norvegicus		amino acid
5	442	Q	356	A			382	T	382	T
	443	L	357	T			383	N	383	D
10	444	V	358	D			384	M	384	L
	445	G					385	E	385	E
							386	T	386	T
							387	N	387	N
15							388	G	388	G
							389	V	389	V
							390	V	390	R
20							391	P	391	S
							392	G	392	G
							393	M	393	M
							394	A	394	
25							395	E	395	
							396	N	396	
							397	L	397	
30							398	Y	398	
							399	F	399	
							400	Q	400	

35 **[0044]** A sequence analysis of more than 700 HPPD sequences from public data bases including sequences of HPPD
 proteins and predicted HPPD proteins such as from plants, mammals, fungi and bacteria was performed using ClustalX.
 The alignment was corrected using the information of the available 3D structures. Identical amino acid sequences with
 different identifiers were included only once and some sequences with obvious sequence errors were excluded. The
 alignment also includes incomplete sequences. Table 2b shows the sequence alignment for a representative set of
 40 HPPD proteins and includes sequences from plants, bacteria, mammals.

45

50

55

Table 2b: Alignment of a representative set of HPPD sequences

5

CLUSTAL X (1.81) multiple sequence alignment

```

RATTUS_NORVEGICUS      ---MTT-----YSNKGPKPE
HOMO-SAPIENS           -----GAKPE
XENOPUS-LAEVIS        ---MTS-----YTDKGPKPD
10 BLEPHARISMA-JAPONICUS ---MTY-----YDKQETRPD
MYCOSPHAERELLA-GRAMINICOLA ---MAPGALLVTSQNG-----RTSPLYDSGDYVPAPAALVVG
ASPERGILLUS-FUMIGATUS ---MAPSAISTS-----PPPTDRVSS
MAGNAPORTHE-GRISEA    ---MSPSAITESPRN-----SVVDHTSGLQVDSLAVQGP
CANDIDA-ALBICANS      -----
PICHIA-STIPITIS       ----LLKELPFLPTSS-----DPITEPDIIDELSDGHVNSKYP
15 RHODOCOCCUS-SP.      ---MTIEQTLTD-----KERLAGLDLQLEQLVGLVEYDGRD
RHODOCOCCUS-ERYTHROPOLIS ---MTVEQTLTD-----DEQLAGLDLEQLRQLVGLVEYDSDHD
JANIBACTER-SP.-HTCC2649 MTDTTITNPTTDTASQPTPLDLTPQEREANLNLEQLKQLVGLVEYDESKD
STREPTOMYCES-AVERMITILIS ---MTQTTHTHP-----DTARQAD
KORDIA-ALGICIDA       ---MAAEIKNLKD-----LQNTHEYGLKLLFDEAED
LEEUWENHOEKIELLA-BLANDENSIS-ME ---MSKELK-----SVDYGLEKIFDGAQD
20 GEMMATIMONAS-AURANTIACA ---MATLTT-----PEIGTEQD
PICROPHILUS-TORRIDUS -----MYGKNLISELRE
ARABIDOPSIS-THALIANA -----MGHQNAAVSENQNHDDGAAS--SPGFKLVGFSGFVRKNPKSD
BRASSICA-RAPA-SUBSP.-PEKINENSI -----MGHENAAVSENQHHDDAATTSASPGFKLVGFSGFVRKNPKSD
COPTIS-JAPONICA-VAR.-DISSECTA -----MVPST-----ASNKLVGHTNFMVHNNPKSD
HEVEA-BRASILIENSIS    -----MGKENDSVPS-----APGFKLLGFSNFVRTNPRSD
25 MEDICAGO-TRUNCATULA -----MAIETETQTQT-----QTGFKLVGFKNFVRANPKSD
GLYCINE-MAX           -----MCNEIQAAQAAQ-----AQPGFKLVGFKNFVRTNPKSD
SOLANUM-LYCOPERSICUM ---MG--MGKETLS--TTDTTG-----ATFKLVGFNNFIRANPRSD
SOLANUM-TUBEROSUM     ---MG--MGKETLSTTTTDTG-----ATFKLG-FNNFIRANPRSD
NICOTIANA-BENTHAMIANA ---MGKLETVTTTATAADDSEL-----TTNFKLVGFKNFIRTNPRSD
DAUCUS-CAROTA         ---MGKKQSEAEILSSNSNTSP-----ATFKLVGFNNFVRANPKSD
30 SOLENOSTEMON-SCUTELLARIOIDES ---MG-----QESTAAAAVVP-----AEFKLVGHKNFVRSNPMSD
HORDEUM-VULGARE       ---MPPTPTTAAAT--GAAAAVTPEHARP-----HRMVRFNPRSD
TRITICUM-AESTIVUM     ---MPPTPTTAAATGAGAAAATPEHARP-----RRMVRFNPRSD
AVENA-SATIVA          ---MPPTPATATGA--AAAATPEHAARS--FPRVVRVNP
ORYZA-SATIVA          ---MPPTPTTAAATGAVSAAAAGENAGFRLVGHRRFVRANPRSD
SORGHUM-BICOLOR       ---MPPTPTTAAAT--GAAVAAAQAAAFRLVGHRRFVRVNP
35 ZEA-MAYS             ---MPPTPTAAAAG-AAVAAAQAAAFRLVGHRRFVRVNP
ABO95005_OLUCIMARINUS ---MATVPS-----KRKLVGCANFVRSNPLSD
OTAURI                ---MTTSAS-----GRKLVGHANFVRCNPLSD
MICROMONAS-PUSILLA-CCMP1545 ---MASSEANAAPA-----AKRHKLVGCKNFVRNPKSD
SYNECHOCOCCUS-SP.    -----MNPSIR
VIBRIO-SP.-MED222     -----MVDTYN
MARINOMONAS-SP.-MED121 -----MNTALKIDYSIN
40 PSEUDOMONAS-FLUORESCENS -----ADLYEN
SULFITOBACTER-SP.-NAS-14.1 -----MGPFPHDAEKSKITDEN
OCEANICOLA-BATSSENSIS-HTCC2597 -----MGPFPHDAPKSEITDEN
BDELLOVIBRIO-BACTERIOVORUS -----MAQVTEKN

45 RATTUS_NORVEGICUS      RGRFLHFHSVTFWVGNNAK--QAASFYCNKMGFEPLAYKGLTGSREVVSH
HOMO-SAPIENS           RGRFLHFHSVTFWVGNNAK--QAASFYCSKMGFEPLAYRGLTGSREVVSH
XENOPUS-LAEVIS        VGRYLAFDHITFYVGNNAK--QAAAYATRFGFNP IAYRGLTGHDRVCTH
BLEPHARISMA-JAPONICUS LGFYGFDHVRFYVSNSE--QAASFYTSRFGFSPVAYEGLETGNQKPCFN
MYCOSPHAERELLA-GRAMINICOLA EVNRYGYHHAEWVGNNAK--QVAQFYITRMGFEPVAHKGLTGSRRFASH
ASPERGILLUS-FUMIGATUS  LASYKGYDHWVWVGNNAK--QAASYITRMGFKRIAYRGLTGCRCVCSH
50 MAGNAPORTHE-GRISEA    FPFPHGYDHWVWVGNNAK--QAASYNTLFGMKI IAYRGLTGSRYFASY
CANDIDA-ALBICANS      -----MSKYLQLAMGFKEVAYKGLTGSKLI GAH
PICHIA-STIPITIS       TDGFIKFFSLKICSSNAK--QMSKYLQLAMDFKEIAYKGLENDSRLVGAH
RHODOCOCCUS-SP.      PFPVSGWDVAVVWVGNAT--QTAHYFQSAFGMTLVAYSQPTTGNRDHHSF
RHODOCOCCUS-ERYTHROPOLIS PFPVSGWDGLEWVGNAT--QTSFFFQSAFGMELVAYSQPTGNRDHHSF
JANIBACTER-SP.-HTCC2649 PFPVSGWDVAIVVWVGNAT--QAAAYYQGTWGMELVGYSGPENGNRDHKAF
55 STREPTOMYCES-AVERMITILIS PFPVSGWDVAVVAVGNNAK--QAAHYYSTAFGMQLVAYSQPENGSRETASY

```

EP 2 453 012 A1

	KORDIA-ALGICIDA	FLPLLGTDYVELYVGNAC--QSAHFYKTAFGFQSEAYAGLETGLTDRVSY
	LEEUEWENHOEKIELLA-BLANDENSIS-ME	FLPLLGTDYVEFYVGNAC--QAAHFYKTAFGFQSEAYSGLETGKKDRVSY
5	GEMMATIMONAS-AURANTIACA	APPINGTDYVEFYVGNAC--QASHYYRAAFGYSLVAYRGPETGVRDRASY
	PICROPHILUS-TORRIDUS	KEIFKRLHHVFEFVSSAK--TWSYFMNRGLGFKTVAYAGPETGIRDKISY
	ARABIDOPSIS-THALIANA	KFKVKRFHHIEFWCGDAT--NVARREFSWGLGMRFSAKSDLSTGNMVHASY
	BRASSICA-RAPA-SUBSP.-PEKINENSI	KFKVKRFHHIEFWCGDAT--NVARREFSWGLGMRFSAKSDLSTGNMVHASY
	COPTIS-JAPONICA-VAR.-DISSECTA	KFHVKRFHHIEFWSTDAT--NTARREFSWGLGMMPVAKSDLSTGNMVHASY
	HEVEA-BRASILIENSIS	LFKVKRFHHVFEWCTDAT--NTACREFSWGLGMFPVAKSDLSTGNVTHASY
10	MEDICAGO-TRUNCATULA	RFNVKRFHHVFEWCTDAT--NTARREFSHGLGMPIVAKSDLSTGNLTHASY
	GLYCINE-MAX	RFQVNRFHHEFWCTDAT--NASRRFSWGLGMPIVAKSDLSTGNQIHASY
	SOLANUM-LYCOPERSICUM	FFSVKRFHHIEFWCGDAT--NTSRRFSWSLGMPI TAKSDLSTGNSVHASY
	SOLANUM-TUBEROSUM	FFSVKRFHHIEFWCGDAT--NTSRRFSWSLGMPI TAKSDLSTGNSVHASY
	NICOTIANA-BENTHAMIANA	FFSVKRFHHIEFWCGDAT--NTSRRFSWSLGMPIAAKSDLSTGNSVHASY
	DAUCUS-CAROTA	HFAVKRFHHIEFWCGDAT--NTSRRFSWGLGMPLVAKSDLSTGNSVHASY
	SOLENOSTEMON-SCUTELLARIOIDES	HFPVHRFHHEFWCGDAT--NTSRRFSWGLGMPLVAKSDLSTGNSAHASY
15	HORDEUM-VULGARE	RFHTLSFHHVFEWCADAA--SAAGRFAFALGAPLAARSDLSTGNSAHASQ
	TRITICUM-AESTIVUM	RFHTLSFHHVFEWCADAA--SAAGRFAFALGAPLAARSDLSTGNSVHASQ
	AVENA-SATIVA	RFHTLSFHHVFEWCADAA--SAAGRFAFALGAPLAARSDLSTGNSAHASL
	ORYZA-SATIVA	RFQALAFHHVELWCADAA--SAAGRFAFALGAPLAARSDLSTGNSAHASL
	SORGHUM-BICOLOR	RFHTLAFHHVELWCADAA--SAAGRFSFGLGAPLAARSDLSTGNTAHASL
	ZEA-MAYS	RFHTLAFHHVELWCADAA--SAAGRFSFGLGAPLAARSDLSTGNSAHASL
20	ABO95005_OLUCIMARINUS	AFECEKFDHIEFWCGDAT--NAAARFGVGLGMGLRCKSDATTGNGTYASY
	OTAURI	AFECVGFHDHVEFWCGDAT--NAASRFGVGLGMSLRAKSDATGNGIYASY
	MICROMONAS-PUSILLA-CCMP1545	LFTMRKRFHHVFEWCRDAT--TTAARFAVGLGMQLVAKSDLTGTGNARYASY
	SYNECHOCOCCUS-SP.	--IVQGIHLLHFYLWDLPL--RWREHFCRVWGFVAVASDAGN-----TL
	VIBRIO-SP.-MED222	PLGTDGFEFVEYTAVDHKGIEQLKALLVSLGFAEIAKHSKE-----AW
	MARINOMONAS-SP.-MED121	PLGTDGFEFVEYTADEKGIADLKALFVSLGFTEVAKHSKE-----VW
25	PSEUDOMONAS-FLUORESCENS	PMGLMGFEFIEFASPTPG---TLEPIFEIMGFTKVATHRSKN-----VH
	SULFITOBACTER-SP.-NAS-14.1	PAGTDGFEFVEFASADPQ---ELRDLFTRMGYAHVANHKTQK-----IE
	OCEANICOLA-BATSENSIS-HTCC2597	PAGTDGFEFVEFAHPDPQ---ELRDLFSKMGYELVGRHKS KD-----VE
	BDELLOVIBRIO-BACTERIOVORUS	PVGLNGVDFIEYSGPDAH---FFEQVFKRYAFKEVGVQVHGKN-----IK
30	RATTUS NORVEGICUS	VIKQ GK--IVFVLC SALNPWN-----
	HOMO-SAPIENS	VIKQ GK--IVFVLC SALNPWN-----
	XENOPUS-LAEVIS	VVRQNN--ATFVFSQPLNPGN-----
	BLEPHARISMA-JAPONICUS	VVRSNH--VVI AFTSALTPED-----
	MYCOSPHAERELLA-GRAMINICOLA	VVQNGG--VRFVFTSPVRS A-----
	ASPERGILLUS-FUMIGATUS	VVRNGD--ITFILTSPLRS-----
35	MAGNAPORTHE-GRISEA	LVGKED--VRFVFTSPIRSHVH-----
	CANDIDA-ALBICANS	VMQNGS--ITLEIINTLETIDDDNVLKFPFFQNDLNKFRNINHEYFLENF
	PICHIA-STIPITIS	VIRNGD--VTLEIVNTLETVEDDNVLKFPYFEKDLKQFPQLNESKYLRDF
	RHODOCOCCUS-SP.	VLESGA--VRFVILKGA VNP DSP-----
	RHODOCOCCUS-ERYTHROPOLIS	VLKSGA--VRFVVKGA VDPASP-----
	JANIBACTER-SP.-HTCC2649	VLKSGS--IRFVLKGA VSPDSP-----
	STREPTOMYCES-AVERMITILIS	VLTNGS--ARFVLT SVIKPATPW-----
40	KORDIA-ALGICIDA	VLKQDK--IRLVLTTP LGKGGE-----
	LEEUEWENHOEKIELLA-BLANDENSIS-ME	VLRQDK--IRLVLTSP LGSASP-----
	GEMMATIMONAS-AURANTIACA	LMQQ GK--IRLVLTTSITADTP-----
	PICROPHILUS-TORRIDUS	VMSQGT--ARISFTSSMNDDSY-----
	ARABIDOPSIS-THALIANA	LLTSGD--LRFLFTAPYSP---SLSAGEI-----
45	BRASSICA-RAPA-SUBSP.-PEKINENSI	LLTSGD--LRFLFTAPYSP---SLSAGEN-----
	COPTIS-JAPONICA-VAR.-DISSECTA	LLRSGE--LNFLFTAPYSP---SIAGNT-----
	HEVEA-BRASILIENSIS	LLRSGD--LSFLFTAPYSP---TIASMENF-----
	MEDICAGO-TRUNCATULA	LLRSGD--LNFLFSAAYSP---SISLSS-----
	GLYCINE-MAX	LLRSGD--LSFLFSAPYSP---SLSAGSS-----
	SOLANUM-LYCOPERSICUM	LLRSVSGELQFVFTAPYSP---SISVPS-----
	SOLANUM-TUBEROSUM	LLRSVSGELQFVFTAPYSP---SISVPS-----
50	NICOTIANA-BENTHAMIANA	LLRPVSGSLQFLFTAPYSP---SISTPS-----
	DAUCUS-CAROTA	LVRASN--LSFVFTAPYSP---STTTSSG-----
	SOLENOSTEMON-SCUTELLARIOIDES	LLRSGE--LSFVFTAPYSP---SLAEPS-----
	HORDEUM-VULGARE	LLRSGS--LAFLEFTAPYAN---GCDA A-----
	TRITICUM-AESTIVUM	LLRSGN--LAFLEFTAPYAN---GCDA A-----
	AVENA-SATIVA	LLRSGA--LAFLEFTAPYAPPQEAATAAAA-----
55	ORYZA-SATIVA	LLRSAS--VAFLEFTAPYGGDHGVGADAAT-----

EP 2 453 012 A1

	SORGHUM-BICOLOR	LLRSGA--LAFLFTAPYAH-----GADAA-----
	ZEA-MAYS	LLRSGS--LSFLFTAPYAH-----GADAA-----
5	ABO95005_OLUCIMARINUS	AMKSNL--LTFVFTAPYG-----VESGGSR-----
	OTAURI	AMKSHD--LTFVFTAPYGDDERAVGCGGSS-----
	MICROMONAS-PUSILLA-CCMP1545	VLQSNL--LRFVFSAPYDVPEGEENDDARS-----
	SYNECHOCOCCUS-SP.	ELEQGS--LRLRLSQPARAG-----
	VIBRIO-SP.-MED222	LYRQGD--INFIVNEQPHS-----
	MARINOMONAS-SP.-MED121	LYRQND--INFIVNSEPNS-----
	PSEUDOMONAS-FLUORESCENS	LYRQGE--INLILNNEPNS-----
10	SULFITOBACTER-SP.-NAS-14.1	LWQQGD--ITYVLNADPDS-----
	OCEANICOLA-BATSENSIS-HTCC2597	LWQQGD--ITYIINAEPGT-----
	BDELLOVIBRIO-BACTERIOVORUS	LFRQGD--INFILNCEPHT-----
15	RATTUS_NORVEGICUS	-----
	HOMO-SAPIENS	-----
	XENOPUS-LAEVIS	-----
	BLEPHARISMA-JAPONICUS	-----
	MYCOSPHAERELLA-GRAMINICOLA	-----
	ASPERGILLUS-FUMIGATUS	-----
	MAGNAPORTHE-GRISEA	-----
20	CANDIDA-ALBICANS	KLTTDDLIFDFVNSRIEESLSFKSDYLKFGKQFYNNIIRSDDYQESMAKVS
	PICHTA-STIPITIS	KITTNLVLVDFVNSRIEESFSVSPNAHYFRRKLYNKIVSSRAFRNNMFDYN
	RHODOCOCCUS-SP.	-----
	RHODOCOCCUS-ERYTHROPOLIS	-----
	JANIBACTER-SP.-HTCC2649	-----
	STREPTOMYCES-AVERMITILIS	-----
25	KORDIA-ALGICIDA	-----
	LEEUWENHOEKIELLA-BLANDENSIS-ME	-----
	GEMMATIMONAS-AURANTIACA	-----
	PICROPHILUS-TORRIDUS	-----
	ARABIDOPSIS-THALIANA	-----
	BRASSICA-RAPA-SUBSP.-PEKINENSI	-----
30	COPTIS-JAPONICA-VAR.-DISSECTA	-----
	HEVEA-BRASILIENSIS	-----
	MEDICAGO-TRUNCATULA	-----
	GLYCINE-MAX	-----
	SOLANUM-LYCOPERSICUM	-----
	SOLANUM-TUBEROSUM	-----
35	NICOTIANA-BENTHAMIANA	-----
	DAUCUS-CAROTA	-----
	SOLENOSTEMON-SCUTELLARIOIDES	-----
	HORDEUM-VULGARE	-----
	TRITICUM-AESTIVUM	-----
	AVENA-SATIVA	-----
	ORYZA-SATIVA	-----
40	SORGHUM-BICOLOR	-----
	ZEA-MAYS	-----
	ABO95005_OLUCIMARINUS	-----
	OTAURI	-----
	MICROMONAS-PUSILLA-CCMP1545	-----
	SYNECHOCOCCUS-SP.	-----
45	VIBRIO-SP.-MED222	-----
	MARINOMONAS-SP.-MED121	-----
	PSEUDOMONAS-FLUORESCENS	-----
	SULFITOBACTER-SP.-NAS-14.1	-----
	OCEANICOLA-BATSENSIS-HTCC2597	-----
	BDELLOVIBRIO-BACTERIOVORUS	-----
50		
	RATTUS_NORVEGICUS	-----KEMGDHLVKHGDGVKDIAFEVEDCEHIVQK
	HOMO-SAPIENS	-----KEMGDHLVKHGDGVKDIAFEVEDCDYIVQK
	XENOPUS-LAEVIS	-----HPISDHVAMHGDGVKDVAFSVEDCRGIYKR
	BLEPHARISMA-JAPONICUS	-----NEVNRHVGVKHSBGVQDIAFSVSDARGMYEK
55	MYCOSPHAERELLA-GRAMINICOLA	-----RQTLKAAPLADQARLDEMYDHLDKHGDGVKDVAFEVDDVLAVYEN

	ASPERGILLUS-FUMIGATUS	-----LDQVDRFPPEEQELLKEIHAHLEKHGDGKDVAFEVDSVDSVIFYA
	MAGNAPORTHE-GRISEA	-----LPEDEPISDEDRALLKEMHAHLEKHGDGKDVCFEVDNVQGVYER
5	CANDIDA-ALBICANS	NFIVQTTINNSEEIYNDMMECTLIQKFLKLHAEGVMDIAFNVDVDITFNR
	PICHIA-STIPITIS	NLILNVINNSEVIYNDIMECTLIQKFLKTHGEGVMDISFLVEDVITTFDK
	RHODOCOCCUS-SP.	-----LIDHHRTHGDGVVDIALAVPDVVKCIAH
	RHODOCOCCUS-ERYTHROPOLIS	-----LIEHHSRHDGIRDIALSVDPVVKCIAH
	JANIBACTER-SP.-HTCC2649	-----LIAHHTKHGDGVVDISLEVPDVKCIAQ
	STREPTOMYCES-AVERMITILIS	-----GHFLADHVAEHGDGVVDLAIIEVPDARAHAAY
	KORDIA-ALGICIDA	-----INEHIDLHGDGVKVVALLVVEDATKAFEE
10	LEEUWENHOEKIELLA-BLANDENSIS-ME	-----INEHIVKHGDGVKVVALLVVEDARSAFEE
	GEMMATIMONAS-AURANTIACA	-----IAEHVHRHGDGVVDYALVVDARLAYET
	PICROPHILUS-TORRIDUS	-----ISNHVKKHGDGVKDIALEVDLDEAKSL
	ARABIDOPSIS-THALIANA	-----KPTTTASIPSFHDGSCRSFFSSHGLGVRVAIEVEDAESAFSI
	BRASSICA-RAPA-SUBSP.-PEKINENSI	-----PPTTTASIPSFHDVTVRSFFSSHGLGVRVAIEVEDAEAAFSI
	COPTIS-JAPONICA-VAR.-DISSECTA	-----LHTTASIPTYSHNLARLFSTHGLAVRAIAIEVQDAELAYNI
15	HEVEA-BRASILIENSIS	-----SHTATASIPTFSEACRNFSAKHGLGVRVAIAIEVEDAEIAYNT
	MEDICAGO-TRUNCATULA	-----PSSTAAIPTFSASTCFSFASASHGLAVRAVAIEVEDAEVAFTT
	GLYCINE-MAX	-----AASSASIPSFDAATCLAFAAKHGFGVRAIAIEVEDAEAAFSI
	SOLANUM-LYCOPERSICUM	-----TAGIPSFSTPTYRDFDTAKHGLGVRVAIEVENAYLAFSA
	SOLANUM-TUBEROSUM	-----TAGIPSFSTSTHRDFDTAKHGLGVRVAIEVENAYLAFSA
	NICOTIANA-BENTHAMIANA	-----GAAIPSFSTSTHRGFAATHGLGVRVAIEVENAYLAFSA
20	DAUCUS-CAROTA	-----SAAIPSFASGFSFAAKHGLAVRAIAIEVEDAVAAAFEA
	SOLENOSTEMON-SCUTELLARIOIDES	-----SASIPTFSDHRAFSSSHGLAVRAVAIQVDSASSAYSA
	HORDEUM-VULGARE	-----TASLPSFSADAARRFSADHGIAVRSVALRVADAEEAFRA
	TRITICUM-AESTIVUM	-----TASLPSFSADAARRFSADHGLAVRSIALRVADAEEAFRA
	AVENA-SATIVA	-----TASIPSFSAADAARTFAAAHGLAVRSVGVVRVADAEEAFRV
	ORYZA-SATIVA	-----TASIPSFSPGAARRFAADHGLAVHVAVALRVADAADAFAFR
25	SORGHUM-BICOLOR	-----TASLPSFSAAEARRFAADHGLAVRAVALRVADAEDAFAFR
	ZEA-MAYS	-----TAALPSFSAAAARRFAADHGLAVRAVALRVADAEDAFAFR
	ABO95005_OLUCIMARINUS	-----GEAPHPG---HEGRAMMRFPEKHGLAARAVGVVVDARAAYEE
	OTAURI	-----VNVPHPG---NERGAMMRFERHGLAARAVGLRVVVDARAAYEE
	MICROMONAS-PUSILLA-CCMP1545	-----SMFEKSGVLSHDPFSMRTFCERHGLAVRAVCLLVDDAAVAFYT
	SYNECHOCOCCUS-SP.	-----DEVDRHLQRHGGVVDVALAVGEQELPALA
30	VIBRIO-SP.-MED222	-----QAEAFKAVHGPSVCGMAFRVNEATAAMEQ
	MARINOMONAS-SP.-MED121	-----QSEAFARIHGPSVCGMAFRVKDASLAMQH
	PSEUDOMONAS-FLUORESCENS	-----IASYFAAEHGPSVCGMAFRVKDSQKAYNR
	SULFITOBACTER-SP.-NAS-14.1	-----FAAGFVAEHGPCAPSMGWRVVDQAQKALDH
	OCEANICOLA-BATSENSIS-HTCC2597	-----HAATFIEEHGPCAPSMGWRVVDQAQAFDHD
	BDELLOVIBRIO-BACTERIOVORUS	-----FATDFAKLHGPCVNATGFRVIDADQAFKT
35	RATTUS_NORVEGICUS	ARERGAKIVREPWVEED-----KFGKVKFAVLQTYG-DTHTTLVEK---
	HOMO-SAPIENS	ARERGAKIMREPWVEEQD-----KFGKVKFAVLQTYG-DTHTTLVEK---
	XENOPUS-LAEVIS	AIERGAKSVREPWEESD-----EFGTVVMATIQTG-DTHTTFVER---
	BLEPHARISMA-JAPONICUS	AIKAGCKSFREPQVLQD-----QFGSVIIASLQTYG-DTVHTLVQN---
	MYCOSPHAERELLA-GRAMINICOLA	AVANGAESVSSPHTDSC-----DEGDVISAIAIKTYG-DTHTTFIQR---
40	ASPERGILLUS-FUMIGATUS	ATNNGAKIVSQPRTLED-----DNGQVRVATIQTG-DTHTTLVER---
	MAGNAPORTHE-GRISEA	AVQQGAVSIAPPKTSLDK-----EHGSVTMAVIQTG-DTHTLLSR---
	CANDIDA-ALBICANS	AIKAGSGIIRLPKIISD-----ENGVVKLATISIPNSDIQHTLIEN---
	PICHIA-STIPITIS	AVAAGAGIIRLPKIISD-----CNGSVRLGTISIPKTDIHTLIEN---
	RHODOCOCCUS-SP.	ARAQGATVLDPEHDVTD-----DHGTVRLAAIATYG-DTRHTLVDR---
	RHODOCOCCUS-ERYTHROPOLIS	AITQGATVLDSEPHDITD-----EHGTVRLASIAIATYG-ETRHTLVDR---
45	JANIBACTER-SP.-HTCC2649	AKAAGARVVQEAETVSD-----EFGSVRIGAIATYG-ETRHTLVQRTVD
	STREPTOMYCES-AVERMITILIS	AIIEHGARSVAEPEYELKD-----EHGTVVLAIAIATYG-KTRHTLVDR---
	KORDIA-ALGICIDA	TTKRGAKPYMEPTKEED-----ENGVVIRSGIYTYG-ETVHVVFVER---
	LEEUWENHOEKIELLA-BLANDENSIS-ME	TTKRGAKPFMEPEVEKED-----EHGEVVRSGIYTYG-ETVHMVFVER---
	GEMMATIMONAS-AURANTIACA	AIARGAIPIQEPQVYSD-----EHGEVVIAAIGTYG-DTIHSLVER---
	PICROPHILUS-TORRIDUS	IEKYGTKVS-KINEIKD-----GNGKIRTAIEIKTYG-ETVHTLIET---
	ARABIDOPSIS-THALIANA	SVANGAIPSSPPIVLNE-----AVTIAEVKLYG-DVVLRYVSYKAE
50	BRASSICA-RAPA-SUBSP.-PEKINENSI	SVSNGAVPSSPPIVLND-----AVTIAEVKLYG-DVVLRYVSYKVA
	COPTIS-JAPONICA-VAR.-DISSECTA	SVANGAKPSSSPIKLDE-----GVVLSEIQLYG-DVVLRYLSFKNT
	HEVEA-BRASILIENSIS	SVARGALPMGGPITLDN-----RAVVAEVHLYG-DVVLRYISYKNS
	MEDICAGO-TRUNCATULA	SVNLGAI PSSPPVILEN-----NVKLAEVHLYG-DVVLRYVSYNDL
	GLYCINE-MAX	SVAKGAEPASPPVLVDD-----RTGFAEVRLYG-DVVLRYVSYKDA
	SOLANUM-LYCOPERSICUM	SVARGAKPRFEPVTIDE-----HVVAEVHLYG-DVVLRFVSLVKD
55	SOLANUM-TUBEROSUM	SVSRGAKPRFEPVTIDE-----HVVAEVHLYG-DVVLRFVSVFKD

	NICOTIANA-BENTHAMIANA	SVSRGAKPMFEPVTIDG-----QVAMAEVHLYG-DVVLRFMS-LKD
	DAUCUS-CAROTA	SVARGARPASAPVELDD-----QAWLAEVELYG-DVVLRFVFSFGRE
5	SOLENOSTEMON-SCUTELLARIOIDES	AVSRGAKPVSPVVLADC-----ETAIAEVHLYG-DTVLRFVSCGSG
	HORDEUM-VULGARE	SRRRGARPAFAPVDLGR-----GFFAEVELYG-DVVLRFVSHPDG
	TRITICUM-AESTIVUM	SVDGGARPAFSPVDLGR-----GFGFAEVELYG-DVVLRFVSHPDD
	AVENA-SATIVA	SVAGGARPAFAPADLGH-----GFGLAEVELYG-DVVLRFVSYPDE
	ORYZA-SATIVA	SVAAGARPAFQPADLGG-----GFGLAEVELYG-DVVLRFVSHPDG
	SORGHUM-BICOLOR	SVAAGARPAFEPVELGL-----GFRLAEVELYG-DVVLRYVSYRDD
	ZEA-MAYS	-----GFRLAEVELYG-DVVLRYVSYRDPG
10	ABO95005_OLUCIMARINUS	AVKRGARGVLAPTTLTHTVDDGCAKGGQVIAEIELYG-DVVLRFVNATDG
	OTAURI	AMKRGARGVLEPTEMRHEKHDGCVMTQII SEVELYG-DVVLRFVSRADG
	MICROMONAS-PUSILLA-CCMP1545	SGQHGGRR-----SPAFSSACDGFAR-----VSEVELYG-DVVLRYYSFHAG
	SYNECHOCOCCUS-SP.	ELLRGRG-----AQLAWIP-AAAALCLHTPYG
	VIBRIO-SP.-MED222	AFKGGGEEYK-TEIGP-----MELSIPAIYIG-ESLLYFVDRYCK
	MARINOMONAS-SP.-MED121	ALANGAKEFS-GNLGA-----MELKLPVYIG-ESTLYFIDRYGD
15	PSEUDOMONAS-FLUORESCENS	ALELGAQPIH-IDTGP-----MELNLPKIGIG-GAPLYLIDRFG
	SULFITOBACTER-SP.-NAS-14.1	AVSKGAEYK-GAG-----KVLDPVPAIKGIG-GSLIYFVDQYYD
	OCEANICOLA-BATSENSIS-HTCC2597	AVKNGATPYE-GDG-----KVMVPAILGIG-GSLIYFIEDYYE
	BDELLOVIBRIO-BACTERIOVORUS	AVARGARPYEGNEHQK-----GATFFPAIYIG-DSLIIYFMDQKNQ
20	RATTUS NORVEGICUS	-INYTG----RFLPGFEAPTYKDT-----LLPKLPSCNLEIIDHIVGNQ
	HOMO-SAPIENS	-MNYIG----QFLPGYEAPAFMDP-----LLPKLPKCSLEIMDHIHIVGNQ
	XENOPUS-LAEVIS	-TNYKAP--AHVFLPNYRA-CEVDP-----INNVLPTVKLLNVDHVVGNQ
	BLEPHARISMA-JAPONICUS	-VDYTG----PFLPGFRAITKDDP-----LNSAFFQVNYDIIDHVVGNQ
	MYCOSPHAERELLA-GRAMINICOLA	-TTYTG----PFLPGYRSCITVDS-----ANKFLPPVNLEAIDHCVGNQ
	ASPERGILLUS-FUMIGATUS	-GSYHG----AFLPGYRMETGVEDP-----ISQLLPGVHLNRIIDHCVGNQ
	MAGNAPORTHE-GRISEA	-DNFRG----TFLPGFRDVRQPAA-----YSALAP-VPLQRIDHCVGNQ
25	CANDIDA-ALBICANS	-INYTG----PFLPGFSQPIYPLADYYQVQLNMMPPVNLTVLDHCVENY
	PICHA-STIPITIS	-IDYTG----PFLPNYSESVTQYNSKYDQMQNIPTVSFQCIDHCVENY
	RHODOCOCCUS-SP.	-SHYTG----PYLPGYTARTSGHT-----KRDGAPKRLFQALDHVGNV
	RHODOCOCCUS-ERYTHROPOLIS	-SRYTG----PYLPGYVERTSSYR-----KRDGAPKRLFQALDHVGNV
	JANIBACTER-SP.-HTCC2649	GQTYSG----PYLPGYVARSSSFV-----KRDGAPKRLFQALDHVGNV
	STREPTOMYCES-AVERMITILIS	-TGYDG----PYLPGYVAAAP-----IVEPPAHRTFQALDHVGNV
30	KORDIA-ALGICIDA	-KNYNG----VFLPGYQRWES-----HYNPEPVGLKFIIDHVMGNV
	LEEUWENHOEKIELLA-BLANDENSIS-ME	-KNYNG----QFLPGYRKWES-----DYNPEPTGLKYIIDHVMGNV
	GEMMATIMONAS-AURANTIACA	-RNYNG----VFLPGFKAVTP-----HYQPSDVGLKYIIDHCVGNV
	PICROPHILUS-TORRIDUS	-GDYNG----VFMPGYEESI-----NSKNTGIKKIIDHIVGNV
	ARABIDOPSIS-THALIANA	DTE-----KSEFLPGFERVEDASSF-----P-LDYGIRRLDHAVGNV
	BRASSICA-RAPA-SUBSP.-PEKINENSI	TV-----FLPRFETVDDTSSF-----P-LDYGIRRLDHAVGNV
35	COPTIS-JAPONICA-VAR.-DISSECTA	N-----QSCP----FLPGFEEVGEVSSS-----RGLDFGIRRLDHAVGNV
	HEVEA-BRASILIENSIS	NPNLNDSSPDSWFLPKFESVDEASSF-----P-LDYGIRRLDHAVGNV
	MEDICAGO-TRUNCATULA	NP---NQPNLFLFLPGFERVSDSSN-----SSLDFGIRRLDHAVGNV
	GLYCINE-MAX	APQAPHADPSRWFLEPGFEAAASSSSS-----PELDYGIRRLDHAVGNV
	SOLANUM-LYCOPERSICUM	ADTL-----IFLPGFEAMDETSSF-----KELDYGIIRLDHAVGNV
	SOLANUM-TUBEROSUM	EDSL-----IFLPGFEAMDETSSF-----KELDYGIIRLDHAVGNV
40	NICOTIANA-BENTHAMIANA	ADSL-----VFLPGFNAMDETASY-----KELDYGIIRLDHAVGNV
	DAUCUS-CAROTA	EG-----LFLPGFEAVEGTASF-----PDLDYGIIRLDHAVGNV
	SOLENOSTEMON-SCUTELLARIOIDES	ADG-----WFLPGFEVVDGVS-----QELDYGIIRLDHAVGNV
	HORDEUM-VULGARE	TDVP-----FLPGFEGVTNP-----DAVDYGLTRFDHVVGNV
	TRITICUM-AESTIVUM	TDVP-----FLPGFEGVSNP-----DAVDYGLTRFDHVVGNV
	AVENA-SATIVA	TDLP-----FLPGFERVSSP-----GAVDYGLTRFDHVVGNV
	ORYZA-SATIVA	ADAP-----FLPGFEGVSNP-----GAVDYGLRRFDHVVGNV
45	SORGHUM-BICOLOR	ADAS-----FLPGFVGTSP-----GAADYGLRRFDHVVGNV
	ZEA-MAYS	AAGEP-----FLPGFEGVASP-----GAADYGLSRFDHVVGNV
	ABO95005_OLUCIMARINUS	-----FDGDFLCNYSATRDAP-----DVSYGLQRLDHAVGNV
	OTAURI	-----FDGDFLCNYEATRDVP-----SVSYGLRRLDHAVGNV
	MICROMONAS-PUSILLA-CCMP1545	EKNA---KPKTFLPGYEDVPLEPPHT-----TPLTYGLQRLDHAVGNV
	SYNECHOCOCCUS-SP.	IRHS-----LIPGLDAAPEAG-----LFSHWDHVVNLN
50	VIBRIO-SP.-MED222	-QSIYD---VDFRFYDDAEQRMAEA-----NVGLYEIDHLTHNV
	MARINOMONAS-SP.-MED121	-KSIYD---VDFNFYENYQEKMLSH-----QAGLYEVDHLTHNV
	PSEUDOMONAS-FLUORESCENS	GSSIYD---IDFVYLEGVERNVP-----AGLKVIDHLTHNV
	SULFITOBACTER-SP.-NAS-14.1	-TSPYN---EYDWIAQS---KPKG-----VGFYYLDHLTHNV
	OCEANICOLA-BATSENSIS-HTCC2597	-TSPYN---AEFDWLAQS---KPRG-----VGFYYLDHLTHNV
55	BDELLOVIBRIO-BACTERIOVORUS	-DKLYN---EIFQVKPED---KAPVG-----VGFVVDHFTNNV

	RATTUS_NORVEGICUS	PDQEMESASEWYLKLNQFHRFWSVDDTQVHTEYSSLRSIVVANYEESI KM
	HOMO-SAPIENS	PDQEMVSASEWYLKLNQFHRFWSVDDTQVHTEYSSLRSIVVANYEESI KM
	XENOPUS-LAEVIS	PDDMMVPAEWYKMLMFHRFWSVDDTQMHTDYSALRSIVVTDYDEVIKM
5	BLEPHARISMA-JAPONICUS	PGGDMTPTVEWYKYLEFHRFWSADESVIHTDYSALRSVVVADWDEVIKM
	MYCOSPHAERELLA-GRAMINICOLA	DWDEMSDACDFYERCLGFHRFWSVDDKICTEFSALKSIVMSSPNQVVKM
	ASPERGILLUS-FUMIGATUS	DWDEMDKVCHEYKALGFHRFWSVDDKQICTEYSALKSIVMASPNEVVKM
	MAGNAPORTHE-GRISEA	DWDDMRAACDFYERCLSFHRFWSVDDNQISTDPSALNSIVMASPNNVVKM
	CANDIDA-ALBICANS	SNWNQMMEQAKLYADMFGFHKYWSVDEDDISTGFTALRSIVMSSSNGQIKM
	PICHIA-STIPITIS	SNWNQMAQAKLYASLFGFHKYWSADDDIATDNTALRSIVMASGNGKIKM
10	RHODOCOCCUS-SP.	ELGKMDHWVDFYNRVMGFVNMAEFVGDIA TDYSALMSKVVSNGNHRVKF
	RHODOCOCCUS-ERYTHROPOLIS	ELGKMDQWVDFYNRVMGFVNMAEFVGGDIATDYSALMSKVVSNGNHRVKF
	JANIBACTER-SP.-HTCC2649	ELGKMDWVDFYNRVMGFVNMAEFVGGDIATDYSALMSKVVSNGNHRVKF
	STREPTOMYCES-AVERMITILIS	ELGRMNEWVGFYKVMGFVNMAEFVGGDIATEYSALMSKVVSNGNHRVKF
	KORDIA-ALGICIDA	GWGEMKEWCEFYAKVMGFAQII SFTDDDI STDFALMSKVMSNGNGRIKF
	LEEUWENHOEKIELLA-BLANDENSIS-ME	GWGEMNTWVKWYEDVMGFVNFLT FDDKQITTEYSALMSKVMSNGNGRIKF
15	GEMMATIMONAS-AURANTIACA	ELGKMNQWVGYYADVLGFRNLIT FDDTDINTEYSGLMSKVMANGNDRIKF
	PICROPHILUS-TORRIDUS	YEGEMDSWVNFYIEKLGFEHLIT FDDKDIRTDYSALRSKVVKY-NDDIVF
	ARABIDOPSIS-THALIANA	P--ELGPALTYVAGFTGFHQFAEFTADDVGTAE SGLNSAVLASNDEMVL
	BRASSICA-RAPA-SUBSP.-PEKINENSI	P--ELGPALTYL SRTLGFHQFAEFTADDVGTAE SGLNSAVLANDET VLL
	COPTIS-JAPONICA-VAR.-DISSECTA	P--NLAEAIGYLKEFTGFHEFAEFTAEDVGTTE SGLNSIVLASNDEMVL
	HEVEA-BRASILLENIS	P--ELAPAVSYVKEFTGFHEFAEFTAEDVGTSE SGLNSIVLANDET VLL
20	MEDICAGO-TRUNCATULA	P--ELSAVKYVQKFTGFHEFAEFTAEDVGTSE SGLNSVLANNEET VLL
	GLYCINE-MAX	P--ELAPAVRYLKGFSGFHEFAEFTAEDVGTSE SGLNSVLANNSETVLL
	SOLANUM-LYCOPERSICUM	P--ELGPVVYDIKAF TGFHEFAEFTAEDVGTAE SGLNSVLANDET VLL
	SOLANUM-TUBEROSUM	P--ELGPVVYDIK EFTGFHEFAEFTAEDVGTAE SGLNSVLANDET VLL
	NICOTIANA-BENTHAMIANA	P--ELGPVVDYIKRFTGFHEFAEFTSE DVGTAESGLNSMVVANND ETVLL
	DAUCUS-CAROTA	T--ELGPVVEYIKGFTGFHEFAEFTAEDVGTLE SGLNSVLANNEEMVLL
25	SOLENOSTEMON-SCUTELLARIOIDES	P--KLEPVVDY LKFKTGFHEFAEFTAEDVGTAE SGLNSVLANNNENVLF
	HORDEUM-VULGARE	P--ELAPAAAYIAGFTGFHEFAEFTAEDVGTTE SGLNSVLANNSEGVLL
	TRITICUM-AESTIVUM	P--ELAPAAAYVAGFAGFHEFAEFTTEDVGTAE SGLNSMVLANNSEGVLL
	AVENA-SATIVA	P--EMAPVIDYMKGFLGFHEFAEFTAEDVGTTE SGLNSVLANNSEAVLL
	ORYZA-SATIVA	P--ELAPVAAYISGFTGFHEFAEFTAEDVGTAE SGLNSVLANNAETVLL
	SORGHUM-BICOLOR	P--ELAPAAAYFAGFTGFHEFAEFTAEDVGTTE SGLNSMVLANNAENVLL
30	ZEA-MAYS	P--ELAPAAAYFAGFTGFHEFAEFTTEDVGTAE SGLNSMVLANNSENVLL
	ABO95005_OLUCIMARINUS	H--DLIETVDYITKVTGFHEFAEFTAEDIGTID SGLNSMVLANNNEYVLL
	OTAURI	H--NLLETVDYIMKITGFHEFAEFTAEDIGTID SGLNSMVLANNNEYVLL
	MICROMONAS-PUSILLA-CCMP1545	P--NLLETVDYITAMTGMHEFAEFTAEDVGTVD SGLNSMVLANDDEMI LLL
	SYNECHOCOCCUS-SP.	EQGSLQAAADWYGRVLGWRRLYRYS---IGTATSGLESVVVDGPEAGIQW
	VIBRIO-SP.-MED222	KQGNMDVWSGFYERLGNFREIRYFDIEGKLTG---LVS RAMTSPCGKIRI
35	MARINOMONAS-SP.-MED121	MRGNMDHWAGFYENIGNFREIRYFDIEGKLTG---LVS RAMTSPCGKIRI
	PSEUDOMONAS-FLUORESCENS	YRGRMVYWANFYEKLFNFREARYFDIKGEYTG---LTSKAMSPDGMIRI
	SULFITOBACTER-SP.-NAS-14.1	FKGNMDVWFKFYGDLFNFREIRFFDIEGKFTG---LTSRALTSPCGRIRI
	OCEANICOLA-BATSENSIS-HTCC2597	FKGNMDT'WFRFYGDLFNFREIRFFDIEGKFTG---LFSRALTSPCGRIRI
	BDELLOVIBRIO-BACTERIOVORUS	PKGEMDKWQH FYEDIFGFYEAKYFDIRGSKTG---LLSRAMRSPCGKFSV
40	RATTUS_NORVEGICUS	PINEPAPGRK-KSQIQEYVDYNGGAGVQHIALRTE DIITTRHLRER---
	HOMO-SAPIENS	PINEPAPGKK-KSQIQEYVDYNGGAGVQHIALKTE DIITAIRHLRER---
	XENOPUS-LAEVIS	PINEPAPGKK-KSQIQEFVEYYGGAGVQHIALRTD DILRDVSAMRAR---
	BLEPHARISMA-JAPONICUS	PINEPADGLR-KSQIQEYVEYYGGAGVQHIALKVNDI IISVISTLRAR---
	MYCOSPHAERELLA-GRAMINICOLA	PINEPAHGKK-KSQIEEYVDFYNGPGVQHIALRTPN IIEAVSNLRSR---
45	ASPERGILLUS-FUMIGATUS	PINEPAKGGK-QSQIEEYVDFYNGAGVQHIALLTDD IIRDIITNLKAR---
	MAGNAPORTHE-GRISEA	PINEPAKGGK-RSQIEEYVTFNSGAGVQHIALLTSD IITTEAMRSR---
	CANDIDA-ALBICANS	PINEPVKSIM-KGQIEEFNDFNGGPGIQHIAFR TNNIIETVMALMQR---
	PICHIA-STIPITIS	PINEPVKSKM-RGQIEEFHDFNGGPGVQHIALRTN DIIDTVCALLAR---
	RHODOCOCCUS-SP.	PLNEPALAKK-RSQIDEYLD FYRGPQAQHLALATND ILTAVDQLTAE---
	RHODOCOCCUS-ERYTHROPOLIS	PLNEPAIAKK-RSQIDEYLEFYQGPQAQHLALAT NDILGAVDALVDE---
	JANIBACTER-SP.-HTCC2649	PLNEPAIAKK-RSQIDEYLD FYQGPQAQHLAVATND ILSVDEL RKE---
50	STREPTOMYCES-AVERMITILIS	PINEPALAKK-KSQIDEYLD FYGGAGVQHIALNTGD IVEIVRTMRAA---
	KORDIA-ALGICIDA	PINEPAEGKK-KSQIEEYLD FYNGSGVQHIAVATDNI IDTVSQMRER---
	LEEUWENHOEKIELLA-BLANDENSIS-ME	PINEPAEGIK-KSQIEEYLD FYEGPGVQHIALAVAT DDIVKTVAAALKAR---
	GEMMATIMONAS-AURANTIACA	PINEPASGKK-KSQIEEYLD FYGGPGAQHLALAT DDILATVTALRDR---
	PICROPHILUS-TORRIDUS	PINEPAKGLR-KSQIEEYLDYRSEGVQHIALLTDD IIKTVSMMEEN---
	ARABIDOPSIS-THALIANA	PINEPVHGTKRKRSQIQTYLEHNEGAGLQHLALM SEDIFRTLREMRKRSS-
55	BRASSICA-RAPA-SUBSP.-PEKINENSI	PVNEPVHGTKRKRSQIQTYLEHNEGAGVQHLALM SEDIFRTLREMRKRSS-

5	COPTIS-JAPONICA-VAR.-DISSECTA HEVEA-BRASILIENSIS MEDICAGO-TRUNCATULA GLYCINE-MAX SOLANUM-LYCOPERSICUM SOLANUM-TUBEROSUM NICOTIANA-BENTHAMIANA DAUCUS-CAROTA SOLENOSTEMON-SCUTELLARIOIDES	PMNEPVYGTKRKRSQIQTYLEHNEGAGVQHLALVSEDIFFTLREMRRRSRG- PLNEPVFGTKRKSQIQTYLEHNEGAGLQHLALVSEDIFKTLREMRRRSRG- PMNEPVYGTKRKRSQIETYLEHNEGAGLQHLALMSADIFFTLREMRRRSRG- PLNEPVYGTKRKRSQIETYLEHNEGAGVQHLALVTHDIFFTLREMRRRSF- PLNEPVYGTKRKRSQIQTYLEHNEGAGVQHLALVTEDEIFFTLREMRRRSRG- PMNEPVYGTKRKRSQIQTYLEHNEGAGVQHLALVTEDEIFFTLREMRRRSRG- PLNEPVYGTKRKRSQIQTYLEHNEGAGVQHLALVTEDEIFKTLKEMRRRSRG- PLNEPVYGTKRKRSQIQTYLEHNEGAGVQHLALVSEDIFFTLREMRRRSRG- PLNEPVYGTKRKRSQIQTYLDHNEGAGVQHLALITEDIFFTLREMRRRSE- PLNEPVHGTKRKRSQIQTFLEHHGGPGVQHI AVASSDVLRTLRKMRARSA- PLNEPVHGTKRKRSQIQTFLEHHGGSGVQHI AVASSDVLRTLRKMRARSA- PLNEPVHGTKRKRSQIQTYLEYHGGPGVQHIALASNDVLRTLRMRRARTP- PLNEPVHGTKRKRSQIQTYLDHGGPGVQHIALASDDVLGTLREMRRARSA- PLNEPVHGTKRKRSQIQTYLDHGGPGVQHIALASDDVLRTLRMRRARSA- PLNEPVHGTKRKRSQIQTFLDHGGPGVQHIALASDDVLRTLRMRRARSA- PVNEPTFGTKRKSQIQTYLEQNNNGPGLQHLALKTDDIFATVREMRRKYSHL PVNEPTFGTKRKSQIQTYLEQNNNGPGLQHLALKTDDIFTTVREMRRKYSHM PVNEPTFGTKRKSQIQTYLECNNGAGLQHLALKSDVDFATVREMRRKHGGG AINEPTCAAS---QIQEFLHAHGGPGIQHAALHSSDIVASLRRLR---- PINE-SSDDK--SQIEEFIREYNGEGIQHIALATDDIYKTVKTLRDR--- PINE-SSDDK--SQIEEFNLQYNGEGIQHIAMSSDIYETVRLQKAG--- PLNEESSKGA--GQIEEFMLQFNNGEGIQHVAFLTDLVLKTDALDKKI--- PINE-DRDEK--GQIVAYLKKYNGEGIQHIAVGARNIYDADAIADN--- PINE-DRGET--GQIVAYLKKYNGEGIQHIAVGARDIYAATDAIAEN--- PINE-PTEEK--SQIQEYLDEYKSGIQHIALLTHDINYSLESLKNS---
10	HORDEUM-VULGARE TRITICUM-AESTIVUM AVENA-SATIVA ORYZA-SATIVA SORGHUM-BICOLOR ZEA-MAYS	
15	ABO95005_OLUCIMARINUS OTAURI MICROMONAS-PUSILLA-CCMP1545 SYNECHOCOCCUS-SP. VIBRIO-SP.-MED222 MARINOMONAS-SP.-MED121	
20	PSEUDOMONAS-FLUORESCENS SULFITOBACTER-SP.-NAS-14.1 OCEANICOLA-BATSSENSIS-HTCC2597 BDELLOVIBRIO-BACTERIOVORUS	
25	RATTUS_NORVEGICUS HOMO-SAPIENS XENOPUS-LAEVIS BLEPHARISMA-JAPONICUS MYCOSPHAERELLA-GRAMINICOLA ASPERGILLUS-FUMIGATUS MAGNAPORTHE-GRISEA	--GMEFLAVP-SSYYRLL-----RENLKTSK--IQVKEN-----MDV --GLEFLSVP-STYYKQL-----REKLTAK--IKVKEN-----IDA --GLEFLTIP-RTYYKNL-----RARLSMSK--VQVEED-----LAE --GVEFLEVP-PKYDLSL-----RKRLAHS--VQIEED-----LKR --GVEFISVP-DTYENM-----RLRLKAAG--MKLEES-----FDI --GVEFIKVP-DTYEDI-----KVRLKAG--LTLHED-----FET --GVEFIEVP-HTYYDTM-----RRRLKTEKRDWELQED-----FDR --GVEFNHTS-ENYNNL-----KQRLNNDG--IKLYED-----FDT --GIEFNHTS-DKYNTL-----ERLLREDD--VALFED-----FDT --GVEFLATP-DSYYEDP-----ELRARI--NVRAP-----IAE --GIEFLSTP-ASYYEDP-----ELRARI--EVRVP-----IEE --GVEFLDTP-DAYDDP-----EMRARI--EVRVP-----IEE --GVQFLDTP-DSYYDT-----LGEWVG--DTRVP-----VDT --GVEFLYVP-DTYDD-----LLERVG--DDED-----VEE --GVEFLPPPQAYDD-----IPRRLGAHMDTMKED-----LNK --GVEFLSVP-TSYED-----LQERVG--KIDEK-----LEE --GIEFLKTP-GSYYES-----LSSRIG--SIDED-----LNE IGGFDFMSPPPPTYYQN-----LKKRVG--DVLSDD-----QIKE VGGFDFMSPPPPTYYKN-----LKNRVG--DVLSEE-----QIEE VGGFDFMSPPPPTYYKN-----LKNRAG--DVLSE-----QIKE VGGFDFMSPPPPTYYRN-----LKNRVG--DVLTD-----QIKE VGGFDFMSPPPPTYYRN-----LKNRVG--DVLSE-----QIKE LGGFDFMSPPPPTYYAN-----LHNRAA--DVLTV-----QIKQ VGGFDFMSPPPPTYYKN-----LRSRAG--DVLSE-----QIQ VGGFDFMSPPPPTYYKN-----LKSRA--DVLSE-----QIQ VGGFDFMSPPPPTYYKN-----LKNRAG--DVLTD-----QIQ LGGFDFMSPPPPTYYKN-----LKNRVG--DVLSE-----QIKE VGGFDFMSPPPPTYYRN-----LKSRA--DVLSE-----QIEE MGGFDFLPPPLPKYYEG-----VRRLAG--DVLSEA-----QIKE MGGFDFLPPRCRKYEG-----VRRLAG--DVLSEA-----QIKE MGGFDFMAPPQAKYYEG-----VRRLAG--DVLSEE-----QIKE MGGFDFLAPPNNYD-----VRRRAG--DVLSEE-----QINE MGGFDFMAPPPEYD-----VRRRAG--DVLTEA-----QIKE MGGFDFMAPPPTSDYD-----VRRRAG--DVLTEA-----QIKE RGGFDFQAPASDDYKQ-----LKAKIG--DALNDE-----QYAL HGGFDFQAPASDDYKH-----LKEKIG--DALTDE-----QYAL RGGFDFQKASADYAN-----LKVAVG--DALTER-----QFKE QGGVDFLQVAP-QYYTS-----LERELGL--ALRSALGQAIWQD --GDMFMTPT-DTYEKVDDRVKGGH-----ED-----TDL
30	CANDIDA-ALBICANS PICHIA-STIPITIS RHODOCOCCUS-SP. RHODOCOCCUS-ERYTHROPOLIS JANIBACTER-SP.-HTCC2649 STREPTOMYCES-AVERMITILIS KORDIA-ALGICIDA	
35	LEEUWENHOEKIELLA-BLANDENSIS-ME GEMMATIMONAS-AURANTIACA PICROPHILUS-TORRIDUS ARABIDOPSIS-THALIANA BRASSICA-RAPA-SUBSP.-PEKINENSI COPTIS-JAPONICA-VAR.-DISSECTA	
40	HEVEA-BRASILIENSIS MEDICAGO-TRUNCATULA GLYCINE-MAX SOLANUM-LYCOPERSICUM SOLANUM-TUBEROSUM NICOTIANA-BENTHAMIANA DAUCUS-CAROTA SOLENOSTEMON-SCUTELLARIOIDES HORDEUM-VULGARE TRITICUM-AESTIVUM AVENA-SATIVA ORYZA-SATIVA	
45	SORGHUM-BICOLOR ZEA-MAYS ABO95005_OLUCIMARINUS OTAURI MICROMONAS-PUSILLA-CCMP1545 SYNECHOCOCCUS-SP. VIBRIO-SP.-MED222	
50		
55		

	MARINOMONAS-SP.-MED121	--GLKFMSTP-DTYAKVNDRVVGHG-----ED-----LEK
	PSEUDOMONAS-FLUORESCENS	--GMRFTAPPDITYEMLEGRLPDHG-----EP-----VDQ
	SULFITOBACTER-SP.-NAS-14.1	--GLKFMPGPPETYYKMSKDRVTGHQ-----EP-----LDR
5	OCEANICOLA-BATSENSIS-HTCC2597	--GVTYMPGPPDAYDMSHDRVKDHG-----EP-----IDR
	BDELLOVIBRIO-BACTERIOVORUS	--EIQLTTPPHSYEMIPERVPGVT-----ED-----ISR
	RATTUS_NORVEGICUS	LEELKILVDYD-----EKGYLLQIFTKPMQDRPTLFLEVI
	HOMO-SAPIENS	LEELKILVDYD-----EKGYLLQIFTKPVQDRPTLFLEVI
	XENOPUS-LAEVIS	IEKLSILVDFD-----EGGYLLQIFTKPLEDRPTLFIEII
10	BLEPHARISMA-JAPONICUS	IEDLHILVDFD-----DRGYLLQIFTKPVEDRPTLFYEII
	MYCOSPHAERELLA-GRAMINICOLA	IQKLNILIDFD-----EGGYLLQLFTKPLMDRPTVFIEII
	ASPERGILLUS-FUMIGATUS	IRSLDILIDFD-----EGGYLLQLFTKHLMDRPTVFIEII
	MAGNAPORTHE-GRISEA	LVRNNILIDYD-----EGGYLLQLFTRPLMDRPTVFIEII
	CANDIDA-ALBICANS	LRSLNILIDYDPTKPKPKSKRKRNNKCNLLQIFSKPLHDRPTLFIEII
	PICHIA-STIPITIS	LRKLNILVDYDISTR-----NKKTGICNYLLQIFTKPLHDRPTLFIEII
15	RHODOCOCCUS-SP.	LQKRGILVDRD-----EDGYLLQIFTKPLVDRPTVFIEII
	RHODOCOCCUS-ERYTHROPOLIS	LQKRGILVDRD-----EDGYLLQIFTKPIGRDPTVFIEII
	JANIBACTER-SP.-HTCC2649	LKSRKILVDRD-----EDGYLLQIFTKPLGRDPTVFIEII
	STREPTOMYCES-AVERMITILIS	LRELKILADR-----EDGYLLQIFTKPVQDRPTVFIEII
	KORDIA-ALGICIDA	LKKHGILIDR-----EGGYLLQLFTKTIQDRPTMFFEVI
20	LEEUEWENHOEKIELLA-BLANDENSIS-ME	LQELLSILVAD-----EGGYLLQIFTKPLQDRPTLFIEII
	GEMMATIMONAS-AURANTIACA	LAALGILVDRD-----PDGYLLQIFTKPVEDRPTLFIEII
	PICROPHILUS-TORRIDUS	IEKHNILVDRD-----ENGYLLQIFTKPVDRPTFFFIEVI
	ARABIDOPSIS-THALIANA	CEELGILVDR-----DDQGTLLQIFTKPLGRDPTIFIEII
	BRASSICA-RAPA-SUBSP.-PEKINENSI	CEELGILVDR-----DDQGTLLQIFTKPLGRDPTIFIEII
	COPTIS-JAPONICA-VAR.-DISSECTA	CEELGILVDR-----DAQGTLLQIFTKPVGDRPTIFIEII
	HEVEA-BRASILIENSIS	CEELGILVDR-----DDQGTLLQIFTKPVGDRPTIFIEII
25	MEDICAGO-TRUNCATULA	CEELGILVDR-----DDQGTLLQIFTKPIGRDPTIFIEII
	GLYCINE-MAX	CEELGILVDR-----DDQGTLLQIFTKPVGDRPTIFIXII
	SOLANUM-LYCOPERSICUM	CEELGILVDR-----DDQGTLLQIFTKPVGDRPTIFIEII
	SOLANUM-TUBEROSUM	CEDLGLVDR-----DDQGTLLQIFTKPVGDRPTIFIEII
	NICOTIANA-BENTHAMIANA	CEDLGLVDR-----DDQGTLLQIFTKPVGDRPTIFIEII
	DAUCUS-CAROTA	CEDLGLVDR-----DDQGTLLQIFTKPVGDRPTLFIEII
30	SOLENOSTEMON-SCUTELLARIOIDES	CEKLGILIDR-----DDQGTLLQIFTKPVGDRPTLFIEII
	HORDEUM-VULGARE	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTLFLEMI
	TRITICUM-AESTIVUM	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTLFLEMI
	AVENA-SATIVA	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTFFLEMI
	ORYZA-SATIVA	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTFFLEMI
	SORGHUM-BICOLOR	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTLFLEII
35	ZEA-MAYS	CQELGVLVDR-----DDQGVLLQIFTKPVGDRPTLFLEII
	AB095005_OLUCIMARINUS	VEELGILLVDR-----DDQGVLIQVFTKPVGDRPTLFLEII
	OTAURI	VEELGILLVDR-----DDQGVLIQVFTKPVGDRPTLFLEII
	MICROMONAS-PUSILLA-CCMP1545	VEELGILLVDR-----DDQGVLVQIFTKPLGRDPTVFIEII
	SYNECHOCOCCUS-SP.	LVEQQILLDATLPASDG-----QDRPLLLQTFQPLFRPTFFFIEVI
	VIBRIO-SP.-MED222	LRDLRVLIDGAPTKDG-----ILLQIFQTQTVIG--PVFFIEII
40	MARINOMONAS-SP.-MED121	LQDLNILIDGAPLKD-----TLLQIFDTVIG--PVFFIEII
	PSEUDOMONAS-FLUORESCENS	LQARGILLDGSSVEGDK-----RLLQIFSETLMG--PVFFIEII
	SULFITOBACTER-SP.-NAS-14.1	MKKHGILIDGEGVVDGGE-----TRILLQIFSKTVIG--PIFFIEII
	OCEANICOLA-BATSENSIS-HTCC2597	MKKHGILIDGEGVVDGGE-----TRILLQIFSKTVIG--PIFFIEII
	BDELLOVIBRIO-BACTERIOVORUS	LEKNAILVDGD--KTG-----KYLQIFTKNTFG--PIFYELI
	RATTUS_NORVEGICUS	QRHN-----HQGFAGNFNLSLFAFEEEQALRGN
45	HOMO-SAPIENS	QRHN-----HQGFAGNFNLSLFAFEEEQNLRGN
	XENOPUS-LAEVIS	QRHN-----HQGFAGNFKALFESIEMEQAIRGN
	BLEPHARISMA-JAPONICUS	QRHN-----NNGFGIGNFKALFESLEQEQRGN
	MYCOSPHAERELLA-GRAMINICOLA	QRNN-----FDGFGAGNFKSLFEATIEREQDLRGN
	ASPERGILLUS-FUMIGATUS	QRHN-----FSGFGAGNFKSLFEATIEREQALRGN
	MAGNAPORTHE-GRISEA	QRNE-----FDGFGAGNFKSLFEATIEREQAERGN
50	CANDIDA-ALBICANS	QRHH-----HNGFGKGTFKGLFESIEEQKLRGT
	PICHIA-STIPITIS	QRHH-----HNGFGKGTFKGLFETIEEQQIRGT
	RHODOCOCCUS-SP.	ERHG-----SLGFGIGNFKALFEATIEREQARGN
	RHODOCOCCUS-ERYTHROPOLIS	ERHG-----SLGFGIGNFKALFEATIEREQAARGN
	JANIBACTER-SP.-HTCC2649	ERHG-----SLGFGKGNFKALFESIEREQDARGN
	STREPTOMYCES-AVERMITILIS	ERHG-----SMGFGKGNFKALFEATIEREQEARGN
55	KORDIA-ALGICIDA	QRKG-----AQSFVGNFKALFEATIEREQAARGT

EP 2 453 012 A1

	LEEUVENHOEKIELLA-BLANDENSIS-ME	ORMG-----AKGFGAGNFKALFESIEREQQRGT
	GEMMATIMONAS-AURANTIACA	QRKG-----AT'SFGKGNFRALFEAIEREQELRGN
5	PICROPHILUS-TORRIDUS	QRKG-----ARSFGNGNFKALFEAIEREQAKRGN
	ARABIDOPSIS-THALIANA	QRVGCMMKDEEGKA-----YQSGGCGGFGKGNFSELFKSI E EYEKTL EA
	BRASSICA-RAPA-SUBSP.-PEKINENSI	QRIGCMKKDEEGRV-----YQSGGCGGFGKGNFSELFKSI E EYEKTL EA
	COPTIS-JAPONICA-VAR.-DISSECTA	QRLGCMKLDDEEKT-----YQKAGCGGFGKGNFSELFKSI E EYEKTL EA
	HEVEA-BRASILIENSIS	QRVGCMIKDETGKE-----YQKGGCGGFGKGNFSELFKSI E EYEKTL EA
	MEDICAGO-TRUNCATULA	QRVGCMLKDEEGKE-----YQKGGCGGFGKGNFSELFKSI E EYEKTL ET
10	GLYCINE-MAX	QRIGCMVEDEEGKV-----YQKAGCGGFGKGNFSELFKSI E EYEKTL EA
	SOLANUM-LYCOPERSICUM	QRIGCMKLDKEGQV-----YQKGGCGGFGKGNFSELFRSI E EYEKML EA
	SOLANUM-TUBEROSUM	QRIGCMKLDENGQV-----YQKGGCGGFGKGNFSELFRSI E EYEKML EA
	NICOTIANA-BENTHAMIANA	QRIGCMKLDKEGQV-----YQKGGCGGFGKGNFSELFRSI E EYEKTL --
	DAUCUS-CAROTA	QRVGCMLKDDAGQM-----YQKGGCGGFGKGNFSELFKSI E EYEKTL EA
	SOLENOSTEMON-SCUTELLARIOIDES	QRVGCMMKDEEGKM-----YQKGGCGGFGKGNFSELFKSI E EYEKML ES
	HORDEUM-VULGARE	QRIGCMEKDERGEE-----YQKGGCGGFGKGNFSELFKSI EDYEKSLEA
15	TRITICUM-AESTIVUM	QRIGCMEKDERGEE-----YQKGGCGGFGKGNFSELFKSI EDYEKSLEA
	AVENA-SATIVA	QRIGCMEKDEVGQE-----YQKGGCGGFGKGNFSELFKSI EDYEKSLEV
	ORYZA-SATIVA	QRIGCMEKDESGQE-----YQKGGCGGFGKGNFSELFKSI E EYEKSLEA
	SORGHUM-BICOLOR	QRIGCMEKDEKGQE-----YQKGGCGGFGKGNFSQLFKSI EDYEKSLEA
	ZEA-MAYS	QRIGCMEKDEKGQE-----YQKGGCGGFGKGNFSQLFKSI EDYEKSLEA
20	AB095005_OLUCIMARINUS	QRIGCMRRKADSES-----FEQAAGCGGFGKGNFSELFKSI EAYEATLQI
	OTAURI	QRVGCMRKKADTDE-----LEQVAGCGGFGKGNFSELFKSI EAYEATLNI
	MICROMONAS-PUSILLA-CCMP1545	QRIGCLREVKSADANAPPRIEQAGGCGGFGKGNFSELFKSI ENYERTLKM
	SYNECHOCOCCUS-SP.	QRLG-----GATGFGEANFQALFEALERQQRHQ
	VIBRIO-SP.-MED222	QRKG-----NEGFGEENFKALFESIEEDQIRRGV
	MARINOMONAS-SP.-MED121	QRKG-----NEGFGEENFKALFESIEEDQIRRGV
	PSEUDOMONAS-FLUORESCENS	QRKG-----DDGFGEENFKALFESIERDQVRRGV
25	SULFITOBACTER-SP.-NAS-14.1	ERKG-----DDGFGEENFKALFESIEEQEIQDSGE
	OCEANICOLA-BATSENSIS-HTCC2597	QRKG-----DDGFGEENFKALFESIEEQEIQDNGE
	BDELLOVIBRIO-BACTERIOVORUS	QRKG-----HDGFGDGNFQALFDAIERDQRERGY
30	RATTUS_NORVEGICUS	LTDLETNGVRSKM-----
	HOMO-SAPIENS	LTNMETNGVVPGMAENLYFQ
	XENOPUS-LAEVIS	L-----
	BLEPHARISMA-JAPONICUS	LI-----
	MYCOSPHAERELLA-GRAMINICOLA	L-----
	ASPERGILLUS-FUMIGATUS	LV-----
	MAGNAPORTHE-GRISEA	L-----
35	CANDIDA-ALBICANS	FVKSQNN-----
	PICHIA-STIPITIS	LVQVDEDDDSQQST-----
	RHODOCOCCUS-SP.	F-----
	RHODOCOCCUS-ERYTHROPOLIS	F-----
	JANIBACTER-SP.-HTCC2649	L-----
	STREPTOMYCES-AVERMITILIS	L-----
	KORDIA-ALGICIDA	L-----
40	LEEUVENHOEKIELLA-BLANDENSIS-ME	L-----
	GEMMATIMONAS-AURANTIACA	L-----
	PICROPHILUS-TORRIDUS	L-----
	ARABIDOPSIS-THALIANA	KQLVG-----
	BRASSICA-RAPA-SUBSP.-PEKINENSI	KQLVG-----
	COPTIS-JAPONICA-VAR.-DISSECTA	KANVVAA-----
45	HEVEA-BRASILIENSIS	KRNAEAR-----
	MEDICAGO-TRUNCATULA	RRTA-----
	GLYCINE-MAX	KRTA-----
	SOLANUM-LYCOPERSICUM	KHVNQVAAVE-----
	SOLANUM-TUBEROSUM	KHVNQVAAA-----
	NICOTIANA-BENTHAMIANA	-----
50	DAUCUS-CAROTA	KQITGSAAA-----
	SOLENOSTEMON-SCUTELLARIOIDES	KLVTKTAMA-----
	HORDEUM-VULGARE	KQSAAVQGS-----
	TRITICUM-AESTIVUM	KQSAAVQGS-----
	AVENA-SATIVA	KQSVVAQKS-----
	ORYZA-SATIVA	KQAPTVOGS-----
55	SORGHUM-BICOLOR	KQAAAAQGS-----

EP 2 453 012 A1

	ZEA-MAYS	KQAAAAAAAAQGS-----
	AB095005_OLUCIMARINUS	-----
	OTAURI	-----
5	MICROMONAS-PUSILLA-CCMP1545	-----
	SYNECHOCOCCUS-SP.	ALTP-----
	VIBRIO-SP.-MED222	LDDA-----
	MARINOMONAS-SP.-MED121	LNDA-----
	PSEUDOMONAS-FLUORESCENS	LATD-----
	SULFITOBACTER-SP.-NAS-14.1	LSEA-----
10	OCEANICOLA-BATSENSIS-HTCC2597	IAAE-----
	BDELLOVIBRIO-BACTERIOVORUS	LT-----

[0045] The overall sequence identity between individual full length HPPD sequences is in general quite low and is shown for the representative HPPD proteins in Table 3. Table 4a shows the sequence alignment of the binding pocket. In contrast, the sequence identity of the 36 amino acids forming the binding site is significantly higher which is shown for the representative HPPD proteins in Table 4b. In particular, the amino acids at 8 positions are strictly conserved in all species and illustrate that these amino acids have a key role (e.g. His226, His308, Glu394 binding the iron required for catalysis). These positions, with reference to the HPPD from Arabidopsis (SEQ ID No. 2) are His226, Ser267, Asn282, His308, Tyr342, Glu394, Gly420, Asn423 (Table 5a). A mutation of any of the amino acids at either of these positions will most likely lead to an inactive protein. The variability at other positions within the binding site is higher. Table 5b shows the 28 variable positions in the binding site and the amino acids which were identified at these positions using the sequence alignment. Some positions have only limited variability which reflects their role in the 3D environment. An example for this represents the position 269. All HPPD proteins have at this position either a Val, Ala or Thr. Looking at the 3D structures it seems that at this position a small apolar amino acid is required and a mutation to a polar amino acid such as Arg, His or Lys will disturb the protein structure locally. Another example represents position 379. Most sequences have a glutamine at position 379. However, there are also some bacterial sequences which have a histidine at this position. Looking at the 3D structure, it seems that only few amino acids are tolerated at this position. Gln379 in *A.thaliana* stabilizes via its H-bond donor the side chain conformation of the strictly conserved Glu394 which in turn interacts with the catalytic iron. In addition, with its H-bond acceptors Gln379 stabilizes the side chain conformation of the strictly conserved Asn423 which in turn interacts with the strictly conserved Tyr342. Only glutamine, asparagine and histidine have an H-bond donor and acceptor required for the stabilization of this particular 3D arrangement which very likely play a key role in the interaction of the C-terminal helix with the core of the HPPD protein. Limited variability is also seen at position 381 with either a phenylalanine or a tyrosine in all HPPD sequences. The aromatic ring stabilizes the binding of HPPD inhibitors and very likely also the binding of the substrate to the HPPD binding. However, the presence of the additional hydroxyl group in tyrosine compared to phenylalanine does not disturb the catalytic activity. The third category of positions includes those positions which display a very high natural variability. These positions may not be crucial for substrate binding and catalysis but influence inhibitor binding. These positions include adjacent positions in strand 248 to 255 and positions in the C-terminal helix 419-427. It can be assumed that the interaction of this particular strand and the C-terminal helix with the core of the protein plays a crucial role in inhibitor binding. Table 5b includes for each variable position those amino acids which have been identified in the sequence alignments using all known HPPD sequences.

45

50

55

Table 3: Pairwise sequence identity of HPPD sequences from the representative set of HPPD proteins

Table with 30 rows and 30 columns showing pairwise sequence identity percentages between various species including RATTUS_NORVEGICUS, HOMO-SAPIENS, XENOPUS-LAEVIS, ASPERGILLUS-FUMIGATUS, etc.

Table 4a: Sequence alignment of amino acids forming the binding pocket in the representative set of HPPD sequences

Table with 2 columns: Species names (e.g., HOMO-SAPIENS, RATTUS_NORVEGICUS) and their corresponding amino acid sequences for the binding pocket.

EP 2 453 012 A1

Table 5a: Amino acid positions which are strictly conserved shown for the crystal structures

	<i>Arabidopsis thaliana</i>		<i>Pseudomonas fluorescens</i>		<i>Streptomyces avermitilis</i>		<i>Homo sapiens</i>		<i>Rattus norvegicus</i>	
	Position	Amino Acid	Position	Amino Acid	Position	Amino Acid	Position	Amino Acid	Position	Amino Acid
5	226	H	162	H	187	H	183	H	183	H
	267	S	202	S	230	S	226	S	226	S
10	282	N	217	N	245	N	241	N	241	N
	308	H	241	H	270	H	266	H	266	H
	342	Y	271	Y	299	Y	295	Y	295	Y
	394	E	323	E	349	E	349	E	349	E
	420	G	334	G	360	G	360	G	360	G
15	423	N	337	N	363	N	363	N	363	N

20

25

30

35

40

45

50

55

Table 5b: Amino acid position with the amino acids at this positions in the known crystal structures and the amino acids a these position within all HPPD sequences

<i>Arabidopsis thaliana</i>		<i>Pseudomonas fluorescens</i>		<i>Streptomyces avermitilis</i>		<i>Homo sapiens</i>		<i>Rattus norvegicus</i>		Natural Variability
Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Amino Acid
228	V	164	T	189	V	185	V	185	V	VTCAG
248	H	186	R	211	T	207	H	207	H	HRQTKEYLAGSN
250	F	188	A	213	M	209	F	209	F	FYILVAQEDGTSMRK
251	A	189	R	214	K	210	W	210	W	AWILSRKHDEPGNY
252	E	190	Y	215	E	211	S	211	S	ESTYFHQNGLMVILIR
253	F	191	F	216	F	212	V	212	V	FVIALWMQHY
265	L	200	L	228	L	224	L	224	L	LMVIA
268	A	203	K	231	K	227	I	227	I	AVLMIKRQY
269	V	204	A	232	V	228	V	228	V	VAT
270	L	205	M	233	V	229	V	229	V	LVMIA
271	A	206	S	234	A	230	A	230	A	ASTVRKELIMHG
280	P	215	P	243	P	239	P	239	P	PAVTNI
293	Q	226	Q	255	Q	251	Q	251	Q	QLAVRSGVFM
294	I	227	I	256	I	252	I	252	I	IMVTASP
307	Q	240	Q	269	Q	265	Q	265	Q	QHN
335	M	264	M	293	L	289	L	289	L	MLIN
368	L	295	L	323	L	323	L	323	L	LM
379	Q	310	Q	334	Q	334	Q	334	Q	QH
381	F	312	F	336	F	336	F	336	F	FY
392	F	321	F	347	F	347	F	347	F	FS
419	F	333	F	359	F	359	F	359	F	FY
421	K	335	E	361	K	361	A	361	A	KQAILVNDEGS
422	G	336	G	362	G	362	G	362	G	GAPVTM
424	F	338	F	364	F	364	F	364	F	FAVIL
425	S	339	K	365	K	365	N	365	N	SNKGRAPSIKQR
426	E	340	A	366	A	366	S	366	S	EQSAIVFT
427	L	341	L	367	L	367	L	367	L	LR
431	I	345	I	371	I	371	F	371	F	IFVMLQR

Table 5c: Amino acid position with the amino acids at this positions in the known crystal structures and most common amino acids a these position within all HPPD sequences

	Arabidopsis thaliana		Pseudomonas fluorescens		Streptomyces avermitilis		Homo sapiens		Rattus norvegicus		Most common
	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Amino Acid
5											
10	228	V	164	T	189	V	185	V	185	V	VTCA
	248	H	186	R	211	T	207	H	207	H	HRQTKEYA
	250	F	188	A	213	M	209	F	209	F	FYILVAEDTM
	251	A	189	R	214	K	210	W	210	W	AWILRKHDEPY
	252	E	190	Y	215	E	211	S	211	S	ESTRY
15	253	F	191	F	216	F	212	V	212	V	FVIALWY
	265	L	200	L	228	L	224	L	224	L	LMVA
	268	A	203	K	231	K	227	I	227	I	AVLMIKRQY
	269	V	204	A	232	V	228	V	228	V	VA
20	270	L	205	M	233	V	229	V	229	V	LVMI
	271	A	206	S	234	A	230	A	230	A	ASTVREGK
	280	P	215	P	243	P	239	P	239	P	PAVT
	293	Q	226	Q	255	Q	251	Q	251	Q	QLA
	294	I	227	I	256	I	252	I	252	I	IMVA
25	307	Q	240	Q	269	Q	265	Q	265	Q	QHN
	335	M	264	M	293	L	289	L	289	L	MLI
	368	L	295	L	323	L	323	L	323	L	LM
	379	Q	310	Q	334	Q	334	Q	334	Q	QH
	381	F	312	F	336	F	336	F	336	F	FY
30	392	F	321	F	347	F	347	F	347	F	F
	419	F	333	F	359	F	359	F	359	F	FY
	421	K	335	E	361	K	361	A	361	A	KQAVLDE
	422	G	336	G	362	G	362	G	362	G	GA
35	424	F	338	F	364	F	364	F	364	F	FAVL
	425	S	339	K	365	K	365	N	365	N	SNKRAIQ
	426	E	340	A	366	A	366	S	366	S	ESAIVF
40	427	L	341	L	367	L	367	L	367	L	LR
	431	I	345	I	371	I	371	F	371	F	IFVMQRL

[0046] Not all amino acids occurring at the variable positions have the same likelihood to be present in an active protein. In some cases most sequences have the same amino acids at a particular position while other amino acids are present at that position in only few HPPD sequences. An example is position 392. Most sequences have at a corresponding position a phenylalanine while few i.e. the *burkholderia* sequences have a serine. Whereas in some rare cases, the rare amino acids may be the result of a sequencing error, in most other cases the resulting protein is active. Table 5c shows a list with the most common amino acids at the variable positions.

[0047] The influence of the amino acids at the variable positions is different. Some of these positions are crucial for catalysis and/or the interaction of HPPD with an inhibitor while others may have less impact. For instances changes at positions 269 and 280 which are in direct contact with the inhibitor and the substrate will very likely have a great impact upon catalysis and inhibitor binding. Also modifications at positions involved in the helix movement induced by inhibitor or substrate binding such as positions 252, 421 and 422 are likely to have high impact on inhibitor binding. In contrast modifications at positions such as 293 are less likely to influence inhibitor binding because this position is quite distant from the active site. Table 6a shows the position with very high impact and table 6b with impact on activity and inhibitor binding.

[0048] From these observations, the present inventors drew the conclusion that amino acids are preferred in the binding sites which naturally occur at the corresponding positions. This means, that those modifications which exchange a naturally occurring amino acid into another are likely providing a catalytically active HPPD protein which may exert a

EP 2 453 012 A1

modified or even increased tolerance to HPPD herbicide inhibitors. Even more promising are those mutant proteins which have the amino acid most often found in nature at the variable position chosen from Table 5c.

Table 6a: Amino acid positions with high priority shown for the x-ray structures

<i>Arabidopsis thaliana</i>		<i>Pseudomonas fluorescens</i>		<i>Streptomyces avermitilis</i>		<i>Homo sapiens</i>		<i>Rattus norvegicus</i>	
Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid
228	V	164	T	189	V	185	V	185	V
250	F	188	A	213	M	209	F	209	F
251	A	189	R	214	K	210	W	210	W
252	E	190	Y	215	E	211	S	211	S
253	F	191	F	216	F	212	V	212	V
265	L	200	L	228	L	224	L	224	L
268	A	203	K	231	K	227	I	227	I
269	V	204	A	232	V	228	V	228	V
270	L	205	M	233	V	229	V	229	V
271	A	206	S	234	A	230	A	230	A
280	P	215	P	243	P	239	P	239	P
307	Q	240	Q	269	Q	265	Q	265	Q
335	M	264	M	293	L	289	L	289	L
368	L	295	L	323	L	323	L	323	L
379	Q	310	Q	334	Q	334	Q	334	Q
392	F	321	F	347	F	347	F	347	F
421	K	335	E	361	K	361	A	361	A
422	G	336	G	362	G	362	G	362	G
426	E	340	A	366	A	366	S	366	S
427	L	341	L	367	L	367	L	367	L

Table 6b: Amino acid positions with very high priority shown for the x-ray structures

<i>Arabidopsis thaliana</i>		<i>Pseudomonas fluorescens</i>		<i>Streptomyces avermitilis</i>		<i>Homo sapiens</i>		<i>Rattus norvegicus</i>	
Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid	Pos.	Amino Acid
252	E	190	Y	215	E	211	S	211	S
269	V	204	A	232	V	228	V	228	V
280	P	215	P	243	P	239	P	239	P
335	M	264	M	293	L	289	L	289	L
368	L	295	L	323	L	323	L	323	L
421	K	335	E	361	K	361	A	361	A
422	G	336	G	362	G	362	G	362	G

[0049] In another embodiment, in the isolated nucleic acid of the invention as defined above, said at least on amino acid is selected from

- a) Ala, Asp, Glu, Phe, Thr, Val or Tyr at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
- b) Ala, Asp, Glu, Ile, Lys, Leu, Pro or Arg at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 2;
- c) Glu, Thr, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;

acid sequence of SEQ ID No. 2;

d) Ala, Phe, Val or Trp at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;

5 e) Leu or Val at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;

f) Leu, Gln, Arg, Val or Tyr at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID NO: 2;

g) Ala or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;

10 h) Ala, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;

i) Gln at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;

15 j) Ile or Met at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;

k) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;

l) Phe at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;

20 m) Asp, Lys, or Asn at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;

n) Ala or Gly at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;

25 o) Ile, Arg or Ser at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2

p) Glu, Phe or Val at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;

q) Ile, Met, Gln or Val or Phe at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2;

30 r) Ala, Cys, Thr or Val at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;

s) Ala, Glu, His, Lys, Gln, Arg, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;

35 t) Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;

u) Ala, Glu, Lys, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;

v) His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2;

40 w) Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

[0050] In an alternative embodiment of the nucleic acid of the invention, said at least one amino acid is selected from

45 a) Glu, Thr, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;

b) Ala or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;

50 c) Ala, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;

d) Ile or Met at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;

e) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;

55 f) Asp., Asn or Lys at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;

g) Ala or Gly at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;

- h) Ala, Cys, Thr or Val at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- i) Ala, Glu, His, Lys, Gln, Arg, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;
- 5 j) Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- k) Ala, Glu, Lys, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;
- l) His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2;
- 10 m) Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

[0051] Various sequences of HPPD proteins or predicted HPPD proteins are known in the art. These include the HPPD sequences of *Streptomyces avermitilis* (Genebank SAV11864), *Daucus carota* (Genebank DCU 87257), *Arabidopsis thaliana* (Genebank AF047834), *Mycosphaerella graminicola* (Genebank AF038152), *oryza sativa* / rice [BAD26248], *Zea mays* / corn [ACN36372], *avena sativa* [ABZ23427], *Pseudomonas fluorescens* [ABF50055], *Synechococcus* sp. [YP_473959], *Blepharisma japonicum* [BAF91881], *Rhodococcus RHA1* sp. ro0240 [YP_702005], *Rhodococcus RHA1* sp. ro0341 [YP_703002], *Picrophilus torridus* [YP_024147], *Kordia algicida* [ZP_02161490], *Sorghum bicolor* [XP_002453359], *Triticum aestivum* / wheat [AAZ67144], or *Hordeum vulgare* / barley [O48604].

[0052] The sequence of the HPPD protein taken as a starting point may be any amino acid sequence encoding a catalytically active HPPD protein. In one embodiment of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 4 [*Oryza sativa*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 247 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 250 of SEQ ID No. 2);
- b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 248 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 251 of SEQ ID No. 2);
- 30 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 249 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 252 of SEQ ID No. 2);
- d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 250 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 253 of SEQ ID No. 2);
- e) Val or Met at position 262 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 265 of SEQ ID No. 2);
- 35 f) Leu, Gln, Arg, Tyr, Ala, Ile, Lys or Met at position 265 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 266 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 269 of SEQ ID No. 2);
- 40 h) Ala, Ile, Asn, Thr or Val at position 277 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 290 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 293 of SEQ ID No. 2);
- 45 j) Met, Ala, Pro, Ser, Thr or Val at position 291 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile, Met or Asn at position 332 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 335 of SEQ ID No. 2);
- l) Met at position 365 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 368 of SEQ ID No. 2);
- m) Tyr at position 378 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 381 of SEQ ID No. 2);
- 50 n) Ser at position 389 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 392 of SEQ ID No. 2);
- o) Tyr at position 416 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 419 of SEQ ID No. 2);
- p) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 418 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 421 of SEQ ID No. 2);
- 55 q) Ala, Met, Pro or Thr at position 419 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 422 of SEQ ID No. 2);
- r) Ala, Ile or Val at position 421 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 424 of SEQ ID No. 2);
- s) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 422 of the amino acid sequence of SEQ ID No. 4 (corresponding

EP 2 453 012 A1

to position 425 of SEQ ID No. 2);

t) Phe, Thr, Val, Ala, Gln or Ser at position 423 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 426 of SEQ ID No. 2);

u) Met, Gln, Val, Phe or Leu at position 428 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 431 of SEQ ID No. 2);

v) Phe at position 431 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 434 of SEQ ID No. 2);

w) Ala, Cys, Gly or Thr at position 225 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 245 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Met or Val at position 267 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 270 of SEQ ID No. 2);

z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 268 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 271 of SEQ ID No. 2);

aa) His at position 376 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 427 of SEQ ID No. 2).

[0053] In another embodiment of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 6 [Zea mays], wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 224 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 250 of SEQ ID No. 2);

b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 225 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 251 of SEQ ID No. 2);

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 226 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 252 of SEQ ID No. 2);

d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 227 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 253 of SEQ ID No. 2);

e) Val or Met at position 239 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Lys at position 242 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 243 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 269 of SEQ ID No. 2);

h) Ala, Ile, Asn, Thr or Val at position 254 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 280 of SEQ ID No. 2);

i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 267 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 293 of SEQ ID No. 2);

j) Met at position 268 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 294 of SEQ ID No. 2);

k) His or Asn at position 281 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 307 of SEQ ID No. 2);

l) Ile, Asn or Leu at position 309 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 335 of SEQ ID No. 2);

m) Met at position 342 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 368 of SEQ ID No. 2);

n) Tyr at position 355 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 366 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 393 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 395 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 421 of SEQ ID No. 2);

r) Ala, Met, Pro or Thr at position 396 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 398 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 399 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 425 of SEQ ID No. 2);

u) Glu, Phe, Thr, Val, Ala or Ser at position 400 of the amino acid sequence of SEQ ID No. 6 (corresponding to

position 426 of SEQ ID No. 2);

v) Met, Gln, Val, Phe or Leu at position 405 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 431 of SEQ ID No. 2);

5 w) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 202 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 222 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Met or Val at position 244 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 270 of SEQ ID No. 2);

10 z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 245 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 271 of SEQ ID No. 2);

aa) Gln at position 353 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 379 of SEQ ID No. 2);

ab) Arg at position 401 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 427 of SEQ ID No. 2).

15 **[0054]** In another embodiment of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 8 [*Avena sativa*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

20 a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 241 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 250 of SEQ ID No. 2), preferably Ala ;

b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 242 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;

25 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 243 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;

d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 244 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

e) Val or Met at position 256 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 265 of SEQ ID No. 2);

30 f) Leu, Gln, Arg, Tyr, Ala, Ile, Lys or Met at position 259 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 260 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 280 of SEQ ID No. 2);

35 i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 284 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 293 of SEQ ID No. 2);

j) Met, Ala, Pro, Ser, Thr or Val at position 285 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 294 of SEQ ID No. 2);

40 k) His or Asn at position 265 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 307 of SEQ ID No. 2);

l) Ile or Asn or Leu at position 326 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 335 of SEQ ID No. 2);

m) Met at position 359 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 368 of SEQ ID No. 2);

n) Tyr at position 372 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 381 of SEQ ID No. 2);

45 o) Ser at position 383 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 410 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 412 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

50 r) Ala, Met, Pro or Thr at position 413 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 415 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 416 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 425 of SEQ ID No. 2);

55 u) Phe, Thr, Val, Ala, Gln or Ser at position 417 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 426 of SEQ ID No. 2);

v) Met, Gln, Val, Phe or Leu at position 422 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 431 of SEQ ID No. 2);

EP 2 453 012 A1

w) Ala, Cys, Gly or Thr at position 219 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 239 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Met or Val at position 261 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 270 of SEQ ID No. 2);

z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 271 of SEQ ID No. 2);

aa) His at position 370 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at position 418 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 427 of SEQ ID No. 2).

[0055] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 10 [*Pseudomonas fluorescens*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Phe, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 188 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 250 of SEQ ID No. 2), preferably Ala;

b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Ser, Gly, His or Tyr at position 189 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 251 of SEQ ID No. 2), preferably Ala or Lys;

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Glu or Thr at position 190 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 252 of SEQ ID No. 2), preferably Ser or Tyr;

d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 191 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 253 of SEQ ID No. 2), preferably Phe or Val;

e) Val or Met at position 200 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val Tyr, Ala, Ile or Met at position 203 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 268 of SEQ ID No. 2);

g) Thr or Val at position 204 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 269 of SEQ ID No. 2), preferably Val;

h) Ala, Ile, Asn, Thr or Val at position 215 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 280 of SEQ ID No. 2);

i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 226 of the amino acid sequence of SEQ ID NO:SEQ ID No. 10 (corresponding to position 293 of SEQ ID No. 2);

j) Met, Thr, Ala, Pro, Ser or Val at position 227 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 294 of SEQ ID No. 2);

k) His or Asn at position 240 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 307 of SEQ ID No. 2);

l) Ile, Asn or Leu at position 264 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 335 of SEQ ID No. 2);

m) Met at position 295 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 368 of SEQ ID No. 2);

n) Tyr at position 312 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 321 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 333 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Lys, Asn, Ala, Cys, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 335 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

r) Ala, Met, Pro or Thr at position 336 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 338 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Ala, Asn, Gly or Gln at position 339 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 425 of SEQ ID No. 2);

u) Phe, Thr or Val at position 340 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 426 of SEQ ID No. 2);

v) Met, Phe, Leu, Gln or Val at position 345 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 431 of SEQ ID No. 2);

w) Ala, Cys, Gly or Val at position 164 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Ser, Thr or Tyr at position 186 of the amino acid sequence of SEQ ID No.

EP 2 453 012 A1

10 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Leu or Val at position 205 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 270 of SEQ ID No. 2);

z) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at position 206 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 271 of SEQ ID No. 2);

aa) His at position 310 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at position 341 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 427 of SEQ ID No. 2).

[0056] In another embodiment of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 14 [*Synechococcus* sp.], wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile or Met at position 169 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 250 of SEQ ID No. 2), preferably Ala or Phe;

b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser, Gly or His at position 170 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;

c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Ser, Val, Tyr or Thr at position 171 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 252 of SEQ ID No. 2), preferably Glu, Ser or Tyr;

d) Ala, Phe, His, Gln, Val or Ile, Leu or Met at position 172 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 253 of SEQ ID No. 2), preferably Phe or Val;

e) Val or Met at position 181 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Tyr, Ala, Ile, Lys or Met at position 184 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 185 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 269 of SEQ ID No. 2), preferably Ala ;

h) Ile, Asn, Pro, Thr or Val at position 196 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 280 of SEQ ID No. 2), preferably Pro;

i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 206 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 293 of SEQ ID No. 2);

j) Met , Ala, Pro, Ser, Thr or Val at position 207 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 294 of SEQ ID No. 2);

k) His or Asn at position 220 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 307 of SEQ ID No. 2);

l) Ile, Met or Asn at position 244 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

m) Met at position 286 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 368 of SEQ ID No. 2);

n) Phe or Tyr at position 301 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 312 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 325 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Lys, Asn, Ala, Cys, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 327 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

r) Gly, Met, Pro or Thr at position 328 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 330 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ser, Ala, Gly, Lys or Asn at position 331 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 425 of SEQ ID No. 2);

u) Glu, Phe, Thr, Val, Gln or Ser at position 332 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

v) Ile, Met, Gln, Val or Phe at position 337 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 431 of SEQ ID No. 2);

w) Ala, Cys, Gly or Thr at position 145 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Ser, Thr or Tyr at position 167 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Leu or Met at position 186 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 270

of SEQ ID No. 2);

z) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 187 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 271 of SEQ ID No. 2);

5 aa) His at a position at position 299 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at a position at position 333 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 427 of SEQ ID No. 2).

10 **[0057]** In another embodiment of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 16 [*Blepharisma japonicum*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Ile, Leu or Met at position 209 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 250 of SEQ ID No. 2), preferably Ala or Phe;

15 b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 210 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg, Lys;

c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val, Tyr or Thr at position 211 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 252 of SEQ ID No. 2), preferably Glu or Tyr;

20 d) Phe, His, Gln, Val, Trp, Ile, Leu or Met at position 212 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 253 of SEQ ID No. 2), preferably Phe or Val;

e) Val or Met at position 224 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Tyr, Ala, Ile, Lys or Met at position 227 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 2268 of SEQ ID No. 2);

25 g) Ala or Thr at position 228 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 239 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 280 of SEQ ID No. 2);

30 i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 251 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 293 of SEQ ID No. 2);

j) Met, Ala, Pro, Ser, Thr or Val at position 252 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 294 of SEQ ID No. 2);

k) His or Asn at position 265 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 307 of SEQ ID No. 2);

35 l) Ile, Met or Asn at position 289 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

m) Met at position 323 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 368 of SEQ ID No. 2);

n) Tyr at position 336 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 347 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 292 of SEQ ID No. 2);

40 p) Tyr at position 359 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Lys, Asn, Ala, Cys, Glu, Gly, His, Leu, Met, Gln, Ser, Thr or Val at position 361 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

r) Ala, Met, Pro or Thr at position 362 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 422 of SEQ ID No. 2);

45 s) Ala, Ile or Val at position 364 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ser, Ala, Gly, Asn or Gln at position 365 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 425 of SEQ ID No. 2);

u) Glu, Phe, Thr, Val, Gln or Ser at position 366 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

50 v) Ile, Met, Gln, Val or Phe at position 371 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 431 of SEQ ID No. 2);

w) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 185 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 228 of SEQ ID No. 2);

55 x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 207 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 229 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 270 of SEQ ID No. 2);

EP 2 453 012 A1

- z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 230 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 271 of SEQ ID No. 2);
- aa) His at a position in an HPPD protein, said position corresponding to position 334 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 379 of SEQ ID No. 2);
- 5 bb) Arg at a position in an HPPD protein, said position corresponding to position 367 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 427 of SEQ ID No. 2).

[0058] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 18 [Rhodococcus RHA1 sp. ro0240], wherein the resulting amino acid sequence comprises at least one amino acid selected from

10

- a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile or Leu at position 231 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;
- b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 232 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;
- 15 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 233 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 252 of SEQ ID No. 2), preferably Ser or Tyr;
- d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 234 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- 20 e) Val or Met at position 246 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Met at position 249 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 250 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- 25 h) Ala, Ile, Asn, Thr or Val at position 261 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 273 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 293 of SEQ ID No. 2);
- 30 j) Met, Ala, Pro, Ser, Thr or Val at position 274 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 294 of SEQ ID No. 2);
- k) His or Asn at position 287 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 307 of SEQ ID No. 2);
- l) Ile, Met or Asn at position 311 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
- 35 m) Met at position 343 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 368 of SEQ ID No. 2);
- n) Tyr at position 356 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 381 of SEQ ID No. 2);
- o) Ser at position 367 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 392 of SEQ ID No. 2);
- p) Tyr at position 379 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 419 of SEQ ID No. 2);
- 40 q) Asp, Lys, Asn, Ala, Cys, Glu, Gly, His, Leu, Met, Gln, Ser, Thr or Val at position 381 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
- r) Ala, Met, Pro or Thr at position 382 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 422 of SEQ ID No. 2);
- s) Ala, Ile or Val at position 384 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 424 of SEQ ID No. 2);
- 45 t) Ile, Pro, Arg, Ser, Ala, Gly, Asn or Gln at position 385 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 425 of SEQ ID No. 2);
- u) Glu, Phe, Thr, Val, Gln or Ser at position 386 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;
- 50 v) Met, Gln, Phe, Val, Phe or Leu at position 391 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 431 of SEQ ID No. 2);
- w) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 207 of the amino acid sequence of SEQ ID No. 1 (corresponding to position 228 of SEQ ID No. 2)8;
- x) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 229 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 248 of SEQ ID No. 2);
- 55 y) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 270 of SEQ ID No. 2);
- z) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at a position in an HPPD protein, said position corresponding to

EP 2 453 012 A1

position 252 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 271 of SEQ ID No. 2);

aa) His at a position in an HPPD protein, said position corresponding to position 354 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at a position in an HPPD protein, said position corresponding to position 387 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 427 of SEQ ID No. 2).

[0059] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 30 [Rhodococcus RHA1 sp. 0341], wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile or Leu at position 232 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;

b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Tyr at position 233 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 234 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 252 of SEQ ID No. 2), preferably Ser or Tyr;

d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 235 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

e) Val or Met at position 247 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Met at position 250 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 251 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 280 of SEQ ID No. 2);

i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 274 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 293 of SEQ ID No. 2);

j) Met, Ala, Pro, Ser, Thr or Val at position 275 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 294 of SEQ ID No. 2);

k) His or Asn at position 288 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 307 of SEQ ID No. 2);

l) Ile, Met or Asn at position 312 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

m) Met at position 344 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 368 of SEQ ID No. 2);

n) Tyr at position 357 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 368 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 380 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Lys, Asn, Ala, Cys, Glu, Gly, His, Leu, Met, Gln, Ser, Thr or Val at position 382 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

r) Ala, Met, Pro or Thr at position 383 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 385 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ser, Ala, Gly, Asn or Gln at position 386 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 425 of SEQ ID No. 2);

u) Glu, Phe, Thr, Val, Gln or Ser at position 387 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

v) Met, Gln, Phe, Val, Phe or Leu at position 392 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 431 of SEQ ID No. 2);

w) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 208 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 230 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 270 of SEQ ID No. 2);

z) Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 271 of SEQ ID No. 2);

- aa) His at a position in an HPPD protein, said position corresponding to position 355 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 379 of SEQ ID No. 2);
 bb) Arg at a position in an HPPD protein, said position corresponding to position 388 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 427 of SEQ ID No. 2).

5

[0060] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 20 [*Picrophilus torridus*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

- 10 a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile or Met at position 201 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;
 b) Ala, Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser, Gly, His or Trp at position 202 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;
 15 c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 203 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 252 of SEQ ID No. 2), preferably Glu, Ser or Tyr;
 d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 204 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
 e) Val or Met at position 216 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 265 of SEQ ID No. 2);
 20 f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Met at position 219 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 268 of SEQ ID No. 2);
 g) Ala or Thr at position 220 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
 h) Ala, Ile, Asn, Thr or Val at position 230 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 280 of SEQ ID No. 2);
 25 i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 242 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 293 of SEQ ID No. 2);
 j) Met, Ala, Pro, Ser, Thr or Val at position 243 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 294 of SEQ ID No. 2);
 30 k) His or Asn at position 256 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 307 of SEQ ID No. 2);
 1) Ile, Met or Asn at position 280 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
 m) Met at position 310 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 368 of SEQ ID No. 2);
 35 n) Phe or Tyr at position 323 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 381 of SEQ ID No. 2);
 o) Ser at position 334 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 392 of SEQ ID No. 2);
 p) Tyr at position 346 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 419 of SEQ ID No. 2);
 q) Asp, Phe, Lys, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 348 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
 40 r) Ala, Met, Pro or Thr at position 349 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 422 of SEQ ID No. 2);
 s) Ala, Ile or Val at position 351 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 424 of SEQ ID No. 2);
 45 t) Ile, Pro, Arg, Ser, Ala, Gly, Lys or Gln at position 352 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 425 of SEQ ID No. 2);
 u) Glu, Phe, Thr, Val, Ala or Gln at position 353 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;
 v) Met, Gln, Phe, Val, Phe or Leu at position 358 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 431 of SEQ ID No. 2);
 50 w) Ala, Cys, Gly or Thr at position 177 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 228 of SEQ ID No. 2);
 x) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 199 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 248 of SEQ ID No. 2);
 55 y) Ala, Ile, Leu or Met at a position at position 221 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 270 of SEQ ID No. 2);
 z) Ala, Glu, His, Ile, Leu, Met, Arg, Ser, Thr or Val at position 222 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 271 of SEQ ID No. 2);

EP 2 453 012 A1

- aa) His at position 321 of the amino acid sequence of SEQ ID No. 20
(corresponding to position 379 of SEQ ID No. 2);
bb) Arg at position 354 of the amino acid sequence of SEQ ID No. 20
(corresponding to position 427 of SEQ ID No. 2).

5

[0061] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 22 [*Kordia algicida*], wherein the resulting amino acid sequence comprises at least one amino acid selected from

- 10 a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Leu or Met at position 219 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;
b) Ala, Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser, Gly, His or Trp at position 220 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;
15 c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val, Tyr or Thr at position 221 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 252 of SEQ ID No. 2), preferably Glu or Tyr;
d) Ala, His, Gln, Val Trp, Ile, Leu or Met at position 222 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
e) Val or Met at position 234 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 265 of SEQ ID No. 2);
20 f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Met at position 237 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 268 of SEQ ID No. 2);
g) Ala or Thr at position 238 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
h) Ala, Ile, Asn, Thr or Val at position 249 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 280 of SEQ ID No. 2);
25 i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 261 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 293 of SEQ ID No. 2);
j) Met, Ala, Pro, Ser, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 294 of SEQ ID No. 2);
30 k) His or Asn at position 275 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 307 of SEQ ID No. 2);
l) Ile, Met or Asn at position 299 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
m) Met at position 329 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 368 of SEQ ID No. 2);
35 n) Tyr at position 342 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 381 of SEQ ID No. 2);
o) Ser at position 353 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 392 of SEQ ID No. 2);
p) Tyr at position 365 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 419 of SEQ ID No. 2);
q) Asp, Phe, Lys, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser or Thr at position 367 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
40 r) Ala, Met, Pro or Thr at position 368 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 422 of SEQ ID No. 2);
s) Ala, Ile or Val at position 370 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 424 of SEQ ID No. 2);
t) Ile, Pro, Arg, Ser, Ala, Gly, Asn or Gln at position 371 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 425 of SEQ ID No. 2);
45 u) Glu, Phe, Thr, Val, Gln or Ser at position 372 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;
v) Met, Gln, Phe, Val, Phe or Leu at position 377 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 431 of SEQ ID No. 2);
50 w) Ala, Cys, Gly or Thr at position 195 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 228 of SEQ ID No. 2);
x) Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 217 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 248 of SEQ ID No. 2);
y) Ala, Ile, Leu or Val at position 239 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 270 of SEQ ID No. 2);
55 z) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at position 240 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 271 of SEQ ID No. 2);
aa) His at a position at position 340 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 379

EP 2 453 012 A1

of SEQ ID No. 2);

bb) Arg at a position at position 373 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 427 of SEQ ID No. 2).

5 **[0062]** In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 24 [Sorghum bicolor], wherein the resulting amino acid sequence comprises at least one amino acid selected from

10 a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 241 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 250 of SEQ ID No. 2), preferably Ala;

b) Asp, Glu, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Trp at position 242 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val, Tyr or Thr at position 243 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;

15 d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 244 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

e) Val or Met at position 256 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 265 of SEQ ID No. 2);

20 f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Lys at position 259 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 260 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 280 of SEQ ID No. 2);

25 i) Leu or Val, Ala, Phe, Gly, Met, Arg or Ser at position 284 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 293 of SEQ ID No. 2);

j) Met, Ala, Pro, Ser, Thr or Val at position 285 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 294 of SEQ ID No. 2);

30 k) His or Asn at position 298 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 307 of SEQ ID No. 2);

l) Ile, Asn or Leu at position 326 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 335 of SEQ ID No. 2);

m) Met at position 359 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 368 of SEQ ID No. 2);

35 n) Tyr at position 372 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 381 of SEQ ID No. 2);

o) Ser at position 383 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 392 of SEQ ID No. 2);

p) Tyr at position 410 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 419 of SEQ ID No. 2);

q) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 412 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 421 of SEQ ID No. 2);

40 r) Ala, Met, Pro or Thr at position 413 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 422 of SEQ ID No. 2);

s) Ala, Ile or Val at position 415 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 424 of SEQ ID No. 2);

t) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 416 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 425 of SEQ ID No. 2);

45 u) Phe, Thr, Val, Ala, Gln or Ser at position 417 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 426 of SEQ ID No. 2);

v) Met, Gln, Phe, Val, Phe or Leu at position 422 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 431 of SEQ ID No. 2);

50 w) Ala, Cys, Gly or Thr at position 219 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 228 of SEQ ID No. 2);

x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 239 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 248 of SEQ ID No. 2);

y) Ala, Ile, Met or Val at position 261 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 270 of SEQ ID No. 2);

55 z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 271 of SEQ ID No. 2);

aa) His at position 370 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 379 of SEQ ID No. 2);

bb) Arg at position 418 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 427 of SEQ ID No. 2).

EP 2 453 012 A1

[0063] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 26 [*Triticum aestivum* / wheat], wherein the resulting amino acid sequence comprises at least one amino acid selected from

- 5 a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 237 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 250 of SEQ ID No. 2), preferably Ala;
- b) Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser, Gly, His or Trp at position 238 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;
- 10 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val or Tyr or Thr at position 239 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;
- d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 240 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- e) Val or Met at position 252 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 265 of SEQ ID No. 2);
- 15 f) Leu, Gln, Arg, Val, Tyr, Ala, Ile or Lys at position 255 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 256 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 267 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 280 of SEQ ID No. 2);
- 20 i) Leu, Val, Ala, Phe, Gly, Met, Arg or Ser at position 280 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 293 of SEQ ID No. 2);
- j) Met, Ala, Pro, Ser, Thr or Val at position 281 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 294 of SEQ ID No. 2);
- 25 k) His or Asn at position 294 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 307 of SEQ ID No. 2);
- l) Ile, Met or Asn at position 322 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
- m) Met at position 355 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 368 of SEQ ID No. 2);
- 30 n) Tyr at position 368 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 381 of SEQ ID No. 2);
- o) Ser at position 379 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 392 of SEQ ID No. 2);
- p) Tyr at position 406 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 419 of SEQ ID No. 2);
- q) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 408 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 421 of SEQ ID No. 2);
- 35 r) Ala, Met, Pro or Thr at position 409 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 422 of SEQ ID No. 2);
- s) Ala, Ile or Val at position 411 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 424 of SEQ ID No. 2);
- t) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 412 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 425 of SEQ ID No. 2);
- 40 u) Phe, Thr or Val, Ala, Gln or Ser at position 413 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 426 of SEQ ID No. 2);
- v) Met, Gln, Phe, Leu or Val at position 418 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 431 of SEQ ID No. 2);
- 45 w) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 215 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 228 of SEQ ID No. 2);
- x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 235 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 248 of SEQ ID No. 2);
- y) Ala, Ile, Met or Val at position 257 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 270 of SEQ ID No. 2);
- 50 z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 258 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 271 of SEQ ID No. 2);
- aa) His at a position at position 366 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 379 of SEQ ID No. 2);
- 55 bb) Arg at position 414 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 427 of SEQ ID No. 2).

[0064] In another embodiment, of the isolated nucleic acid of the invention, said HPPD protein comprises the amino acid sequence of SEQ ID No. 2 [*Arabidopsis thaliana*], wherein the resulting amino acid sequence comprises at least

one amino acid selected from

- (a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val, Tyr, Ile, Leu or Met at position 250 of the amino acid sequence of SEQ ID No. 2;
- 5 (b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Ser, Gly, His or Trp at position 251 of the amino acid sequence of SEQ ID No. 2;
- (c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Tyr or Thr at position 252 of the amino acid sequence of SEQ ID No. 2;
- (d) Ala, His, Gln, Val, Trp, Ile, Leu or Met at position 253 of the amino acid sequence of SEQ ID No. 2;
- 10 (e) Val or Met at a position at position 265 of the amino acid sequence of SEQ ID No. 2;
- (f) Leu, Gln, Arg, Val, Tyr, Ile, Lys or Met at position 268 of the amino acid sequence of SEQ ID No. 2;
- (g) Ala or Thr at position 269 of the amino acid sequence of SEQ ID No. 2;
- (h) Ala, Ile, Asn, Thr or Val at position 280 of the amino acid sequence of SEQ ID No. 2;
- (i) Gln, Val, Ala, Phe, Gly, Met, Arg or Ser at a in an HPPD protein, said position corresponding to position 293 of
- 15 the amino acid sequence of SEQ ID No. 2;
- (j) Met, Ala, Pro, Ser, Thr or Val at position 294 of the amino acid sequence of SEQ ID No. 2;
- (k) His or Asn at position 307 of the amino acid sequence of SEQ ID No. 2;
- (l) Ile, Asn or Leu at position 335 of the amino acid sequence of SEQ ID No. 2;
- (m) Met at position 368 of the amino acid sequence of SEQ ID No. 2;
- 20 (n) Tyr at position 381 of the amino acid sequence of SEQ ID No. 2;
- (o) Ser at position 392 of the amino acid sequence of SEQ ID No. 2;
- (p) Tyr at position 419 of the amino acid sequence of SEQ ID No. 2;
- (q) Asp, Phe, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at position 421 of the amino acid sequence of SEQ ID No. 2 ;
- 25 (r) Ala, Met, Pro or Thr at position 422 of the amino acid sequence of SEQ ID No. 2;
- (s) Ala, Ile or Val at position 424 of the amino acid sequence of SEQ ID No. 2;
- (t) Ile, Pro, Arg, Ala, Gly, Lys, Asn or Gln at position 425 of the amino acid sequence of SEQ ID No. 2;
- (u) Phe, Thr, Val, Ala, Gln or Ser at position 426 of the amino acid sequence of SEQ ID No. 2;
- (v) Met, Gln, Val, Phe or Leu position 431 of the amino acid sequence of SEQ ID No. 2;
- 30 (w) Ala, Cys, Gly or Thr at position 228 of the amino acid sequence of SEQ ID No. 2;
- (x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 248 of the amino acid sequence of SEQ ID No. 2;
- (y) Ala, Ile, Met or Val at position 270 of the amino acid sequence of SEQ ID No. 2;
- (z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 2;
- (aa) His at position 379 of the amino acid sequence of SEQ ID No. 2; or
- 35 (bb) Arg at position 427 of the amino acid sequence of SEQ ID No. 2.

[0065] In a further embodiment of the nucleic acid of the invention, in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises (a) Glu, Ser or Tyr at position 252; (b) Val or Ala at position 269; (c) Pro, Val or Ala at position 280; (d) Asp, Lys or Asn at position 421; and (e) Gly or Ala at position 422. These positions correspond to amino acid sequence of SEQ ID No 2.

[0066] In a further embodiment of the nucleic acid of the invention, in said mutated HPPD protein at least two amino acids have been replaced.

[0067] An isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, wherein in said mutated HPPD protein at least one amino acid at position 228, 248, 270, 271, 379 and/or 427 has been replaced by another amino acid.

[0068] In an alternative embodiment of the nucleic acid of the invention having at least one amino acid at position 228, 248, 270, 271, 379 and/or 427 deleted or replaced by another amino acid as defined above, said mutated HPPD protein comprises

- a) a His at a position in an HPPD protein, said position corresponding to position 226 of the amino acid sequence of SEQ ID No. 2;
- b) a Ser at a position in an HPPD protein, said position corresponding to position 267 comprising the amino acid sequence of SEQ ID No. 2 or at a position corresponding thereto in a different HPPD enzyme;
- 55 c) an Asn at a position in an HPPD protein, said position corresponding to position 282 of the amino acid sequence of SEQ ID No. 2;
- d) a His at a position in an HPPD protein, said position corresponding to position 308 of the amino acid sequence of SEQ ID No. 2;

EP 2 453 012 A1

- e) a Tyr at a position in an HPPD protein, said position corresponding to position 342 of the amino acid sequence of SEQ ID No. 2;
- f) a Glu at a position in an HPPD protein, said position corresponding to position 394 of the amino acid sequence of SEQ ID No. 2;
- 5 g) a Gly at a position in an HPPD protein, said position corresponding to position 420 of the amino acid sequence of SEQ ID No. 2; and
- h) an Asn at a position in an HPPD protein, said position corresponding to position 423 of the amino acid sequence of SEQ ID No. 2.

10 **[0069]** In another embodiment of the isolated nucleic acid as defined above, in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence has at least one selected from

- a. Ala, Cys, Gly, Thr or Val at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- 15 b. Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;
- c. Ala, Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- 20 d. Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;
- e. His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2; and
- f. Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

25 **[0070]** In another embodiment of the isolated nucleic acid as defined above, in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence has at least one selected from

- a. Val or Thr at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- 30 b. Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- c. Ala or Ser at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2,
- 35 d. Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2; and
- e. Leu at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

40 **[0071]** In another embodiment of the nucleic acid as defined above, said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD (also called HPPD inhibitor herbicide).

[0072] In another embodiment, the present invention relates to a protein encoded by the isolated nucleic acid of the invention.

45 **[0073]** In a further embodiment, the present invention relates to a chimeric gene comprising a coding sequence comprising the nucleic acid of the invention operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region.

[0074] As a regulatory sequence which functions as a promoter in plant cells and plants, use may be made of any promoter sequence of a gene which is naturally expressed in plants, in particular a promoter which is expressed especially in the leaves of plants, such as for example "constitutive" promoters of bacterial, viral or plant origin, or "light-dependent" promoters, such as that of a plant ribulose-biscarboxylase/oxygenase (RuBisCO) small subunit gene, or any suitable known promoter-expressible which may be used. Among the promoters of plant origin, mention will be made of the histone promoters as described in EP 0 507 698 A1, the rice actin promoter (US 5,641,876), or a plant ubiquitin promoter (US 5,510,474). Among the promoters of a plant virus gene, mention will be made of that of the cauliflower mosaic virus (CaMV 19S or 35S, Sanders et al. (1987), Nucleic Acids Res. 15(4):1543-58.), the circovirus (AU 689 311) or the Cassava vein mosaic virus (CsVMV, US 7,053,205).

55 **[0075]** In one embodiment of this invention, a promoter sequence specific for particular regions or tissues of plants can be used to express the HPPD proteins of the invention, such as promoters specific for seeds (Datla, R. et al., 1997, Biotechnology Ann. Rev. 3, 269-296), especially the napin promoter (EP 255 378 A1), the phaseolin promoter, the

EP 2 453 012 A1

glutenin promoter, the helianthinin promoter (WO 92/17580), the albumin promoter (WO 98/45460), the oleosin promoter (WO 98/45461), the SAT1 promoter or the SAT3 promoter (PCT/US98/06978).

[0076] Use may also be made of an inducible promoter advantageously chosen from the phenylalanine ammonia lyase (PAL), HMG-CoA reductase (HMG), chitinase, glucanase, proteinase inhibitor (PI), PR1 family gene, nopaline synthase (nos) and vspB promoters (US 5 670 349, Table 3), the HMG2 promoter (US 5 670 349), the apple beta-galactosidase (ABG1) promoter and the apple aminocyclopropane carboxylate synthase (ACC synthase) promoter (WO 98/45445).

[0077] According to the invention, use may also be made, in combination with the promoter, of other regulatory sequences, which are located between the promoter and the coding sequence, such as transcription activators ("enhancers"), for instance the translation activator of the tobacco mosaic virus (TMV) described in Application WO 87/07644, or of the tobacco etch virus (TEV) described by Carrington & Freed 1990, J. Virol. 64: 1590-1597, for example, or introns such as the adh1 intron of maize or intron 1 of rice actin.

[0078] As a regulatory terminator or polyadenylation sequence, use may be made of any corresponding sequence of bacterial origin, such as for example the nos terminator of *Agrobacterium tumefaciens*, of viral origin, such as for example the CaMV 35S terminator, or of plant origin, such as for example a histone terminator as described in published Patent Application EP 0 633 317 A1.

[0079] A method of obtaining a mutated HPPD protein capable of modulating the tolerance of a plant to at least one herbicide acting on HPPD, wherein said mutated HPPD protein has HPPD activity, the method comprising

i. providing an HPPD protein, said HPPD optionally comprising an amino acid sequence, wherein

- a) a His is present at a position in an HPPD protein, said position corresponding to position 226 of the amino acid sequence of SEQ ID No. 2;
- b) a Ser is present at a position in an HPPD protein, said position corresponding to position 267 of the amino acid sequence of SEQ ID No. 2;
- c) an Asn is present at a position in an HPPD protein, said position corresponding to position 282 of the amino acid sequence of SEQ ID No. 2;
- d) a His is present at a position in an HPPD protein, said position corresponding to position 308 of the amino acid sequence of SEQ ID No. 2;
- e) a Tyr is present at a position in an HPPD protein, said position corresponding to position 342 of the amino acid sequence of SEQ ID No. 2;
- f) a Glu is present at a position in an HPPD protein, said position corresponding to position 394 of the amino acid sequence of SEQ ID No. 2;
- g) a Gly is present at a position in an HPPD protein, said position corresponding to position 420 of the amino acid sequence of SEQ ID No. 2; and
- h) an Asn is present at a position in an HPPD protein, said position corresponding to position 423 of the amino acid sequence of SEQ ID No. 2

ii. replacing at least one amino acid in said HPPD enzyme so that the resulting amino acid sequence has at least one selected from

- a. Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val, Ile, Leu, Met or Tyr at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
- b. Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg, Gly, His, Tyr or Ser at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 2;
- c. Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;
- d. Ala, Phe, His, Gln, Val, Ile, Leu, Met or Trp at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;
- e. Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;
- f. Leu, Gln, Arg, Val, Ala, Ile, Lys, Met or Tyr at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID No. 2;
- g. Ala, Thr or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;
- h. Ala, Ile, Asn, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- i. Leu, Gln, Ala, Phe, Gly, Met, Arg, Ser or Val at a position in an HPPD protein, said position corresponding to

- position 293 of the amino acid sequence of SEQ ID No. 2;
- j. Ile, ala, Pro, Ser, Thr, Val or Met at a position in an HPPD protein, said position corresponding to position 294 of the amino acid sequence of SEQ ID No. 2;
- k. Gln, His or Asn at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;
- l. Ile, Met, Leu or Asn at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- m. Leu or Met at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- n. Phe or Tyr at a position in an HPPD protein, said position corresponding to position 381 of the amino acid sequence of SEQ ID No. 2;
- o. Phe or Ser at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;
- p. Phe or Tyr at a position in an HPPD protein, said position corresponding to position 419 of the amino acid sequence of SEQ ID No. 2;
- q. Asp, Phe, Lys, Asn, Ala, Cys, Glu, Gly, His, Ile, Leu, Met, Gln, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- r. Ala, Gly, Met, Pro or Thr at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- s. Ala, Phe, Ile or Val at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 2 or;
- t. Ile, Pro, Arg, Ala, Gly, Lys, Asn, Gln or Ser at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2;
- u. Glu, Phe, Thr, Ala, Gln, Ser or Val at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;
- v. Ile, Met, Gln, Phe, Leu or Val at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2;
- w. an amino acid deletion or replacement at least one position in an HPPD protein, said position corresponding to at least one of positions 228, 248, 270, 271, 379 and 427 of the amino acid sequence of SEQ ID No. 2;

iii. determining the inhibition of the resulting HPPD protein by at least one herbicide acting on HPPD;

wherein an inhibition of the resulting protein of less or more than that observed with a reference HPPD protein is indicative that the resulting protein is capable of modulating the tolerance of a plant to said herbicide.

[0080] It is to be understood that also the (more specific) amino acids and positions listed above for other embodiments, such as the nucleic acid of the invention, may be applied to the method of obtaining a mutated HPPD protein as described above.

[0081] In an alternative embodiment of the method of obtaining a mutated HPPD protein as described above, said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD.

[0082] Within the above method of obtaining in mutated HPPD protein, different herbicides acting on HPPD may be chosen. Accordingly, in another embodiment of the method of obtaining a mutated HPPD protein as described above, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, the herbicide acting on HPPD is selected from triketones, or pyrazolines, preferably tembotrione, mesotrione, topramezone or sulcotrione, bicyclopiron, pyrasulfotole, pyrazolate, benzofenap and tefuryltrione, particularly tembotrione and such plants containing the HPPD of the invention have an agronomically acceptable tolerance to an HPPD inhibitor herbicide particularly to triketones, or pyrazolines, preferably tembotrione, mesotrione, topramezone or sulcotrione, bicyclopiron, pyrasulfotole, pyrazolate, benzofenap and tefuryltrione, particularly tembotrione.

[0083] In another embodiment, the present invention relates to a method of producing a transgenic plant comprising introducing into a said plant genome the nucleic acid of the present invention operably linked to a plant expressible promoter, the chimeric gene of the invention or a nucleic acid encoding the HPPD enzyme identified by the method of of claim 27 or 28.

[0084] In an alternative embodiment of the method of producing a transgenic plant as described above, the nucleic acid of the invention, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, or a nucleic acid identified by the method of obtaining a mutated HPPD protein, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, both operably linked to a plant expressible promoter, or the chimeric gene of the invention comprising a nucleic acid, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, is introduced into said plant.

[0085] In another embodiment, the present invention relates to a plant cell comprising the isolated nucleic acid of the invention or the chimeric gene of the invention in its genetic information.

[0086] The present invention also relates to a plant, a part of a plant or plant tissue consisting essentially of the plant cells of the invention.

5 [0087] Furthermore, the present invention relates to a plant obtainable from the method of obtaining a mutated HPPD protein capable of modulating or increasing the tolerance of a plant to at least one herbicide acting on HPPD in all alternative aspects described above.

[0088] The plant of the present invention can be any plant. Non-limiting examples of plants of the invention include wheat, cotton, canola, rice, corn, soy bean, sorghum, canola, sunflower, tobacco, sugarbeet, cotton, maize, wheat, barley, 10 rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, cabbage, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax and oilseed rape, and nut producing plants. The present invention also relates to a seed of the plant of the invention. Furthermore, the invention relates to progeny of the plant of the invention or the seed of the invention.

15 [0089] In a further embodiment, the present invention relates to a method of modulating a plant's tolerance to at least one herbicide acting on HPPD comprising introducing the isolated nucleic acid of the invention operably linked to a plant expressible promoter or the chimeric gene of the invention into a plant's genome

[0090] In an alternative embodiment, the present invention relates to a method of increasing a plant's tolerance to at least one herbicide acting on HPPD or of obtaining a plant tolerant to an HPPD inhibitor herbicide comprising introducing the isolated nucleic acid of the invention, wherein said nucleic acid encodes a mutated HPPD protein which is capable 20 of increasing the tolerance of a plant to at least one herbicide acting on HPPD, operably linked to a plant expressible promoter or the chimeric gene of the invention comprising a nucleic acid of the invention, wherein said nucleic acid encodes a mutated HPPD protein which is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, into a plant's genome.

25 [0091] Furthermore, the present invention relates to a method for controlling weeds comprising spraying at least one herbicide acting on HPPD on or around a crop plant, wherein said crop plant comprises the nucleic acid of the present invention, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD, operably linked to a plant expressible promoter or the chimeric gene of the invention comprising the nucleic acid of the invention, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at 30 least one herbicide acting on HPPD. In alternative embodiment of the method of controlling weeds, the tolerance of said plant to at least one herbicide acting on HPPD is increased.

[0092] In addition, the present invention relates to the use of a chimeric gene of the invention or the nucleic acid of the invention operably linked to a plant expressible promoter for modulating the tolerance of a plant to at least one herbicide acting on HPPD.

35 [0093] In an alternative embodiment, the present invention relates to the use of a chimeric gene of the invention or the nucleic acid of the invention operably linked to a plant expressible promoter for increasing the tolerance of a plant to at least one herbicide acting on HPPD. In this embodiment of the invention, the chimeric gene used comprises the nucleic acid of the invention, wherein the mutated HPPD protein encoded thereby is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD. Alternatively, if a nucleic acid operably linked to a plant expressible promoter is used, said nucleic acid is chosen such that the mutated HPPD protein encoded thereby is capable of increasing the 40 tolerance of a plant to at least one herbicide acting on HPPD.

[0094] The present invention also relates to the plant cell of the invention and the plant of the invention which may comprise a further useful trait as described further below.

45 [0095] While a number of herbicide-tolerant crop plants are presently commercially available, one issue that has arisen for many commercial herbicides and herbicide/crop combinations is that individual herbicides typically have incomplete spectrum of activity against common weed species. For most individual herbicides which have been in use for some time, populations of herbicide resistant weed species and biotypes have become more prevalent (see, e.g., Tranel and Wright (2002) Weed Science 50: 700-712; Owen and Zelaya (2005) Pest Manag. Sci. 61: 301-311). Transgenic plants which are resistant to more than one herbicide have been described (see, e.g., WO2005/012515). However, improvements in every aspect of crop production, weed control options, extension of residual weed control, and improvement in crop 50 yield are continuously in demand.

[0096] The HPPD protein or gene of the invention is advantageously combined in plants with other genes which encode proteins or RNAs that confer useful agronomic properties to such plants. Among the genes which encode proteins or RNAs that confer useful agronomic properties on the transformed plants, mention can be made of the DNA sequences encoding proteins which confer tolerance to one or more herbicides that, according to their chemical structure, differ 55 from HPPD inhibitor herbicides, and others which confer tolerance to certain insects, those which confer tolerance to certain diseases, DNAs that encodes RNAs that provide nematode or insect control, etc...

[0097] Such genes are in particular described in published PCT Patent Applications WO 91/02071 and WO95/06128.

[0098] Among the DNA sequences encoding proteins which confer tolerance to certain herbicides on the transformed

plant cells and plants, mention can be made of a bar or PAT gene or the *Streptomyces coelicolor gene* described in WO2009/152359 which confers tolerance to glufosinate herbicides, a gene encoding a suitable EPSPS which confers tolerance to herbicides having EPSPS as a target, such as glyphosate and its salts (US 4,535,060, US 4,769,061, US 5,094,945, US 4,940,835, US 5,188,642, US 4,971,908, US 5,145,783, US 5,310,667, US 5,312,910, US 5,627,061, US 5,633,435), or a gene encoding glyphosate oxydoreductase (US 5,463,175).

[0099] Among the DNA sequences encoding a suitable EPSPS which confer tolerance to the herbicides which have EPSPS as a target, mention will more particularly be made of the gene which encodes a plant EPSPS, in particular maize EPSPS, particularly a maize EPSPS which comprises two mutations, particularly a mutation at amino acid position 102 and a mutation at amino acid position 106 (WO 2004/074443), and which is described in Patent Application US 6566587, hereinafter named double mutant maize EPSPS or 2mEPSPS, or the gene which encodes an EPSPS isolated from *Agrobacterium* and which is described by sequence ID No. 2 and sequence ID No. 3 of US Patent 5,633,435, also named CP4.

[0100] Among the DNA sequences encoding a suitable EPSPS which confer tolerance to the herbicides which have EPSPS as a target, mention will more particularly be made of the gene which encodes an EPSPS GRG23 from *Arthro-bacter globiformis*, but also the mutants GRG23 ACE1, GRG23 ACE2, or GRG23 ACE3, particularly the mutants or variants of GRG23 as described in WO2008/100353, such as GRG23(ace3)R173K of SEQ ID No. 29 in WO2008/100353.

[0101] In the case of the DNA sequences encoding EPSPS, and more particularly encoding the above genes, the sequence encoding these enzymes is advantageously preceded by a sequence encoding a transit peptide, in particular the "optimized transit peptide" described in US Patent 5,510,471 or 5,633,448.

[0102] In WO 2007/024782, plants being tolerant to glyphosate and at least one ALS (acetolactate synthase) inhibitor are disclosed. More specifically plants containing genes encoding a GAT (Glyphosate-N-Acetyltransferase) polypeptide and a polypeptide conferring resistance to ALS inhibitors are disclosed. In US 6855533, transgenic tobacco plants containing mutated *Arabidopsis* ALS/AHAS genes were disclosed.

[0103] In US 6,153,401, plants containing genes encoding 2,4-D-monooxygenases conferring tolerance to 2,4-D (2,4-dichlorophenoxyacetic acid) by metabolisation are disclosed.

[0104] In US 2008/0119361 and US 2008/0120739, plants containing genes encoding Dicamba monooxygenases conferring tolerance to dicamba (3,6-dichloro-2-methoxybenzoic acid) by metabolisation are disclosed.

[0105] All the above mentioned herbicide tolerance traits can be combined with those performing HPPD tolerance which are subject matter of this invention.

[0106] Among the DNA sequences encoding proteins concerning properties of tolerance to insects, mention will more particularly be made of the Bt proteins widely described in the literature and well known to those skilled in the art. Mention will also be made of proteins extracted from bacteria such as *Photorhabdus* (WO 97/17432 & WO 98/08932).

[0107] Among such DNA sequences encoding proteins of interest which confer novel properties of tolerance to insects, mention will more particularly be made of the Bt Cry or VIP proteins widely described in the literature and well known to those skilled in the art. These include the Cry1 F protein or hybrids derived from a Cry1 F protein (e.g., the hybrid Cry1A-Cry1F proteins described in US 6,326,169; US 6,281,016; US 6,218,188, or toxic fragments thereof), the Cry1A-type proteins or toxic fragments thereof, preferably the Cry1Ac protein or hybrids derived from the Cry1Ac protein (e.g., the hybrid Cry1Ab-Cry1Ac protein described in US 5,880,275) or the Cry1Ab or Bt2 protein or insecticidal fragments thereof as described in EP451878, the Cry2Ae, Cry2Af or Cry2Ag proteins as described in WO02/057664 or toxic fragments thereof, the Cry1A.105 protein described in WO 2007/140256 (SEQ ID No. 7) or a toxic fragment thereof, the VIP3Aa19 protein of NCBI accession ABG20428, the VIP3Aa20 protein of NCBI accession ABG20429 (SEQ ID No. 2 in WO 2007/142840), the VIP3A proteins produced in the COT202 or COT203 cotton events (WO 2005/054479 and WO 2005/054480, respectively), the Cry proteins as described in WO01/47952, the VIP3Aa protein or a toxic fragment thereof as described in Estruch et al. (1996), Proc Natl Acad Sci U S A. 28;93(11):5389-94 and US 6,291,156, the insecticidal proteins from *Xenorhabdus* (as described in WO98/50427), *Serratia* (particularly from *S. entomophila*) or *Photorhabdus* species strains, such as Tc-proteins from *Photorhabdus* as described in WO98/08932 (e.g., Waterfield et al., 2001, Appl Environ Microbiol. 67(11):5017-24; Ffrench-Constant and Bowen, 2000, Cell Mol Life Sci.; 57(5):828-33). Also any variants or mutants of any one of these proteins differing in some (1-10, preferably 1-5) amino acids from any of the above sequences, particularly the sequence of their toxic fragment, or which are fused to a transit peptide, such as a plastid transit peptide, or another protein or peptide, is included herein.

[0108] The FIGURES show:

FIGURE1: Superposition of the x-ray structure of HPPD from *Arabidopsis thaliana* (dark grey) and (a) *Pseudomonas fluorescens* (light grey), (b) *Streptomyces avermitilis*, (c) *Homo sapiens*, (d) *Rattus norvegicus*. The structures are shown as ribbon plot.

FIGURE2: Amino acids forming the binding site of (a) *Arabidopsis thaliana*, (b) *Pseudomonas fluorescens* (c) *Streptomyces avermitilis* (d) *Homo sapiens*, and (e) *Rattus norvegicus* (represented by bold lines). The core

EP 2 453 012 A1

of the HPPD protein is shown as C_{alpha} trace and the iron is marked.

FIGURE3: Brown test color in *Escherichia coli*

5 SEQUENCES LISTING

[0109]

- 10 SEQ ID No. 1: Nucleic acid sequence encoding *Arabidopsis thaliana* HPPD
- SEQ ID No. 2: Protein encoded by SEQ ID No. 1
- SEQ ID No. 3: Nucleic acid sequence encoding *Oryza sativa* HPPD
- 15 SEQ ID No. 4: Protein encoded by SEQ ID No. 3
- SEQ ID No. 5: Nucleic acid sequence encoding *Zea mays* HPPD
- SEQ ID No. 6: Protein encoded by SEQ ID No. 5
- 20 SEQ ID No. 7: Nucleic acid sequence encoding *Avena sativa* HPPD
- SEQ ID No. 8: Protein encoded by SEQ ID No. 7
- 25 SEQ ID No. 9: Nucleic acid sequence encoding *Pseudomonas fluorescens* HPPD
- SEQ ID No. 10: Protein encoded by SEQ ID No. 9
- SEQ ID No. 13: Nucleic acid sequence encoding *Synechococcus* sp. HPPD
- 30 SEQ ID No. 14: Protein encoded by SEQ ID No. 13
- SEQ ID No. 15: Nucleic acid sequence encoding *Blepharsima japonicum* HPPD
- 35 SEQ ID No. 16: Protein encoded by SEQ ID No. 15
- SEQ ID No. 17: Nucleic acid sequence encoding *Rhodococcus* RHA1 isolate ro0341 HPPD
- SEQ ID No. 18: Protein encoded by SEQ ID No. 17
- 40 SEQ ID No. 19: Nucleic acid sequence encoding *Picrophilus torridus* HPPD
- SEQ ID No. 20: Protein encoded by SEQ ID No. 19
- 45 SEQ ID No. 21: Nucleic acid sequence encoding *Kordia algicida* HPPD
- SEQ ID No. 22: Protein encoded by SEQ ID No. 21
- SEQ ID No. 23: Nucleic acid sequence encoding *Sorghum bicolor* HPPD
- 50 SEQ ID No. 24: Protein encoded by SEQ ID No. 23
- SEQ ID No. 25: Nucleic acid sequence encoding *Triticum aestivum* HPPD
- 55 SEQ ID No. 26: Protein encoded by SEQ ID No. 25
- SEQ ID No. 27: Nucleic acid sequence encoding *Hordeum vulgare* HPPD

EP 2 453 012 A1

- SEQ ID No. 28: Protein encoded by SEQ ID No. 27
- SEQ ID No. 29: Nucleic acid sequence encoding Rhodococcus RHA1 isolate ro0240 HPPD
- 5 SEQ ID No. 30: Protein encoded by SEQ ID No. 29
- SEQ ID No. 31: Nucleic acid sequence encoding Arabidopsis thaliana wild type HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 10 SEQ ID No. 32: Protein encoded by SEQ ID No. 31
- SEQ ID No. 33: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 15 SEQ ID No. 34: Protein encoded by SEQ ID No. 33,
- SEQ ID No. 35: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 20 SEQ ID No. 36: Protein encoded by SEQ ID No. 35,
- SEQ ID No. 37: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 25 SEQ ID No. 38: Protein encoded by SEQ ID No. 37,
- SEQ ID No. 39: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 30 SEQ ID No. 40: Protein encoded by SEQ ID No. 39,
- SEQ ID No. 41: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 35 SEQ ID No. 42: Protein encoded by SEQ ID No. 41,
- SEQ ID No. 43: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 40 SEQ ID No. 44: Protein encoded by SEQ ID No. 43,
- SEQ ID No. 45: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 45 SEQ ID No. 46: Protein encoded by SEQ ID No. 45
- SEQ ID No. 47: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 50 SEQ ID No. 48: Protein encoded by SEQ ID No. 47
- SEQ ID No. 49: Nucleic acid sequence encoding mutant HPPD polypeptide, plus containing at the 5' end a nucleic acid encoding an alanine and 6 histidine amino acids
- 55 SEQ ID No. 50: Protein encoded by SEQ ID No. 49,

[0110] The Examples illustrate the invention

Example1:

[0111] A mutation of strictly conserved amino acids leads to an inactive protein.

[0112] The point mutants S267A (SEQ ID No. 34) in *A. thaliana* and N282A (SEQ ID No. 36) in *A. thaliana* are inactive. The amino acid position given are referring to the position of SEQ ID No. 2.

[0113] Mutant HPPD polypeptides of the presenting invention have amino acids changes at one or more positions relative to the starting wild type sequence from which they are derived.

[0114] The DNA sequence SEQ ID No. 2 encoding the wild HPPD protein from *Arabidopsis thaliana* (1335 bp; Genebank AF047834; WO 96/38567) was cloned into the vector pSE420(RI)NX (modified from the the cloning and expression vector pSE420(RI)NX (5261 bp) is based on the plasmid pSE420 by Invitrogen (Karlsruhe, Germany)). At the 5' end, directly downstream to the ATG was inserted a nucleic acid sequence coding for an alanine amino acid and a nucleic acid sequence encoding a N-terminal HIS6-Tag (6x HIS, encoded by: cat cat cat cac cat cat). The resulting sequence is presented as SEQ ID No. 31. Upstream to the ATG, two additional cysteine base pairs were added in order to obtain a sequence corresponding to the recognition site of the restriction enzyme NcoI and downstream to the stop codon the sequences corresponding to the recognition site of the restriction enzyme XbaI were added. The resulting plasmid was then used to transform *E. coli* cells BL21 (DE3) with 50pg/ml kanamycin or 100µg/ml carbenicillin selection as described in European patent applications "EP09015984.9"; EP09015985.6"; EP 09015986.4" EP 09015987.2"; and EP09015988.0" all filed on 23. December 2009.

[0115] Quick test of the activity of HPPD protein: Production of brown color

[0116] Colorimetric Screening Test for Active HPPD Enzymes:

A YT-broth-type culture medium with 1% agarose, 5mM L-Tyrosine and 42mM Succinate, which contains the selection agent for the vector pSE420 is poured into deep well plates. *E. coli* culture in the exponential growth phase which contains the vector pSE420-HPPDx (any gene coding for a putative HPPD enzyme/protein) is applied to each well. After 16 hours at 37°C, the wells which do not contain the culture medium, those which have been seeded with an *E. coli* culture containing the empty vector pSE420 are transparent, or those which have been seeded with an *E.*

coli culture containing a vector pSE420 containing a gene coding for an inactive HPPD are transparent, while the wells seeded with an *E. coli* culture containing the vector pSE420-HPPD coding for active HPPD are brown. It has been previously demonstrated that this test reflects the HPPD activity, whatever the origin of this activity, and allows the identification of HPPD activities (US 6,768,044).

As it can be seen on Figure 3, the culture from bacteria containing the gene coding for the mutant HPPD did not develop a brown color while the one containing the gene coding of the wild type HPPD developed a strong brown color reflecting the activity of the HPPD enzymes. It can be concluded that the two HPPD mutants are not able to convert HPP into homogentisate. The two HPPD mutants are inactive.

One can conclude that the amino acid positions 267 and 282 (referring to position in SEQ ID No. 2) are essential for HPPD activity.

[0117] The expression of the HPPD protein was then done as following.

[0118] Overnight cultures grown at 37°C were used to inoculate LB media at a ratio 1:100. Cells were allowed to grow until OD reached 0.5, then expression was initiated from the *trp-lac* (*trc*) promoter by induction with 1 mM IPTG which binds to the *lac* repressor and causes its dissociation from the *lac* operon. Expression was carried out over 15 h at 28 °C.

[0119] To prepare the pre-starter culture, 2 mL of TB medium (100 µg*mL⁻¹ carbenicillin) were inoculated with 50 µL of an *E. coli* K-12 BL21 glycerol stock. The pre-starter culture was incubated at 37 °C with shaking at 140 rpm for 15 h. 200µl of the pre-starter culture was used to initiate the starter culture (5mL TB supplement with 100 µg*L⁻¹), which was incubated 3 h at 37°C.

[0120] To prepare the main culture, 400 mL of TB medium (100 µg*mL⁻¹ carbenicillin) were inoculated with 4 mL of the starter culture. This starter culture was incubated at 37 °C with shaking at 140 rpm until OD₆₀₀ 0.5 was reached. Then recombinant protein expression was induced with 400 µl of 1 M IPTG solution. The cells were allowed to grow for an additional hour under these conditions, then the temperature was lowered to 28°C and the culture was shaken at 140 rpm for 15 h. Cells were harvested by centrifugation at 6000 x g for 15 min at 4 °C. Then cell pellets were stored at -80 °C.

[0121] Isolation and purification of His₆-AtHPPD in native form

Lysis of cells

[0122] Cells were lysed using Lysozyme, an enzyme that cleaves the 1,4-β-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan which forms the bacterial cell wall. Cell membranes were then

disrupted by the internal pressure of the bacterial cell. In addition, the lysis buffer contained Benzonase® Nuclease, an endonuclease that hydrolyzes all forms of DNA and RNA without damaging proteins and thereby largely reduces viscosity of the cell lysate. Lysis under native conditions was carried out on ice.

[0123] For purification of His₆-tagged proteins the QIAexpress® Ni-NTA Fast Start Kit was used following the user manual instruction.

[0124] Purification of His₆-tagged proteins by immobilized metal ion affinity chromatography (IMAC)

[0125] The cleared cell lysate (10 mL) obtained after centrifugation of the lysis reaction was loaded onto a Ni-NTA Fast Start Column from the QIAexpress® Ni-NTA Fast Start Kit (Qiagen, Hilden, Germany) and purification was carried out according to the instruction manual. The His₆-tagged protein was eluted with 2.5 mL of elution buffer.

Desalting of HPPD solutions by gel filtration

[0126] HPPD solutions eluted from a Ni-NTA Fast Start Column with 2.5 mL of elution buffer were applied to a Sephadex G-25 PD-10 column (GE Healthcare, Freiburg, Germany) following the user manual instruction. After the whole sample had entered the gel bed, elution was performed with 3.5 mL of storage buffer. The HPPD solutions eluted from the desalting column were frozen at -80 °C in 1 mL aliquots.

[0127] Determination of HPPD protein concentration using the Bradford protein assay Protein concentration was determined using the standard Bradford assay (Bradford, (1976), Anal Biochem 72: 248-254).

Determination of purity of HPPD solutions using SDS-PAGE

[0128] The integrity of the eluted protein was checked by SDS-PAGE protein gel electrophoresis using the gel NuPAGE® Novex 4-12 % Bis-Tris Gels (Invitrogen, Karlsruhe, Germany), approximately 10 µg of protein were loaded. 10 µL of Laemmli Sample Buffer was added to 1-10 µL of protein solution and the mixture was incubated at 90 °C for 10 min. After short centrifugation step, the whole mixture was loaded into a slot of an SDS gel previously fixed in a XCell SureLock™ Novex Mini-Cell gel chamber filled with NuPAGE® MOPS SDS Running Buffer (diluted from the 20 x-solution with ddH₂O). A voltage of 150 was then applied to the gel chamber for 1 h. For staining of protein bands, the gel was immersed in Coomassie Brilliant Blue R-250 Staining Solution. For destaining of the polyacrylamide gel, it was immersed in Coomassie Brilliant Blue R-250 Destaining Solution until protein bands appear blue on a white gel.

[0129] The HPPD activity was checked by the standard spectrophotometric assay (method extensively described in WO 2009/144079)

[0130] In this content, pI₅₀-value means the log value of the concentration of inhibitor necessary to inhibit 50% of the enzyme activity in molar concentration.

[0131] pI₅₀-values for HPPD inhibitors were determined from dose-response plots of HPPD activity versus inhibitor concentration using the assay extensively described in WO 2009/144079 at 2 mM fixed HPP concentration and 3 minutes fixed incubation time using the ID Business Solutions Ltd. XLfit software suite.

Table 7: Determination of pI50 HPPD enzymes (*Arabidopsis thaliana* wild type HPPD "SEQ ID No. 32", the mutants S267A (SEQ ID No. 34) and N282A (SEQ ID No. 36)" and the tolerance to the several listed below HPPD inhibitors tembotrione, diketonitrile, mesotrione, bicyclopyrone, pyrasulfotole, sulcotrione, pyrazolate, tefuryltrione, and benzofenap. The symbol ">" means that the value was far higher than the one indicated but could not be precisely calculated within in the range of concentration of inhibitor tested (2.5×10^{-6} , 5.0×10^{-6} , 1.0×10^{-5} , 2.5×10^{-5} , 6.3×10^{-5} , and 2.5×10^{-4} M).

	Bicyclopyrone	Benzofenap	Diketonitrile	Mesotrione
WT (SEQ ID No. 32)	5.2	>5.6	>5.6	>5.6
S267A (SEQ ID No. 34)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)
N282A (SEQ ID No. 36)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)

	Pyrasulfotole	Pyrazolate	Sulcotrione	Tefuryltrione	Tembotrione
WT (SEQ ID No. 32)	5.4	5.4	>5.6	>5.6	>5.6
S267A (SEQ ID No. 34)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)
N282A (SEQ ID No. 36)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)	nd - la (P)

[0132] As previously demonstrated, the 2 protein mutants are not able to convert HPP into Homogentisate, confirming that the 2 mutant proteins are inactive. It confirms the hypothesis that the position 267 and 282 (referring to position in SEQ ID No. 2) are absolutely essential for obtaining an active HPPD

Example 2: Single point mutants displayed increased tolerance to HPPD inhibitor herbicides:

[0133] Kinetic characterization and evaluation of tolerance to HPPD inhibitors of HPPD enzyme "SEQ ID No. 32".

[0134] The HPPD activity was checked by the standard spectrophotometric assay (method extensively described in WO 2009/144079)

Determination of HPPD in vitro kinetic properties

[0135] K_m , V_{max} , and k_{cat} values for different HPPD enzyme preparations and K_i , $K_1=K_{on}$, and $K_{-1}=K_{off}$ for different HPPD inhibitors were determined using a HPLC assay for measurements of HPPD activity. The assay mixtures contained in a volume of 1 ml 150 mM Tris-HCl buffer at pH 7.8, 10 mM sodium ascorbate, 650 units of bovine catalase (Sigma C30 (Sigma-Aldrich, Munich, Germany), 34 mg protein/ml, 23,000 units/mg), and appropriate amounts of HPP, purified HPPD enzyme and HPPD inhibitors. For K_m , V_{max} , and k_{cat} value determination HPP concentrations in the assay mixture were varied between 10 and 400 μ M. For K_i , $K_1=K_{on}$, and $K_{-1}=K_{off}$ value determination 2 mM HPP was used. All assays were started by the addition of HPPD enzyme to the assay mixture and stopped at a series of times between 0 and 240 s by addition of 200 μ l of the reaction mixture to reaction assay tubes containing 20 μ l 10% perchloric acid. Precipitated protein was pelleted by a 5 minute centrifugation at 10,000 g. 100 μ l of the supernatant were loaded onto a 250 x 4mm Knauer (Berlin, Germany) Eurospher 100-5 C18-column equilibrated with 10% methanol, 0.1 % trifluoroacetic acid (buffer A). The column was eluted, also at 1.5 ml/min, using a 4 minute wash with buffer A, followed by a 3 min wash with 95% methanol and by a further 2 minute wash with buffer A. The elution of HGA (homogentisic acid) and HPP (hydroxyphenylpyruvate) was monitored at 292 nm. HGA elutes at around 5 minutes and HPP elutes later. A standard set of concentrations of HGA were used to provide a standard curve in order to calibrate the 292 nm absorbance of the HGA peak versus HGA concentration. For K_m and V_{max} value determinations the initial rates of the HPPD reaction at different substrate concentrations were determined from plots of HGA formed versus time and fitted to the Michaelis-Menten equation for unreactant enzymes using the ID Business Solutions Ltd. (www.idbs.com) XLfit software suite. For the determination of K_i , $K_1=K_{on}$, and $K_{-1}=K_{off}$ values the time-courses of the HPPD reaction at different inhibitor concentrations were fitted to the equations for Mechanism A, competitive inhibition, for tight-binding inhibitors (Cha, S. (1975) Tight-binding inhibitors - I. Kinetic behaviour. Biochemical Pharmacology 24, 2177-2185) using the ID Business Solutions Ltd. XLfit software suite

Table 8

[0136] Protein SEQ ID No. 32 consists of protein SEQ ID No. 2 with an insertion of one amino acid Ala and six amino acids His directly behind the first methionine.

[0137] Kinetic characterization of HPPD enzymes (*Arabidopsis thaliana* "SEQ ID No. 32" and the respective tolerance to the HPPD inhibitors tembotrione and diketonitrile. In below given table1, " K_m " (Michaelis-Menten constant) means the kinetic parameter that is used to characterise an enzyme, and it is defined as the concentration of substrate that permits half maximal rate of the reaction. K_m is further defined as the substrate concentration at which the reaction rate reaches half of its maximum value ($V_{max}/2$) where V_{max} has the meaning of being the maximum velocity of the reaction. $K_{on}=K_1$ equals the association rate constant of the enzyme-substrate binding and $K_{off}=K_{-1}$ equals the rate constant of the enzyme-inhibitor complex dissociation. K_i defines the inhibition constant.

	HPP		Tembotrione			Diketonitrile		
	K_m (μ M)	V_{max} (μ M)	k_1 ($M^{-1} s^{-1}$)	k_{-1} (s^{-1})	K_1 (μ M)	k_1 (M^{-1}) (s^{-1})	k_{-1} (s^{-1})	k_1 (μ M)
SEQ ID No. 32	6.3	1.2	2.3E+05	3.5E-03	0.015	6.1E+05	1.1 E-02	0.018

[0138] The kinetic parameters K_m and V_{max} of the plant HPPD "SEQ ID No. 32" summarized in Table 8 are well in the range of the specific activities measured from purified plant HPPD as for example for the carrot HPPD (Garcia et al. 2000, Biochemistry, 39, 7501-7507). The *Arabidopsis thaliana* HPPD is also sensitive in the similar range as the carrot HPPD to diketonitrile. It is the first time, that the kinetic parameter of *Arabidopsis thaliana* HPPD in presence of tembotrione are measured and being in a comparable range as the one measured in presence of the HPPD inhibitor diketonitrile.

[0139] Determination of HPPD activity in presence of several HPPD inhibitors

[0140] In this content, pl_{50} -value means the log value of the concentration of inhibitor necessary to inhibit 50% of the enzyme activity in molar concentration.

[0141] pl_{50} -values for HPPD inhibitors were determined from dose-response plots of HPPD activity versus inhibitor concentration using the assay extensively described in WO 2009/144079 at 2 mM fixed HPP concentration and 3 minutes fixed incubation time using the ID Business Solutions Ltd. XLfit software suite.

5 Table 9: Determination of pI50 HPPD enzymes (*Arabidopsis thaliana* “SEQ ID
 No. 32” and some *Arabidopsis* HPPD single point mutants “SEQ ID No. 35,
 10 SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44, SEQ ID No. 46, SEQ ID No. 48, and
 SEQ ID No. 50”) and their respective tolerance to the several listed below HPPD
 inhibitors tembotrione, diketonitrile, mesotrione, bicyclopyrone, pyrasulfotole,
 15 sulcotrione, pyrazolate, tefuryltrione, and benzofenap. The symbol “>” means that
 the value was far higher than the one indicated but could not be precisely calculated
 within in the range of concentration of inhibitor tested (2.5×10^{-6} , 5.0×10^{-6} , 1.0×10^{-5} ,
 2.5×10^{-5} , 6.3×10^{-5} , and 2.5×10^{-4} M).

	Bicyclopyrone	Benzofenap	Diketonitrile	Mesotrione	Pyrasulfotole
20 SEQ ID No. 32	5.2	>5.6	>5.6	>5.6	5.4
25 E252S (SEQ ID No. 36)	4.3	5.2	4.9	5.3	4.3
V269A (SEQ ID No. 40)	4.3	5.2	5.2	5.2	4.4
30 P280A SEQ ID No. 42	4.3	5.2	5.2	5.3	4.4
35 L368M SEQ ID No. 44	4.5	>5.6	5.6	5.4	5.0
K421I SEQ ID No. 46	4.2	5.1	5.0	5.2	4.3
40 K421Q SEQ ID No. 48	4.7	>5.6	>5.6	>5.6	4.8
45 K421V SEQ ID No. 50	4.2	5.2	5.1	5.3	4.4

	Pyrazolat	Sulcotrione	Tefuryltrione	Tembotrione
5 SEQ ID No. 32	5.4	>5.6	>5.6	>5.6
10 E252S (SEQ ID No. 35)	4.7	5.1	5.2	5.5
15 V269A (SEQ ID No. 40)	4.4	5.0	5.4	>5.6
20 P280A SEQ ID No. 42	4.7	5.0	5.5	>5.6
25 L368M SEQ ID No. 44	4.9	5.2	>5.6	>5,6
30 K421I SEQ ID No. 46	4.5	5.0	5.2	5.6
K421Q SEQ ID No. 48	5.0	>5.6	>5.6	>5.6
K421V SEQ ID No. 50	4.5	5.1	5.4	>5.6

35 **[0142]** Measurements show that the pI50 in case of the point mutants is reduced compared to the wild-type protein.

40 **[0143]** In Table 9, it can be clearly seen that the HPPD mutants are all affected in their tolerance to at least one HPPD inhibitors and some to several HPPD inhibitors. All the tested mutants are more active (do show an increased tolerance concerning the various applied HPPD inhibitors) in the presence of at least one of the selected HPPD inhibitors, therefore the mutant enzyme-inhibitor complex should be less stable the wild-type enzyme-inhibitor complex. It can be concluded that the positions 252, 269, 280, 368 and 421 (reference taken in SEQ ID No. 2) are all important in the modulation of tolerance of HPPD enzyme to HPPD inhibitors.

45

50

55

EP 2 453 012 A1

SEQUENCE LISTING

5 <110> Bayer CropScience AG
 <120> HPPD variants and methods of use
 <130> BCS 10-1029
 10 <160> 48
 <170> PatentIn version 3.3
 <210> 1
 <211> 1335
 15 <212> DNA
 <213> Arabidopsis thaliana
 <400> 1
 atgggccacc aaaacgccgc cgtttcagag aatcaaaacc atgatgacgg cgctgcgtcg 60
 20 tcgccgggat tcaagctcgt cggattttcc aagttcgtaa gaaagaatcc aaagtctgat 120
 aaattcaagg ttaagcgctt ccatcacatc gagttctggt gcggcgacgc aaccaacgctc 180
 gctcgtcgtc tctcctgggg tctggggatg agattctccg ccaaatccga tctttccacc 240
 25 ggaaacatgg ttcacgcctc ttacctactc acctccggtg acctccgatt ccttttctact 300
 gctccttact ctccgtctct ctccgccgga gagattaaac cgacaaccac agcttctatc 360
 ccaagtttcg atcacggctc ttgtcgttcc ttcttctctt cacatggtct cggtggttaga 420
 30 gccgttgcca ttgaagtaga agacgcagag tcagctttct ccatcagtgt agctaattggc 480
 gctattcctt cgtcgcctcc tatcgtctct aatgaagcag ttacgatcgc tgagggttaa 540
 ctatacggcg atgttgttct ccgatatggt agttacaaag cagaagatac cgaaaaatcc 600
 35 gaattcttgc caggggttca gcgtgtagag gatgcgctct cgttcccatt ggattatggt 660
 atccggcggc ttgaccacgc cgtgggaaac gttcctgagc ttggtccggc ttaacttat 720
 gtagcggggg tcaactggtt tcaccaatc gcagagttca cagcagacga cgttgggaacc 780
 40 gccgagagcg gtttaaattc agcggctctg gctagcaatg atgaaatggt tcttctaccg 840
 attaacgagc cagtgcacgg aacaaagagg aagagtcaga ttcagacgta tttggaacat 900
 aacgaaggcg cagggctaca acatctggct ctgatgagt aagacatatt caggaccctg 960
 45 agagagatga ggaagaggag cagtattgga ggattcgact tcatgccttc tctcgcctc 1020
 acttactacc agaatctcaa gaaacgggtc ggcgacgtgc tcagcgatga tcagatcaag 1080
 50 gagtgtgagg aattaggat tcttgtagac agagatgatc aaggacggt gcttcaaact 1140
 ttcacaaaac cactaggtga caggccgacg atatttatag agataatcca gagagtagga 1200
 tgcgatgatga aagatgagga agggaaggct taccagagtg gaggatgtgg tggttttggc 1260
 55

EP 2 453 012 A1

```

aaaggcaatt tctctgagct cttcaagtcc attgaagaat acgaaaagac tcttgaagcc 1320
5 aaacagtttag tggga 1335

<210> 2
<211> 445
<212> PRT
10 <213> Arabidopsis thaliana

<400> 2

Met Gly His Gln Asn Ala Ala Val Ser Glu Asn Gln Asn His Asp Asp
1 5 10 15
Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val Gly Phe Ser Lys Phe
20 25 30
Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys Val Lys Arg Phe His
35 40 45
His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn Val Ala Arg Arg Phe
50 55 60
Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys Ser Asp Leu Ser Thr
65 70 75 80
30 Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr Ser Gly Asp Leu Arg
85 90 95
Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu Ser Ala Gly Glu Ile
35 100 105 110
Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe Asp His Gly Ser Cys
40 115 120 125
Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val Arg Ala Val Ala Ile
45 130 135 140
Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile Ser Val Ala Asn Gly
145 150 155 160
Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn Glu Ala Val Thr Ile
50 165 170 175
Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu Arg Tyr Val Ser Tyr
180 185 190
55

```

EP 2 453 012 A1

5 Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu Pro Gly Phe Glu Arg
195 200 205

Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr Gly Ile Arg Arg Leu
210 215 220

10 Asp His Ala Val Gly Asn Val Pro Glu Leu Gly Pro Ala Leu Thr Tyr
225 230 235 240

15 Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala Glu Phe Thr Ala Asp
245 250 255

Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser Ala Val Leu Ala Ser
260 265 270

20 Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu Pro Val His Gly Thr
275 280 285

25 Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu His Asn Glu Gly Ala
290 295 300

Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp Ile Phe Arg Thr Leu
305 310 315 320

30 Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly Phe Asp Phe Met Pro
325 330 335

35 Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys Lys Arg Val Gly Asp
340 345 350

40 Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu Glu Leu Gly Ile Leu
355 360 365

Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln Ile Phe Thr Lys Pro
370 375 380

45 Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile Ile Gln Arg Val Gly
385 390 395 400

50 Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr Gln Ser Gly Gly Cys
405 410 415

Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu Phe Lys Ser Ile Glu

55

EP 2 453 012 A1

	420	425	430	
5	Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu Val Gly			
	435	440	445	
	<210> 3			
	<211> 1341			
10	<212> DNA			
	<213> Oryza sativa			
	<400> 3			
	atgcctccca ctcccacccc caccgccacc accggcgccg tctcggccgc tgcggcgccg			60
15	ggggagaacg cggggttccg cctcgtcggg caccgccgct tcgtccgcgc caaccgcggg			120
	agcgaccggg tccagggcgt cgcgttccac cacgtcgagc tctggtgcgc cgacgccggg			180
	tccgcgcggg gccggttcgc cttcgccctg ggcgcgccgc tcgccgccag gtccgacctc			240
20	tccacgggga actccgcgca cgcctccctc ctctccgct ccgcctccgt cgcgttccctc			300
	ttcaccgccc cctacggcgg cgaccacggc gtcggcgccg acgcggccac caccgcctcc			360
	atcccttccg tctccccagg cgcgcggcgg aggttcgcgc cggaccacgg cctcgcgggtg			420
25	cacgccgtgg cgctgcgcgt cgcgcacggc gccgacgct tccgcgccag cgtcgcggcc			480
	ggtgcgcgcc cggcgttcca gcccgccgac ctcggcggtg gcttcggcct cgcggaggtg			540
	gagctctacg gcgacgtcgt gctccgcttc gtcagccacc cggacggcgc cgacgcgccc			600
30	ttctcccgg gtttcgaggg cgctcagcaac ccgggcgccc tggactacgg cctccgccgg			660
	ttcgaccacg tcgtcggcaa cgtgccggag ctccgtccgg tagccgcgta catctccggg			720
35	ttcaccgggt tccacgagtt cgcgcgagtt accgccgagg acgtgggcac cgcgcgagac			780
	ggcctcaact cgggtggtgct cgccaacaac gcggagaccg tgctgctgcc gctcaacgag			840
	ccgggtgcacg gcaccaagcg gcggagccag atacagacgt acctggacca ccacggcggc			900
40	ccgggggtgc agcacatcgc gctggccagc gacgacgtgc tcgggacgct gagggagatg			960
	cgggcgcgct ccgccatggg cggcttcgag ttcttggggc cgccgccgcc caactactac			1020
	gacggcgtgc ggccggcgcg cggggacgtg ctctcggagg agcagatcaa cgagtgccag			1080
45	gagctcgggg tgctcgtgga cagggatgac cagggggtgt tgctccagat cttaccaag			1140
	ccagtaggag acaggccaac ctttttcttg gagatgatac aaaggattgg gtgcatggag			1200
	aaggatgaga gtgggcagga gtaccagaag ggcggtcgcg gcgggtttgg gaaggcaac			1260
50	ttctcggagc tgttcaagtc cattgaggag tatgagaaat cccttgaagc caagcaagcc			1320
	cctacagttc aaggatccta g			1341
55				

EP 2 453 012 A1

<210> 4
 <211> 446
 <212> PRT
 5 <213> Oryza sativa

 <400> 4

 10 Met Pro Pro Thr Pro Thr Pro Thr Ala Thr Thr Gly Ala Val Ser Ala
 1 5 10 15

 Ala Ala Ala Ala Gly Glu Asn Ala Gly Phe Arg Leu Val Gly His Arg
 20 25 30

 15 Arg Phe Val Arg Ala Asn Pro Arg Ser Asp Arg Phe Gln Ala Leu Ala
 35 40 45

 20 Phe His His Val Glu Leu Trp Cys Ala Asp Ala Ala Ser Ala Ala Gly
 50 55 60

 Arg Phe Ala Phe Ala Leu Gly Ala Pro Leu Ala Ala Arg Ser Asp Leu
 25 65 70 75 80

 25 Ser Thr Gly Asn Ser Ala His Ala Ser Leu Leu Leu Arg Ser Ala Ser
 85 90 95

 30 Val Ala Phe Leu Phe Thr Ala Pro Tyr Gly Gly Asp His Gly Val Gly
 100 105 110

 Ala Asp Ala Ala Thr Thr Ala Ser Ile Pro Ser Phe Ser Pro Gly Ala
 35 115 120 125

 Ala Arg Arg Phe Ala Ala Asp His Gly Leu Ala Val His Ala Val Ala
 130 135 140

 40 Leu Arg Val Ala Asp Ala Ala Asp Ala Phe Arg Ala Ser Val Ala Ala
 145 150 155 160

 Gly Ala Arg Pro Ala Phe Gln Pro Ala Asp Leu Gly Gly Gly Phe Gly
 45 165 170 175

 Leu Ala Glu Val Glu Leu Tyr Gly Asp Val Val Leu Arg Phe Val Ser
 180 185 190

 50 His Pro Asp Gly Ala Asp Ala Pro Phe Leu Pro Gly Phe Glu Gly Val
 195 200 205

 55

EP 2 453 012 A1

Ser Asn Pro Gly Ala Val Asp Tyr Gly Leu Arg Arg Phe Asp His Val
 210 215 220

5

Val Gly Asn Val Pro Glu Leu Ala Pro Val Ala Ala Tyr Ile Ser Gly
 225 230 235 240

10

Phe Thr Gly Phe His Glu Phe Ala Glu Phe Thr Ala Glu Asp Val Gly
 245 250 255

15

Thr Ala Glu Ser Gly Leu Asn Ser Val Val Leu Ala Asn Asn Ala Glu
 260 265 270

20

Thr Val Leu Leu Pro Leu Asn Glu Pro Val His Gly Thr Lys Arg Arg
 275 280 285

25

Ser Gln Ile Gln Thr Tyr Leu Asp His His Gly Gly Pro Gly Val Gln
 290 295 300

30

His Ile Ala Leu Ala Ser Asp Asp Val Leu Gly Thr Leu Arg Glu Met
 305 310 315 320

35

Arg Ala Arg Ser Ala Met Gly Gly Phe Glu Phe Leu Ala Pro Pro Pro
 325 330 335

40

Pro Asn Tyr Tyr Asp Gly Val Arg Arg Arg Ala Gly Asp Val Leu Ser
 340 345 350

45

Glu Glu Gln Ile Asn Glu Cys Gln Glu Leu Gly Val Leu Val Asp Arg
 355 360 365

50

Asp Asp Gln Gly Val Leu Leu Gln Ile Phe Thr Lys Pro Val Gly Asp
 370 375 380

55

Arg Pro Thr Phe Phe Leu Glu Met Ile Gln Arg Ile Gly Cys Met Glu
 385 390 395 400

60

Lys Asp Glu Ser Gly Gln Glu Tyr Gln Lys Gly Gly Cys Gly Gly Phe
 405 410 415

65

Gly Lys Gly Asn Phe Ser Glu Leu Phe Lys Ser Ile Glu Glu Tyr Glu
 420 425 430

70

Lys Ser Leu Glu Ala Lys Gln Ala Pro Thr Val Gln Gly Ser
 435 440 445

EP 2 453 012 A1

5 <210> 5
 <211> 1281
 <212> DNA
 <213> Zea mays

<400> 5
 10 atgccccga cccccacagc cgccgcagcc ggcgcgcgcg tggcggcggc atcagcagcg 60
 gagcaggcgg cgttccgect cgtggggccac cgcaacttcg tccgcttcaa cccgcgctcc 120
 gaccgcttcc acacgctcgc gttccaccac gtggagctct ggtgcgccga cgcggcctcc 180
 15 gccgcggggc gcttctcctt cggcctgggc gcgccgctcg ccgcacgctc cgacctctcc 240
 acgggcaact ccgcgcacgc gtccctgctg ctccgctccg gctccctctc cttcctcttc 300
 acgggcacct acgcgcacgg cgccgacgct gccaccgccc cgtgcccctc cttctccgcc 360
 20 gccgcgcgcg ggcgcttcgc agccgaccac ggcctcgcgg tgccgcgcgt ccgcctccgc 420
 gtcgccgacg ccgaggacgc cttccggggc ttccgcctcg ccgaggtcga gctctacggc 480
 gacgtcgtgc tccggtacgt gagctaccgg gacggcgcgg cgggcgagcc cttcctgccc 540
 25 gggttcagag gogtggccag ccccgggggc gccgactacg ggtgagcag gttcagaccac 600
 atcgtcggca acgtgccgga gctggcgccc gccccgcctt acttcgccgg cttcacgggg 660
 ttccacgagt tcgccgagtt cacgacggag gacgtgggca ccgcggagag cggcctcaac 720
 30 tccatggtgc tcgccaacaa ctccggagaac gtgctgctcc cgtcaacga gccgggtgac 780
 ggcaccaagc gccgcagcca gatacaaacg ttctgggacc accacggcgg ccccggcgtg 840
 cagcacatgg cgctggccag cgacgacgtg ctcaggacgc tgagggagat gcaggcgcgc 900
 35 tcggccatgg gcggcttcga gttcatggcg cctcccacat ccgactacta tgacggcgtg 960
 aggcggcgcg ccggggacgt gctcacggaa gcacagatta aggagtcca ggagctaggg 1020
 gtgctggtgg acagggatga ccagggcgtg ctgctccaaa tcttcaccaa gccagtgggg 1080
 40 gacaggccaa cgctgttctt ggaaatcatc caaaggatcg ggtgcatgga gaaggatgag 1140
 aaggggcaag aatacaaaa gggtggtcgc ggcgggttcg gcaaggaaa cttctcgag 1200
 45 ctgttcaagt ccatcgagga ttatgagaag tcccttgaag ccaagcaagc tgctgcagca 1260
 gctgcagctc agggatccta g 1281

50 <210> 6
 <211> 426
 <212> PRT
 <213> Zea mays

<400> 6

55

EP 2 453 012 A1

Met Pro Pro Thr Pro Thr Ala Ala Ala Ala Gly Ala Ala Val Ala Ala
 1 5 10 15
 Ala Ser Ala Ala Glu Gln Ala Ala Phe Arg Leu Val Gly His Arg Asn
 20 25 30
 Phe Val Arg Phe Asn Pro Arg Ser Asp Arg Phe His Thr Leu Ala Phe
 35 40 45
 His His Val Glu Leu Trp Cys Ala Asp Ala Ala Ser Ala Ala Gly Arg
 50 55 60
 Phe Ser Phe Gly Leu Gly Ala Pro Leu Ala Ala Arg Ser Asp Leu Ser
 65 70 75 80
 Thr Gly Asn Ser Ala His Ala Ser Leu Leu Leu Arg Ser Gly Ser Leu
 85 90 95
 Ser Phe Leu Phe Thr Ala Pro Tyr Ala His Gly Ala Asp Ala Ala Thr
 100 105 110
 Ala Ala Leu Pro Ser Phe Ser Ala Ala Ala Ala Arg Arg Phe Ala Ala
 115 120 125
 Asp His Gly Leu Ala Val Arg Ala Val Ala Leu Arg Val Ala Asp Ala
 130 135 140
 Glu Asp Ala Phe Arg Gly Phe Arg Leu Ala Glu Val Glu Leu Tyr Gly
 145 150 155 160
 Asp Val Val Leu Arg Tyr Val Ser Tyr Pro Asp Gly Ala Ala Gly Glu
 165 170 175
 Pro Phe Leu Pro Gly Phe Glu Gly Val Ala Ser Pro Gly Ala Ala Asp
 180 185 190
 Tyr Gly Leu Ser Arg Phe Asp His Ile Val Gly Asn Val Pro Glu Leu
 195 200 205
 Ala Pro Ala Ala Ala Tyr Phe Ala Gly Phe Thr Gly Phe His Glu Phe
 210 215 220
 Ala Glu Phe Thr Thr Glu Asp Val Gly Thr Ala Glu Ser Gly Leu Asn
 225 230 235 240

55

EP 2 453 012 A1

5 Ser Met Val Leu Ala Asn Asn Ser Glu Asn Val Leu Leu Pro Leu Asn
245 250 255

Glu Pro Val His Gly Thr Lys Arg Arg Ser Gln Ile Gln Thr Phe Leu
260 265 270

10 Asp His His Gly Gly Pro Gly Val Gln His Met Ala Leu Ala Ser Asp
275 280 285

15 Asp Val Leu Arg Thr Leu Arg Glu Met Gln Ala Arg Ser Ala Met Gly
290 295 300

Gly Phe Glu Phe Met Ala Pro Pro Thr Ser Asp Tyr Tyr Asp Gly Val
305 310 315 320

20 Arg Arg Arg Ala Gly Asp Val Leu Thr Glu Ala Gln Ile Lys Glu Cys
325 330 335

25 Gln Glu Leu Gly Val Leu Val Asp Arg Asp Asp Gln Gly Val Leu Leu
340 345 350

Gln Ile Phe Thr Lys Pro Val Gly Asp Arg Pro Thr Leu Phe Leu Glu
355 360 365

Ile Ile Gln Arg Ile Gly Cys Met Glu Lys Asp Glu Lys Gly Gln Glu
370 375 380

35 Tyr Gln Lys Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Gln
385 390 395 400

40 Leu Phe Lys Ser Ile Glu Asp Tyr Glu Lys Ser Leu Glu Ala Lys Gln
405 410 415

Ala Ala Ala Ala Ala Ala Ala Gln Gly Ser
420 425

45 <210> 7
<211> 1323
<212> DNA
<213> Avena sativa

50 <400> 7
atgccgccca cccccgccac cgccaccggc gccgccggg ccgccgtgac tccagagcac 60
gcggcccgga gctttccccg agtggtccgc gtcaaccgc gcagcgaccg cttccccgtg 120

55

EP 2 453 012 A1

ctctccttcc accacgtcga gctctggtgc gccgacgccg cctcagcggc cggacgcttc 180
 5 tcttctcgcgc tgggcgcgcc gctcgccgcc cggttccgacc tctccacggg gaactccgcg 240
 cacgcctccc tctgtctccg ctggggcgcc ctgccttcc tcttcacggc gccctacgcg 300
 ccgcccggcg aggaggccgc cacggccgca gccaccgctt ccatcccctc cttctccgcc 360
 10 gacgccgcgc ggacgttcgc cgcgcccac ggctcgcggg tgcgctccgt cgggggtccgc 420
 gtcgctgacg ccgcccgggc cttccgcgctc agcgtagccg gcggcgctcg cccggccttc 480
 gccccagccg acctcggcca tggcttcggc ctgcgaggg tcgagctcta cggcgacgctc 540
 15 gtgctacgct tcgtcagcta cccggacgag acagacctgc cattcctgcc agggttcgag 600
 cgcgtgagca gccccggcgc cgtggactac ggctcaccgc ggttcgacca cgtcgtgggc 660
 aacgtcccgg agatggcccc ggtcatagac tacatgaaag gcttcttggg gttccacgag 720
 20 ttcgccgagt tcaccgccga ggacgtgggc acgaccgaga gcgggctcaa ctcggtggtg 780
 ctgccaaaca actccgaggc cgtgctgctg ccgctcaacg agcccgtgca cggcaciaaag 840
 cgacggagcc agatacagac gtacctggag tatcaccggc ggccccggcgt gcagcacatc 900
 25 gcgctcgcca gcaacgacgt gctcaggacg ctccaggaga tgcgggcgcg cacgcccattg 960
 gggggcttcg agttcatggc gccaccgcag gcgaaatact atgaaggcgt gcggcgcatc 1020
 gcaggtgacg tgctctcgga agagcagatc aaggaatgcc aggagctggg ggtgctagt 1080
 30 gacagggatg atcaaggggt gttgctccaa atcttcacca agccagtagg ggacaggcca 1140
 acgtttttcc tggagatgat ccaaagaatc ggtgcatgg agaaggacga ggtcgggcaa 1200
 35 gagtaccaga aggggtggctg cggcggggtt ggcaagggca atttctccga gctgttcaag 1260
 tccattgagg actatgagaa atccottgag gtcaagcaat ctggttagc tcagaaatcc 1320
 tag 1323

40 <210> 8
 <211> 440
 <212> PRT
 <213> Avena sativa

45 <400> 8

Met Pro Pro Thr Pro Ala Thr Ala Thr Gly Ala Ala Ala Ala Val
 1 5 10 15

50 Thr Pro Glu His Ala Ala Arg Ser Phe Pro Arg Val Val Arg Val Asn
 20 25 30

55

EP 2 453 012 A1

Pro Arg Ser Asp Arg Phe Pro Val Leu Ser Phe His His Val Glu Leu
35 40 45

5 Trp Cys Ala Asp Ala Ala Ser Ala Ala Gly Arg Phe Ser Phe Ala Leu
50 55 60

10 Gly Ala Pro Leu Ala Ala Arg Ser Asp Leu Ser Thr Gly Asn Ser Ala
65 70 75 80

15 His Ala Ser Leu Leu Leu Arg Ser Gly Ala Leu Ala Phe Leu Phe Thr
85 90 95

Ala Pro Tyr Ala Pro Pro Pro Gln Glu Ala Ala Thr Ala Ala Ala Thr
100 105 110

20 Ala Ser Ile Pro Ser Phe Ser Ala Asp Ala Ala Arg Thr Phe Ala Ala
115 120 125

25 Ala His Gly Leu Ala Val Arg Ser Val Gly Val Arg Val Ala Asp Ala
130 135 140

Ala Glu Ala Phe Arg Val Ser Val Ala Gly Gly Ala Arg Pro Ala Phe
145 150 155 160

30 Ala Pro Ala Asp Leu Gly His Gly Phe Gly Leu Ala Glu Val Glu Leu
165 170 175

35 Tyr Gly Asp Val Val Leu Arg Phe Val Ser Tyr Pro Asp Glu Thr Asp
180 185 190

Leu Pro Phe Leu Pro Gly Phe Glu Arg Val Ser Ser Pro Gly Ala Val
195 200 205

40 Asp Tyr Gly Leu Thr Arg Phe Asp His Val Val Gly Asn Val Pro Glu
210 215 220

45 Met Ala Pro Val Ile Asp Tyr Met Lys Gly Phe Leu Gly Phe His Glu
225 230 235 240

Phe Ala Glu Phe Thr Ala Glu Asp Val Gly Thr Thr Glu Ser Gly Leu
245 250 255

50 Asn Ser Val Val Leu Ala Asn Asn Ser Glu Ala Val Leu Leu Pro Leu
260 265 270

55

EP 2 453 012 A1

Asn Glu Pro Val His Gly Thr Lys Arg Arg Ser Gln Ile Gln Thr Tyr
 275 280 285

5

Leu Glu Tyr His Gly Gly Pro Gly Val Gln His Ile Ala Leu Ala Ser
 290 295 300

10

Asn Asp Val Leu Arg Thr Leu Arg Glu Met Arg Ala Arg Thr Pro Met
 305 310 315 320

15

Gly Gly Phe Glu Phe Met Ala Pro Pro Gln Ala Lys Tyr Tyr Glu Gly
 325 330 335

Val Arg Arg Ile Ala Gly Asp Val Leu Ser Glu Glu Gln Ile Lys Glu
 340 345 350

20

Cys Gln Glu Leu Gly Val Leu Val Asp Arg Asp Asp Gln Gly Val Leu
 355 360 365

25

Leu Gln Ile Phe Thr Lys Pro Val Gly Asp Arg Pro Thr Phe Phe Leu
 370 375 380

30

Glu Met Ile Gln Arg Ile Gly Cys Met Glu Lys Asp Glu Val Gly Gln
 385 390 395 400

Glu Tyr Gln Lys Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser
 405 410 415

35

Glu Leu Phe Lys Ser Ile Glu Asp Tyr Glu Lys Ser Leu Glu Val Lys
 420 425 430

40

Gln Ser Val Val Ala Gln Lys Ser
 435 440

<210> 9
 <211> 1077
 <212> DNA
 <213> Pseudomonas fluorescens

45

<400> 9
 atggcagatc tatacgaaaa cccaatgggc ctgatgggct ttgaattcat cgaattcgcg 60
 tcgccgacgc cgggtaccct ggagccgatc ttcgagatca tgggcttcac caaagtcgcg 120
 50 acccaccgtt ccaagaacgt gcacctgtac cgccagggcg agatcaacct gatcctcaac 180
 aacgagccca acagcatcgc ctctacttt gcggccgaac acggcccgtc ggtgtgcggc 240

55

EP 2 453 012 A1

atggcgttcc gcgtgaagga ctcgcaaaag gcctacaacc gcgccctgga actcggcgcc 300
 cagccgatcc atattgacac cgggccgatg gaattgaacc tgccggcgat caagggcatc 360
 5 ggcggcgcgc cgttgtacct gatcgaccgt ttcggcgaag gcagctcgat ctacgacatc 420
 gacttcgtgt acctcgaagg tgtggagcgc aatccggctg gtgcaggctt caaagtcatc 480
 gaccacctga cccacaacgt ctatcgcggc cgcattgtct actgggcca cttctacgag 540
 10 aaattgttca acttccgtga agcgcgttac ttcgatatca agggcgagta caccggcctg 600
 acttccaagg coatgagtgc gccggacggc atgatccgca tcccgtgaa cgaagagtcg 660
 tccaagggcg cggggcagat cgaagagttc ctgatgcagt tcaacggcga aggcattccag 720
 15 cacgtggcgt tcctcaccga cgacctggtc aagacctggg acgcgttgaa gaaaatcggc 780
 atgcgcttca tgaccgcgcc gccagacact tattacgaaa tgctcgaagg ccgcctgcct 840
 gaccacggcg agccgggtga tcaactgcag gcacgcggta tcctgctgga cggatcttcc 900
 20 gtggaaggcg acaaacgcct gctgctgcag atcttctcgg aaaccctgat gggcccggtg 960
 ttcttcgaat tcattccagc caagggcgac gatgggtttg gcgagggcaa cttcaaggcg 1020
 25 ctgttcgagt ccattcgaac tgaccaggtg cgtcgtggtg tattgaccgc cgattaa 1077

<210> 10
 <211> 358
 <212> PRT
 30 <213> Pseudomonas fluorescens

<400> 10
 Met Ala Asp Leu Tyr Glu Asn Pro Met Gly Leu Met Gly Phe Glu Phe
 35 1 5 10 15
 Ile Glu Phe Ala Ser Pro Thr Pro Gly Thr Leu Glu Pro Ile Phe Glu
 20 25 30
 40 Ile Met Gly Phe Thr Lys Val Ala Thr His Arg Ser Lys Asn Val His
 35 40 45
 45 Leu Tyr Arg Gln Gly Glu Ile Asn Leu Ile Leu Asn Asn Glu Pro Asn
 50 55 60
 Ser Ile Ala Ser Tyr Phe Ala Ala Glu His Gly Pro Ser Val Cys Gly
 65 70 75 80
 50 Met Ala Phe Arg Val Lys Asp Ser Gln Lys Ala Tyr Asn Arg Ala Leu
 85 90 95
 55

EP 2 453 012 A1

Glu Leu Gly Ala Gln Pro Ile His Ile Asp Thr Gly Pro Met Glu Leu
 100 105 110
 5
 Asn Leu Pro Ala Ile Lys Gly Ile Gly Gly Ala Pro Leu Tyr Leu Ile
 115 120 125
 10
 Asp Arg Phe Gly Glu Gly Ser Ser Ile Tyr Asp Ile Asp Phe Val Tyr
 130 135 140
 Leu Glu Gly Val Glu Arg Asn Pro Val Gly Ala Gly Leu Lys Val Ile
 145 150 155 160
 15
 Asp His Leu Thr His Asn Val Tyr Arg Gly Arg Met Val Tyr Trp Ala
 165 170 175
 20
 Asn Phe Tyr Glu Lys Leu Phe Asn Phe Arg Glu Ala Arg Tyr Phe Asp
 180 185 190
 Ile Lys Gly Glu Tyr Thr Gly Leu Thr Ser Lys Ala Met Ser Ala Pro
 195 200 205
 25
 Asp Gly Met Ile Arg Ile Pro Leu Asn Glu Glu Ser Ser Lys Gly Ala
 210 215 220
 30
 Gly Gln Ile Glu Glu Phe Leu Met Gln Phe Asn Gly Glu Gly Ile Gln
 225 230 235 240
 35
 His Val Ala Phe Leu Thr Asp Asp Leu Val Lys Thr Trp Asp Ala Leu
 245 250 255
 Lys Lys Ile Gly Met Arg Phe Met Thr Ala Pro Pro Asp Thr Tyr Tyr
 260 265 270
 40
 Glu Met Leu Glu Gly Arg Leu Pro Asp His Gly Glu Pro Val Asp Gln
 275 280 285
 45
 Leu Gln Ala Arg Gly Ile Leu Leu Asp Gly Ser Ser Val Glu Gly Asp
 290 295 300
 Lys Arg Leu Leu Leu Gln Ile Phe Ser Glu Thr Leu Met Gly Pro Val
 305 310 315 320
 50
 Phe Phe Glu Phe Ile Gln Arg Lys Gly Asp Asp Gly Phe Gly Glu Gly
 325 330 335
 55

EP 2 453 012 A1

Asn Phe Lys Ala Leu Phe Glu Ser Ile Glu Arg Asp Gln Val Arg Arg
 5 340 345 350

Gly Val Leu Thr Ala Asp
 355

10 <210> 13
 <211> 1053
 <212> DNA
 <213> Synechococcus sp.

15 <400> 13
 atgaaccCGT ccattcgaat tgtccaaggg atccaccacc tgcacttcta cctttgggat 60
 ctgccccgtt ggcgggaaca cttttgtcgg gtttggggct tccgggtggc aagcgacgcc 120
 20 ggcaacaccc tggagctgga gcagggatcc ctgcgcttgc gcctgtctca gccggcacgg 180
 gcgggggacg aggtggaccg ccatttgcag cggcatgggc cgggggtggt ggatgtggcc 240
 ttggcgggtg gagagcagga gctaccggcc ttggcggagc tgttgcgggg ccgaggcgcc 300
 25 caactggcgt ggatcccggc agcagcggcg ctctgcctcc acacccccta cgggatccgg 360
 cattctctga tccctggccc cttggatgcc gccctgccg aagcgggcct gttttccac 420
 tgggatcacg tgggtgtgaa cgtggagcag ggatccctgc aggcggcagc cgactggtat 480
 30 gggcgggtgc tgggctggcg gcggtgtac cgtacagca tcggcaccgc cacctccggc 540
 ctggaaagcg tgggtggtgg ggatccggaa gcggggatcc aatgggccat caacgagccc 600
 acctgtgccg ctteccagat tcaggagttt ttgcatgccc atggcggccc gggcattcag 660
 35 cacgcggcgc tgcacagctc agacattggt gccagcctgc gccggttgcg gcagggggga 720
 gtggactttt tgcaagtggc gccgcagtac tacaccagcc tggaaaggga gctgggggtg 780
 gcgctccgtt ctgcccttgg gcaggccatc tcctggcaag acctggtgga gcagcagatc 840
 40 cttctggatg ctaccctgcc cgtttctgat ggccaggatc gcccccttct gctgcagacc 900
 tttaccagc ccctctttgg tcggcccacc tttttctttg aagtcattca acggctaggc 960
 45 ggggccacgg gctttggcga ggccaatfff caggctttgt tcgaggccct ggaacggcaa 1020
 cagcgacagc gacaccaggc gctgaccctt tag 1053

50 <210> 14
 <211> 350
 <212> PRT
 <213> Synechococcus sp.

<400> 14

55

EP 2 453 012 A1

Met Asn Pro Ser Ile Arg Ile Val Gln Gly Ile His His Leu His Phe
 1 5 10 15

5 Tyr Leu Trp Asp Leu Pro Arg Trp Arg Glu His Phe Cys Arg Val Trp
 20 25 30

10 Gly Phe Arg Val Ala Ser Asp Ala Gly Asn Thr Leu Glu Leu Glu Gln
 35 40 45

15 Gly Ser Leu Arg Leu Arg Leu Ser Gln Pro Ala Arg Ala Gly Asp Glu
 50 55 60

20 Val Asp Arg His Leu Gln Arg His Gly Pro Gly Val Val Asp Val Ala
 65 70 75 80

25 Leu Ala Val Gly Glu Gln Glu Leu Pro Ala Leu Ala Glu Leu Leu Arg
 85 90 95

30 Gly Arg Gly Ala Gln Leu Ala Trp Ile Pro Ala Ala Ala Ala Leu Cys
 100 105 110

35 Leu His Thr Pro Tyr Gly Ile Arg His Ser Leu Ile Pro Gly Pro Leu
 115 120 125

40 Asp Ala Ala Pro Ala Glu Ala Gly Leu Phe Ser His Trp Asp His Val
 130 135 140

45 Val Leu Asn Val Glu Gln Gly Ser Leu Gln Ala Ala Ala Asp Trp Tyr
 145 150 155 160

50 Gly Arg Val Leu Gly Trp Arg Arg Leu Tyr Arg Tyr Ser Ile Gly Thr
 165 170 175

55 Ala Thr Ser Gly Leu Glu Ser Val Val Val Gly Asp Pro Glu Ala Gly
 180 185 190

Ile Gln Trp Ala Ile Asn Glu Pro Thr Cys Ala Ala Ser Gln Ile Gln
 195 200 205

Glu Phe Leu His Ala His Gly Gly Pro Gly Ile Gln His Ala Ala Leu
 210 215 220

His Ser Ser Asp Ile Val Ala Ser Leu Arg Arg Leu Arg Gln Gly Gly
 225 230 235 240

EP 2 453 012 A1

5 Val Asp Phe Leu Gln Val Ala Pro Gln Tyr Tyr Thr Ser Leu Glu Arg
 245 250 255

Glu Leu Gly Leu Ala Leu Arg Ser Ala Leu Gly Gln Ala Ile Ser Trp
 260 265 270

10 Gln Asp Leu Val Glu Gln Gln Ile Leu Leu Asp Ala Thr Leu Pro Ala
 275 280 285

15 Ser Asp Gly Gln Asp Arg Pro Leu Leu Leu Gln Thr Phe Thr Gln Pro
 290 295 300

Leu Phe Gly Arg Pro Thr Phe Phe Phe Glu Val Ile Gln Arg Leu Gly
 305 310 315 320

20 Gly Ala Thr Gly Phe Gly Glu Ala Asn Phe Gln Ala Leu Phe Glu Ala
 325 330 335

25 Leu Glu Arg Gln Gln Arg Gln Arg His Gln Ala Leu Thr Pro
 340 345 350

30 <210> 15
 <211> 1149
 <212> DNA
 <213> Blepharisma japonicum

<400> 15
 atgacttatt acgacaagca agaaacgcgt ccagatcttg gccaattcta tggtttccat 60

35 cacgttcggt tttacgtctc caactcagag caagccgctt cgttctacac atctcgcttt 120

gggttttctc cggttgccta tgaaggattg gaaacaggaa accaaaaatt ctgtaccaat 180

gtcgtccgaa gcaacatgt agtcatcgtt tttacctcag ctctcactcc tgaagacaat 240

40 gaagtgaacc gtcacgttgg caagcatagt gatggagttc aagacattgc ctttagtgta 300

agtgacgcaa gagggatgta tgagaaagcg atagctaaag gctgtaaaag cttccgtgag 360

45 ccacaggttt tacaagatca atttggatct gttataatag cgtctctcca gacttatgga 420

gacactgttc acacattagt ccaaaatgct gactatacag gacccttttt gcctggcttc 480

agagcaatca caaaagatga tccattaaac tctgcctttc ctcaggtaaa ttatgacatt 540

50 attgatcatg ttgtaggaaa tcagcctggg ggcgatatga ctctacagt agaatggat 600

gagaaatc tagaatttca tcgatattgg tctgctgatg agtctgtaat ccataccgat 660

tattcagcat taaggtctgt tgtggttgct gattgggatg aagtgatcaa aatgcctatt 720

55

EP 2 453 012 A1

aatgagcctg ctgatggact tagaaaaagt caaatccaag aatatgtcga atattatggt 780
 5 ggagcaggcg tacaacatat tgccttaaaa gtcaatgata ttatttcagt aataagcacc 840
 ttaagggcta gaggtgtgga attccttagaa gttcctocta aatattatga tagcttaaga 900
 aaaagacttg cgcattctgc ggtacaaaatt gaagaagact taaaaagaat tgaagacctt 960
 10 catatcttgg ttgactttga cgaccgtggg tatttacttc agattttcac aaaaccagta 1020
 gaagacagac ctactctgtt ttatgaaatt attcaaagac ataataacaa tggattcggga 1080
 attggaaatt ttaaagccct atttgaatca ttggaacaag agcaagaaag aagaggtaat 1140
 15 ttgatctaa 1149

<210> 16
 <211> 382
 <212> PRT
 20 <213> Blepharisma japonicum
 <400> 16

Met Thr Tyr Tyr Asp Lys Gln Glu Thr Arg Pro Asp Leu Gly Glu Phe
 25 1 5 10 15

Tyr Gly Phe His His Val Arg Phe Tyr Val Ser Asn Ser Glu Gln Ala
 30 20 25 30

Ala Ser Phe Tyr Thr Ser Arg Phe Gly Phe Ser Pro Val Ala Tyr Glu
 35 35 40 45

Gly Leu Glu Thr Gly Asn Gln Lys Phe Cys Thr Asn Val Val Arg Ser
 40 50 55 60

Asn His Val Val Ile Ala Phe Thr Ser Ala Leu Thr Pro Glu Asp Asn
 45 65 70 75 80

Glu Val Asn Arg His Val Gly Lys His Ser Asp Gly Val Gln Asp Ile
 50 85 90 95

Ala Phe Ser Val Ser Asp Ala Arg Gly Met Tyr Glu Lys Ala Ile Ala
 55 100 105 110

Lys Gly Cys Lys Ser Phe Arg Glu Pro Gln Val Leu Gln Asp Gln Phe
 60 115 120 125

Gly Ser Val Ile Ile Ala Ser Leu Gln Thr Tyr Gly Asp Thr Val His
 65 130 135 140

EP 2 453 012 A1

5 Thr Leu Val Gln Asn Val Asp Tyr Thr Gly Pro Phe Leu Pro Gly Phe
 145 150 155 160

Arg Ala Ile Thr Lys Asp Asp Pro Leu Asn Ser Ala Phe Pro Gln Val
 165 170 175

10 Asn Tyr Asp Ile Ile Asp His Val Val Gly Asn Gln Pro Gly Gly Asp
 180 185 190

15 Met Thr Pro Thr Val Glu Trp Tyr Glu Lys Tyr Leu Glu Phe His Arg
 195 200 205

Tyr Trp Ser Ala Asp Glu Ser Val Ile His Thr Asp Tyr Ser Ala Leu
 210 215 220

20 Arg Ser Val Val Val Ala Asp Trp Asp Glu Val Ile Lys Met Pro Ile
 225 230 235 240

25 Asn Glu Pro Ala Asp Gly Leu Arg Lys Ser Gln Ile Gln Glu Tyr Val
 245 250 255

Glu Tyr Tyr Gly Gly Ala Gly Val Gln His Ile Ala Leu Lys Val Asn
 260 265 270

30 Asp Ile Ile Ser Val Ile Ser Thr Leu Arg Ala Arg Gly Val Glu Phe
 275 280 285

35 Leu Glu Val Pro Pro Lys Tyr Tyr Asp Ser Leu Arg Lys Arg Leu Ala
 290 295 300

40 His Ser Ala Val Gln Ile Glu Glu Asp Leu Lys Arg Ile Glu Asp Leu
 305 310 315 320

His Ile Leu Val Asp Phe Asp Asp Arg Gly Tyr Leu Leu Gln Ile Phe
 325 330 335

45 Thr Lys Pro Val Glu Asp Arg Pro Thr Leu Phe Tyr Glu Ile Ile Gln
 340 345 350

50 Arg His Asn Asn Asn Gly Phe Gly Ile Gly Asn Phe Lys Ala Leu Phe
 355 360 365

Glu Ser Leu Glu Gln Glu Gln Glu Arg Arg Gly Asn Leu Ile

55

EP 2 453 012 A1

370 375 380

5 <210> 17
 <211> 1206
 <212> DNA
 <213> Rhodococcus sp.

<400> 17

10 atgacgatcg agcagactct caccgacaag gaacgcctgg caggtctcga cctcggccag 60
 ctcgagcagt tggtcgggct cgtcgagtag gacggcacc cgcacccggt cccggtcagc 120
 ggctgggatg ccgtcgtctg ggtggtcggc aacgccacc agaccgcca ctacttccag 180

15 tccgcgttcg ggatgaccct cgtcgcctac tccggacca ccaccgcaa ccgcgaccac 240
 cacagcttcg tectcgaatc cggggcgcgc cgttcgtca tcaaaggcgc cgtgaaccgc 300
 gacagcccc tgatcgacca ccaccgcacc cacggcgacg gcgtcgtcga catcgccctc 360

20 gccgtccccg acgtcgaaa gtgcatcgcc cacgcccgcg cccagggcgc caccgtcctc 420
 gacgaacccc acgacgtgac cgacgaccac ggacccgtcc gcctcgcgc gatcgccacc 480
 tacggcgaca ccgccacac cctcgtcgac cgcagccact acaccggccc ctacctgcc 540

25 ggctacaccg cccgcacctc cggccacacc aaacgggacg gggcaccaa gcgcctgttc 600
 caggccctcg accacgtcgt cggcaacgtc gaactcggca agatggacca ctgggtcgac 660

30 ttctacaacc gggtcatggg ctttacgaac atggccgagt tcgtcggcga ggacatcgcc 720
 accgactact ccgcgctgat gagcaaggtc gtcctcaacg gcaaccaccg ggtcaagttc 780
 cccctcaacg aaccgcctc cgccaagaaa cgtcgcgaga tcgacgaata cctcgacttc 840

35 taccgcggcc ccggcgccca gcacctggcc ctggccacca atgacatcct caccgccgtc 900
 gaccagctga ccgccgagg cgtogagttc ctggccacc ccgactccta ctacgaggac 960
 cccgaactgc gggcccggat cggcaacgtc cgcgccccca tcgccgaact gcagaaacgc 1020

40 ggcacccctc togaccgca cgaagacggc tacctgctgc agatcttcac caaacccctc 1080
 gtcgaccggc ccaccgtggt cttcgaactc atcgaacgcc acggctccct cggcttcggc 1140
 atcggcaact tcaaagccct cttcgaggcc atcgaacgcg aacaagccgc ccgcggaac 1200

45 ttctga 1206

<210> 18
 <211> 401
 <212> PRT
 <213> Rhodococcus sp.

<400> 18

55

EP 2 453 012 A1

Met Thr Ile Glu Gln Thr Leu Thr Asp Lys Glu Arg Leu Ala Gly Leu
 1 5 10 15

5 Asp Leu Gly Gln Leu Glu Gln Leu Val Gly Leu Val Glu Tyr Asp Gly
 20 25 30

Thr Arg Asp Pro Phe Pro Val Ser Gly Trp Asp Ala Val Val Trp Val
 10 35 40 45

Val Gly Asn Ala Thr Gln Thr Ala His Tyr Phe Gln Ser Ala Phe Gly
 50 55 60

15 Met Thr Leu Val Ala Tyr Ser Gly Pro Thr Thr Gly Asn Arg Asp His
 65 70 75 80

20 His Ser Phe Val Leu Glu Ser Gly Ala Val Arg Phe Val Ile Lys Gly
 85 90 95

Ala Val Asn Pro Asp Ser Pro Leu Ile Asp His His Arg Thr His Gly
 100 105 110

25 Asp Gly Val Val Asp Ile Ala Leu Ala Val Pro Asp Val Asp Lys Cys
 115 120 125

30 Ile Ala His Ala Arg Ala Gln Gly Ala Thr Val Leu Asp Glu Pro His
 130 135 140

Asp Val Thr Asp Asp His Gly Thr Val Arg Leu Ala Ala Ile Ala Thr
 145 150 155 160

35 Tyr Gly Asp Thr Arg His Thr Leu Val Asp Arg Ser His Tyr Thr Gly
 165 170 175

40 Pro Tyr Leu Pro Gly Tyr Thr Ala Arg Thr Ser Gly His Thr Lys Arg
 180 185 190

Asp Gly Ala Pro Lys Arg Leu Phe Gln Ala Leu Asp His Val Val Gly
 195 200 205

45 Asn Val Glu Leu Gly Lys Met Asp His Trp Val Asp Phe Tyr Asn Arg
 210 215 220

50 Val Met Gly Phe Thr Asn Met Ala Glu Phe Val Gly Glu Asp Ile Ala
 225 230 235 240

55

EP 2 453 012 A1

Thr Asp Tyr Ser Ala Leu Met Ser Lys Val Val Ser Asn Gly Asn His
 245 250 255
 5
 Arg Val Lys Phe Pro Leu Asn Glu Pro Ala Leu Ala Lys Lys Arg Ser
 260 265 270
 10
 Gln Ile Asp Glu Tyr Leu Asp Phe Tyr Arg Gly Pro Gly Ala Gln His
 275 280 285
 15
 Leu Ala Leu Ala Thr Asn Asp Ile Leu Thr Ala Val Asp Gln Leu Thr
 290 295 300
 Ala Glu Gly Val Glu Phe Leu Ala Thr Pro Asp Ser Tyr Tyr Glu Asp
 305 310 315 320
 20
 Pro Glu Leu Arg Ala Arg Ile Gly Asn Val Arg Ala Pro Ile Ala Glu
 325 330 335
 25
 Leu Gln Lys Arg Gly Ile Leu Val Asp Arg Asp Glu Asp Gly Tyr Leu
 340 345 350
 Leu Gln Ile Phe Thr Lys Pro Leu Val Asp Arg Pro Thr Val Phe Phe
 355 360 365
 30
 Glu Leu Ile Glu Arg His Gly Ser Leu Gly Phe Gly Ile Gly Asn Phe
 370 375 380
 35
 Lys Ala Leu Phe Glu Ala Ile Glu Arg Glu Gln Ala Ala Arg Gly Asn
 385 390 395 400
 Phe
 40
 <210> 19
 <211> 1107
 <212> DNA
 <213> *Picrophilus torridus*
 45
 <400> 19
 atgtatggca aaaatttaat ctcagaacta agggaaaagg agatctttaa acgattacat 60
 cacgtggaat tttacgttag cagtgcctaaa acatggtcat atttcatgaa caggggtctt 120
 50
 ggatttaaaa cagtggcata tgccgggtcca gaaaccggga taagggacaa gatatacctat 180
 gttatgtccc agggcactgc aaggatatct tttacatcat caatgaatga tgatagctat 240
 55

EP 2 453 012 A1

5
 10
 15
 20
 25

```

atatcgaatc atgttaaaaa acacggggat ggcgtaaagg atatagcact tgaggtcgat 300
gatctggacg aggcaaaaag cctgatagaa aagtatggaa caaaggtttc aaaaataaat 360
gaaataaagg atggaaatgg aaagataaga actgcagaga taaaaacgta cggtgaaacc 420
gttcatacat taatagaaac cggggattac aatggcgtat tcatgcccgg ttatgaggaa 480
tctgaaataa attcaaaaaa cactgggata aaaaagatcg atcatatagt tggaaatgtc 540
tatgagggcg agatggatag ctgggttaat ttttacatag aaaaacttgg ctttgagcat 600
ttaataacct ttgatgataa agatataaga actgattaca gcgattaag atcaaaggtt 660
gtaaaataca atgacgatat cgtattttcca ataaatgagc ctgcaaaggg cttaagaaaa 720
tcacagatag aggaatatct tgactattac aggtctgagg gcgttcagca catagcactg 780
ttaactgatg atataataaa aactgtatcc atgatggagg aaaacggcat agaattttta 840
aaaacaccag gatcatacta tgaatcccta tcatcaagga taggctcaat agacgaggat 900
ttaaatgaaa tagagaaaca taacatactt gtggatcgtg atgagaacgg atacctatta 960
cagatcttca caaagcctgt tactgacagg ccaacgttct tctttgaggt catacagaga 1020
aagggtgcaa ggtcattcgg caacggtaac ttaaggcac tttttgaggc gatagaaagg 1080
gagcaggcaa agagaggaaa cctatga 1107
  
```

30
 <210> 20
 <211> 368
 <212> PRT
 <213> *Picrophilus torridus*

<400> 20

35
 Met Tyr Gly Lys Asn Leu Ile Ser Glu Leu Arg Glu Lys Glu Ile Phe
 1 5 10 15

40
 Lys Arg Leu His His Val Glu Phe Tyr Val Ser Ser Ala Lys Thr Trp
 20 25 30

Ser Tyr Phe Met Asn Arg Gly Leu Gly Phe Lys Thr Val Ala Tyr Ala
 35 40 45

45
 Gly Pro Glu Thr Gly Ile Arg Asp Lys Ile Ser Tyr Val Met Ser Gln
 50 55 60

50
 Gly Thr Ala Arg Ile Ser Phe Thr Ser Ser Met Asn Asp Asp Ser Tyr
 65 70 75 80

Ile Ser Asn His Val Lys Lys His Gly Asp Gly Val Lys Asp Ile Ala

55

EP 2 453 012 A1

				85					90					95			
5	Leu	Glu	Val	Asp	Asp	Leu	Asp	Glu	Ala	Lys	Ser	Leu	Ile	Glu	Lys	Tyr	
				100					105					110			
	Gly	Thr	Lys	Val	Ser	Lys	Ile	Asn	Glu	Ile	Lys	Asp	Gly	Asn	Gly	Lys	
10			115					120					125				
	Ile	Arg	Thr	Ala	Glu	Ile	Lys	Thr	Tyr	Gly	Glu	Thr	Val	His	Thr	Leu	
		130					135					140					
15	Ile	Glu	Thr	Gly	Asp	Tyr	Asn	Gly	Val	Phe	Met	Pro	Gly	Tyr	Glu	Glu	
	145					150					155					160	
	Ser	Glu	Ile	Asn	Ser	Lys	Asn	Thr	Gly	Ile	Lys	Lys	Ile	Asp	His	Ile	
20				165						170				175			
	Val	Gly	Asn	Val	Tyr	Glu	Gly	Glu	Met	Asp	Ser	Trp	Val	Asn	Phe	Tyr	
				180					185					190			
25	Ile	Glu	Lys	Leu	Gly	Phe	Glu	His	Leu	Ile	Thr	Phe	Asp	Asp	Lys	Asp	
			195					200					205				
30	Ile	Arg	Thr	Asp	Tyr	Ser	Ala	Leu	Arg	Ser	Lys	Val	Val	Lys	Tyr	Asn	
		210					215					220					
	Asp	Asp	Ile	Val	Phe	Pro	Ile	Asn	Glu	Pro	Ala	Lys	Gly	Leu	Arg	Lys	
35		225				230					235					240	
	Ser	Gln	Ile	Glu	Glu	Tyr	Leu	Asp	Tyr	Tyr	Arg	Ser	Glu	Gly	Val	Gln	
					245					250					255		
40	His	Ile	Ala	Leu	Leu	Thr	Asp	Asp	Ile	Ile	Lys	Thr	Val	Ser	Met	Met	
				260					265					270			
	Glu	Glu	Asn	Gly	Ile	Glu	Phe	Leu	Lys	Thr	Pro	Gly	Ser	Tyr	Tyr	Glu	
45			275					280					285				
	Ser	Leu	Ser	Ser	Arg	Ile	Gly	Ser	Ile	Asp	Glu	Asp	Leu	Asn	Glu	Ile	
		290					295					300					
50	Glu	Lys	His	Asn	Ile	Leu	Val	Asp	Arg	Asp	Glu	Asn	Gly	Tyr	Leu	Leu	
	305					310					315					320	

55

EP 2 453 012 A1

Gln Ile Phe Thr Lys Pro Val Thr Asp Arg Pro Thr Phe Phe Phe Glu
 325 330 335

5 Val Ile Gln Arg Lys Gly Ala Arg Ser Phe Gly Asn Gly Asn Phe Lys
 340 345 350

10 Ala Leu Phe Glu Ala Ile Glu Arg Glu Gln Ala Lys Arg Gly Asn Leu
 355 360 365

<210> 21

<211> 1164

<212> DNA

15 <213> Kordia algicida

<400> 21

atggcagcag aaataaaaaa cttaaaagat ttacaaaata cagaatacgg actcaaaaaa 60
 20 ttatattgacg aagcagaaga ctttcttcca cttttaggaa cagactacgt agaattatac 120
 gtcgggaacg ccaacaatc ggcacatttc taaaaacgg cttttggttt tcaatcagaa 180
 gcttacgcag gattggaaac aggattaacc gacagagttt catacgtatt aaaacaagat 240
 25 aaaattcgct tggctttaac aacaccatta ggaaaagggtg gcgaaatcaa tgagcatatc 300
 gatttacacg gcgatggcgt aaaagtagta gcactttggg tagaagatgc taaaaagcc 360
 tttgaagaaa cgacccaaaag aggcgcaaaa ccgtacatgg aaccaacaaa agaagaagat 420
 30 gaaaacggat atgtaattcg ctcaggaatc tatacgtacg gagaaacggg tcatgttttt 480
 gtagaacgta aaaactataa cggagctctt ttaccaggat atcaaagatg ggaatctcac 540
 tacaatccgg agccagttgg cttaaaattc atcgatcaca tggtaggaaa tgtaggttgg 600
 35 ggagaaatga aagaatgggtg tgaattctac gcgaaagtaa tgggatttgc gcaaattatc 660
 tcctttacag atgatgatat ttctaccgat tttactgcgt tgatgagtaa agtaatgagt 720
 aatggaaatg gtagaatcaa atttccaatc aatgaaccgg cagaaggaaa aaagaaatcg 780
 40 caaattgaag aatatctaga cttttacaat ggttcaggag tacaacatat tgcggttgc 840
 acagacaata ttattgatac ggtttcgcaa atgcgcgaac gtggagtaga attcttatac 900
 gttccagata catattatga tgacttgta gaacgtggtg gcgacatcga tgaagatgta 960
 45 gaagaactca aaaaacacgg aatcttaatt gatcgtgatg aagaaggata cttattgcag 1020
 ttatttacca aaaccattgt agacagacca acaatgttct ttgaagtcac tcagcgtaaa 1080
 50 ggcgcaaat catttgagat aggaaacttt aaagctttat ttgaagcgat agaaagagaa 1140
 caagctgctc gcggaacatt gtaa 1164

55

EP 2 453 012 A1

<210> 22
 <211> 387
 <212> PRT
 <213> Kordia algicida
 5
 <400> 22
 Met Ala Ala Glu Ile Lys Asn Leu Lys Asp Leu Gln Asn Thr Glu Tyr
 1 5 10 15
 10
 Gly Leu Lys Lys Leu Phe Asp Glu Ala Glu Asp Phe Leu Pro Leu Leu
 20 25 30
 15
 Gly Thr Asp Tyr Val Glu Leu Tyr Val Gly Asn Ala Lys Gln Ser Ala
 35 40 45
 20
 His Phe Tyr Lys Thr Ala Phe Gly Phe Gln Ser Glu Ala Tyr Ala Gly
 50 55 60
 Leu Glu Thr Gly Leu Thr Asp Arg Val Ser Tyr Val Leu Lys Gln Asp
 65 70 75 80
 25
 Lys Ile Arg Leu Val Leu Thr Thr Pro Leu Gly Lys Gly Gly Glu Ile
 85 90 95
 30
 Asn Glu His Ile Asp Leu His Gly Asp Gly Val Lys Val Val Ala Leu
 100 105 110
 Trp Val Glu Asp Ala Thr Lys Ala Phe Glu Glu Thr Thr Lys Arg Gly
 115 120 125
 35
 Ala Lys Pro Tyr Met Glu Pro Thr Lys Glu Glu Asp Glu Asn Gly Tyr
 130 135 140
 40
 Val Ile Arg Ser Gly Ile Tyr Thr Tyr Gly Glu Thr Val His Val Phe
 145 150 155 160
 Val Glu Arg Lys Asn Tyr Asn Gly Val Phe Leu Pro Gly Tyr Gln Arg
 165 170 175
 45
 Trp Glu Ser His Tyr Asn Pro Glu Pro Val Gly Leu Lys Phe Ile Asp
 180 185 190
 50
 His Met Val Gly Asn Val Gly Trp Gly Glu Met Lys Glu Trp Cys Glu
 195 200 205
 55

EP 2 453 012 A1

Phe Tyr Ala Lys Val Met Gly Phe Ala Gln Ile Ile Ser Phe Thr Asp
 210 215 220

5 Asp Asp Ile Ser Thr Asp Phe Thr Ala Leu Met Ser Lys Val Met Ser
 225 230 235 240

Asn Gly Asn Gly Arg Ile Lys Phe Pro Ile Asn Glu Pro Ala Glu Gly
 10 245 250 255

Lys Lys Lys Ser Gln Ile Glu Glu Tyr Leu Asp Phe Tyr Asn Gly Ser
 260 265 270

15 Gly Val Gln His Ile Ala Val Ala Thr Asp Asn Ile Ile Asp Thr Val
 275 280 285

20 Ser Gln Met Arg Glu Arg Gly Val Glu Phe Leu Tyr Val Pro Asp Thr
 290 295 300

Tyr Tyr Asp Asp Leu Leu Glu Arg Val Gly Asp Ile Asp Glu Asp Val
 305 310 315 320

25 Glu Glu Leu Lys Lys His Gly Ile Leu Ile Asp Arg Asp Glu Glu Gly
 325 330 335

30 Tyr Leu Leu Gln Leu Phe Thr Lys Thr Ile Val Asp Arg Pro Thr Met
 340 345 350

Phe Phe Glu Val Ile Gln Arg Lys Gly Ala Gln Ser Phe Gly Val Gly
 35 355 360 365

Asn Phe Lys Ala Leu Phe Glu Ala Ile Glu Arg Glu Gln Ala Ala Arg
 370 375 380

40 Gly Thr Leu
 385

<210> 23
 45 <211> 1323
 <212> DNA
 <213> Sorghum bicolor

<400> 23
 50 atgccccga cccccaccac agccgcccga accggcgccg ccgtggcggc ggcacacgca 60
 gagcaggcgg cgttccgcct cgtggggccac cgcaacttcg tccgctgaa cccgcgetcc 120
 gaccgcttcc acacgctcgc gttccaccac gtggagctct ggtgcccga cgcggcctcc 180

55

EP 2 453 012 A1

gcccgcgggcc gcttctcctt cgggctcggc gcgcccctcg ccgcgcggtc cgacctctcc 240
5 acggggaaca ccgcgcacgc gtccctgctg ctccgctcgg gcgccctcgc gttcctcttc 300
acggcgcctt acgcgcacgg cgcgcacgcc gccacggcct cgctgccctc cttctccgcc 360
gccgaggcgc ggcgcttcgc ggccgaccac ggcctcgcgg tgcgcgccgt cgcgctccgc 420
10 gtggccgacg cggaggacgc ctccgcgcgc agcgtcgcgg ccggcgcgcg cccggcgttc 480
gagcccgtcg agctcggcct cggcttcgcg ctccgcgaag tcgagctcta cggcgacgtc 540
gtgctccggt acgtgagcta cccggacgac gcggacgcgt ccttctgcc ggggttcgtg 600
15 ggcgtgacca gccccggcgc ggccgactac ggcgtgagga ggttcgacca catcgtcggc 660
aacgtgccgg agctggcgcc ggccggcgcc tacttcgctg gcttcacggg gttccacgag 720
ttcgccgagt tcacggcgga ggacgtgggc accacggaga gcgggctcaa ctcgatggtg 780
20 ctcgccaaca acgcggagaa cgtgctgctc cactcaacg agccggtgca cggcaccaag 840
cgccgcagcc agatacagac gtacttgac caccacggcg gccccggcgt gcagcacatg 900
gcgctggcca gcgacgacgt gctcaggacg ctgagggaga tgcaagcgcg ctcggccatg 960
25 gggcgcttcg agttcatggc gcctccggcg cccgaatact atgacggcgt gaggcggcgc 1020
gccggggacg tgctcacgga ggcacagatt aaggagtgtc aggaactagg ggtgctggtg 1080
gacagagatg accagggcgt gctgctccag atcttcacca agccagtggg ggacaggcca 1140
30 acgttggtct tggagatcat tcaaaggatc ggtgcatgg agaaggatga gaaggggcaa 1200
gaataccaga aggggtggctg tggcggggtt ggcaaggaa acttctcca gctgttcaaa 1260
35 tccattgagg attatgagaa gtcccttgaa gctaagcaag ctgcagcagc tcagggatcc 1320
tag 1323

40 <210> 24
<211> 440
<212> PRT
<213> Sorghum bicolor

<400> 24

45 Met Pro Pro Thr Pro Thr Thr Ala Ala Ala Thr Gly Ala Ala Val Ala
1 5 10 15

50 Ala Ala Ser Ala Glu Gln Ala Ala Phe Arg Leu Val Gly His Arg Asn
20 25 30

Phe Val Arg Val Asn Pro Arg Ser Asp Arg Phe His Thr Leu Ala Phe
35 40 45

55

EP 2 453 012 A1

5 His His Val Glu Leu Trp Cys Ala Asp Ala Ala Ser Ala Ala Gly Arg
50 55 60

Phe Ser Phe Gly Leu Gly Ala Pro Leu Ala Ala Arg Ser Asp Leu Ser
65 70 75 80

10 Thr Gly Asn Thr Ala His Ala Ser Leu Leu Leu Arg Ser Gly Ala Leu
85 90 95

15 Ala Phe Leu Phe Thr Ala Pro Tyr Ala His Gly Ala Asp Ala Ala Thr
100 105 110

Ala Ser Leu Pro Ser Phe Ser Ala Ala Glu Ala Arg Arg Phe Ala Ala
115 120 125

20 Asp His Gly Leu Ala Val Arg Ala Val Ala Leu Arg Val Ala Asp Ala
130 135 140

25 Glu Asp Ala Phe Arg Ala Ser Val Ala Ala Gly Ala Arg Pro Ala Phe
145 150 155 160

Glu Pro Val Glu Leu Gly Leu Gly Phe Arg Leu Ala Glu Val Glu Leu
165 170 175

30 Tyr Gly Asp Val Val Leu Arg Tyr Val Ser Tyr Pro Asp Asp Ala Asp
180 185 190

35 Ala Ser Phe Leu Pro Gly Phe Val Gly Val Thr Ser Pro Gly Ala Ala
195 200 205

40 Asp Tyr Gly Leu Arg Arg Phe Asp His Ile Val Gly Asn Val Pro Glu
210 215 220

Leu Ala Pro Ala Ala Ala Tyr Phe Ala Gly Phe Thr Gly Phe His Glu
225 230 235 240

45 Phe Ala Glu Phe Thr Ala Glu Asp Val Gly Thr Thr Glu Ser Gly Leu
245 250 255

50 Asn Ser Met Val Leu Ala Asn Asn Ala Glu Asn Val Leu Leu Pro Leu
260 265 270

Asn Glu Pro Val His Gly Thr Lys Arg Arg Ser Gln Ile Gln Thr Tyr

55

EP 2 453 012 A1

	275		280		285	
5	Leu Asp His His Gly Gly Pro Gly Val Gln His Met Ala Leu Ala Ser 290 295 300					
10	Asp Asp Val Leu Arg Thr Leu Arg Glu Met Gln Ala Arg Ser Ala Met 305 310 315 320					
	Gly Gly Phe Glu Phe Met Ala Pro Pro Ala Pro Glu Tyr Tyr Asp Gly 325 330 335					
15	Val Arg Arg Arg Ala Gly Asp Val Leu Thr Glu Ala Gln Ile Lys Glu 340 345 350					
20	Cys Gln Glu Leu Gly Val Leu Val Asp Arg Asp Asp Gln Gly Val Leu 355 360 365					
	Leu Gln Ile Phe Thr Lys Pro Val Gly Asp Arg Pro Thr Leu Phe Leu 370 375 380					
25	Glu Ile Ile Gln Arg Ile Gly Cys Met Glu Lys Asp Glu Lys Gly Gln 385 390 395 400					
30	Glu Tyr Gln Lys Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser 405 410 415					
	Gln Leu Phe Lys Ser Ile Glu Asp Tyr Glu Lys Ser Leu Glu Ala Lys 420 425 430					
35	Gln Ala Ala Ala Ala Gln Gly Ser 435 440					
40	<210> 25 <211> 1311 <212> DNA <213> Triticum aestivum					
45	<400> 25 atgccgccca cccccaccac ccccgagcc accggcgccg gcgctgccgc cgcggtgacg 60 ccggagcacg cgcggccgcg ccgaatggtc cgcttcaacc cgcgcagcga ccgcttccac 120 acgctctcct tcaccacgt cgagttctgg tgcgaggacg ccgcctccgc cgcgggccgc 180 ttcgcttcg cgctcggcgc gccgctcgcc gccaggtcg acctctccac ggggaactcc 240 gtgcacgcct ccagctgct ccgctcgggc aacctgcct tcctcttcac cgcgccctac 300					
55						

EP 2 453 012 A1

gcgaacggct gcgacgccgc caccgcctcc ctgccctcct tctccgccga cgccgcgcgc 360
 cggttctccg cggaccacgg gctcgcagtg cgtccatag cactgcgcgt cgcagacgcc 420
 5 gcagaggcct tccgcgccag cgtcgcagga ggcgcgcgcc cggccttcag ccccgtggac 480
 ctccgccgcg gcttcggcct cgcggaggtc gagctctaag gcgacgtcgt gctccgcttc 540
 gtcagtcacc cggatgacac ggacgtgccc ttcttgccgg ggttcgaggg cgtgagcaac 600
 10 ccggatgccg tggactacgg cctgacgcgg ttccgaccag tegtccgcaa cgtcccggag 660
 cttgcccccg ccgccgata cgtcgcggg ttccgcgggt tccacgagtt cgcagagttc 720
 acgacggagg acgtgggac ggccgagagc gggctcaact cgatggtgct cgccaacaac 780
 15 tcggagggcg tgctgctgcc gctcaacgag ccggtgcacg gcaccaagcg ccggagccag 840
 atacagacgt tcttgaaca ccacggcggc tcgggcgtgc agcacatcgc ggtggccagc 900
 agcgacgtgc tcaggacgct cagggagatg cgtcgcgcgt ccgccatggg cggcttcgac 960
 20 ttctgccac ccgctgccg aaagtactac gaaggcgtgc ggcgcacgc cggggatgtg 1020
 ctctcggagg cgcagatcaa ggaatgccag gagctggggg tgctcgtcga cagggacgac 1080
 caaggggtgt tgctacaaat cttcaciaaag ccagtggggg acaggccaac gctgttctctg 1140
 gagatgatcc aaaggatcgg gtgcatggag aaggacgaga gaggggaaga gtaccagaag 1200
 ggtggctcgc gcgggttcgg caaaggcaac ttctccgagc tgttcaagtc cattgaagat 1260
 30 tacgagaagt cccttgaagc caagcaatct gctgcagttc agggatcata g 1311

<210> 26
 <211> 436
 <212> PRT
 35 <213> Triticum aestivum

<400> 26

Met Pro Pro Thr Pro Thr Thr Pro Ala Ala Thr Gly Ala Gly Ala Ala
 40 1 5 10 15

Ala Ala Val Thr Pro Glu His Ala Arg Pro Arg Arg Met Val Arg Phe
 20 25 30

Asn Pro Arg Ser Asp Arg Phe His Thr Leu Ser Phe His His Val Glu
 35 40 45

Phe Trp Cys Ala Asp Ala Ala Ser Ala Ala Gly Arg Phe Ala Phe Ala
 50 55 60

Leu Gly Ala Pro Leu Ala Ala Arg Ser Asp Leu Ser Thr Gly Asn Ser

55

EP 2 453 012 A1

	65				70					75				80		
5	Val	His	Ala	Ser	Gln	Leu	Leu	Arg	Ser	Gly	Asn	Leu	Ala	Phe	Leu	Phe
					85					90					95	
	Thr	Ala	Pro	Tyr	Ala	Asn	Gly	Cys	Asp	Ala	Ala	Thr	Ala	Ser	Leu	Pro
10				100					105					110		
	Ser	Phe	Ser	Ala	Asp	Ala	Ala	Arg	Arg	Phe	Ser	Ala	Asp	His	Gly	Leu
			115					120					125			
15	Ala	Val	Arg	Ser	Ile	Ala	Leu	Arg	Val	Ala	Asp	Ala	Ala	Glu	Ala	Phe
		130					135					140				
	Arg	Ala	Ser	Val	Asp	Gly	Gly	Ala	Arg	Pro	Ala	Phe	Ser	Pro	Val	Asp
20	145					150				155						160
	Leu	Gly	Arg	Gly	Phe	Gly	Phe	Ala	Glu	Val	Glu	Leu	Tyr	Gly	Asp	Val
					165					170					175	
25	Val	Leu	Arg	Phe	Val	Ser	His	Pro	Asp	Asp	Thr	Asp	Val	Pro	Phe	Leu
				180					185					190		
	Pro	Gly	Phe	Glu	Gly	Val	Ser	Asn	Pro	Asp	Ala	Val	Asp	Tyr	Gly	Leu
30			195					200					205			
	Thr	Arg	Phe	Asp	His	Val	Val	Gly	Asn	Val	Pro	Glu	Leu	Ala	Pro	Ala
		210					215					220				
35	Ala	Ala	Tyr	Val	Ala	Gly	Phe	Ala	Gly	Phe	His	Glu	Phe	Ala	Glu	Phe
	225					230					235					240
	Thr	Thr	Glu	Asp	Val	Gly	Thr	Ala	Glu	Ser	Gly	Leu	Asn	Ser	Met	Val
40					245					250					255	
	Leu	Ala	Asn	Asn	Ser	Glu	Gly	Val	Leu	Leu	Pro	Leu	Asn	Glu	Pro	Val
45				260					265					270		
	His	Gly	Thr	Lys	Arg	Arg	Ser	Gln	Ile	Gln	Thr	Phe	Leu	Glu	His	His
			275					280					285			
50	Gly	Gly	Ser	Gly	Val	Gln	His	Ile	Ala	Val	Ala	Ser	Ser	Asp	Val	Leu
		290					295					300				
55																

EP 2 453 012 A1

Arg Thr Leu Arg Glu Met Arg Ala Arg Ser Ala Met Gly Gly Phe Asp
 305 310 315 320

5 Phe Leu Pro Pro Arg Cys Arg Lys Tyr Tyr Glu Gly Val Arg Arg Ile
 325 330 335

Ala Gly Asp Val Leu Ser Glu Ala Gln Ile Lys Glu Cys Gln Glu Leu
 10 340 345 350

Gly Val Leu Val Asp Arg Asp Asp Gln Gly Val Leu Leu Gln Ile Phe
 355 360 365

15 Thr Lys Pro Val Gly Asp Arg Pro Thr Leu Phe Leu Glu Met Ile Gln
 370 375 380

Arg Ile Gly Cys Met Glu Lys Asp Glu Arg Gly Glu Glu Tyr Gln Lys
 20 385 390 395 400

Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu Phe Lys
 405 410 415

25 Ser Ile Glu Asp Tyr Glu Lys Ser Leu Glu Ala Lys Gln Ser Ala Ala
 420 425 430

30 Val Gln Gly Ser
 435

<210> 27
 <211> 1305
 <212> DNA
 <213> Hordeum vulgare

<400> 27
 atgccgccca cccccaccac ccccgcggt accggcgccg ccgccgcggt gacgccggag 60
 40 cacgcgcgac cgcaccgaat ggtccgcttc aaccgcgcga gcgaccgctt ccacacgctc 120
 tccttcacc acgtcgagtt ctggtgcgcg gacgccgctt ccgccgcgg cgccttcgcg 180
 ttgcgcctcg gcgcgccgct gcgcgccagg tccgacctct ccacggggaa ctccgcgcac 240
 45 gcctcccagc tgctccgctc gggctccctc gccttctctt tcaccgcgcc ctacgccaac 300
 ggctgcgacg ccgccaccgc ctccctgccc tccttctcgg ccgacgcgc gcgccggttc 360
 50 tccgccgacc acgggatcgc ggtgcgctcc gtagcgctgc gcgtcgcaga cgcgccgag 420
 gccttccgcg ccagtcgtcg acggggcgcg cgcgccgctt tcgccccgt ggacctcgcg 480
 cgcggcttcg cgttcgcgga ggtcgagctc tacggcgacg tcgtgctccg cttcgtcagc 540

55

EP 2 453 012 A1

caccgacg gcacggacgt gcccttcttg ccggggttcg agggcgtaac caaccgac 600
 5 gccgtggact acggcctgac gcggttcgac cacgtcgtcg gcaacgtccc ggagcttgcc 660
 cccgccgacg cctacatcgc cgggttcacg gggttccacg agttcgcga gttcacggcg 720
 gaggacgtgg gcacgaccga gaggggctc aactcgggtg tgctcgcaa caactcggag 780
 10 ggcgtgctgc tgccgctcaa cgagccggtg cacggcacca agcgcgggag ccagatacag 840
 acgttctctg aacaccacgg cggcccgggc gtgcagcaca tcgcggtggc cagcagtgc 900
 gtgctcagga cgctcaggaa gatgcgtgcg cgctccgcca tgggcggctt cgacttctg 960
 15 ccacccccgc tgccgaagta ctacgaaggc gtgcgacgcc ttgccgggga tgcctctcg 1020
 gaggcgcaga tcaaggaatg ccaggagctg ggtgtgctcg tcgataggga cgaccaaggg 1080
 gtgttgctcc aaatcttcac caagccagta gggacagggc cgacctgtt cctggagatg 1140
 20 atccagagga tcgggtgcat ggagaaggac gagagagggg aagagtacca gaagggtggc 1200
 tcggcgggt tcggcaaagg caacttctcc gagctgttca agtccattga agattacgag 1260
 aagtccctg aagccaagca atctgctgca gttcagggat catag 1305

25

<210> 28
 <211> 434
 <212> PRT
 <213> Hordeum vulgare

30

<400> 28

Met Pro Pro Thr Pro Thr Thr Pro Ala Ala Thr Gly Ala Ala Ala Ala
 1 5 10 15

35

Val Thr Pro Glu His Ala Arg Pro His Arg Met Val Arg Phe Asn Pro
 20 25 30

40

Arg Ser Asp Arg Phe His Thr Leu Ser Phe His His Val Glu Phe Trp
 35 40 45

45

Cys Ala Asp Ala Ala Ser Ala Ala Gly Arg Phe Ala Phe Ala Leu Gly
 50 55 60

50

Ala Pro Leu Ala Ala Arg Ser Asp Leu Ser Thr Gly Asn Ser Ala His
 65 70 75 80

55

Ala Ser Gln Leu Leu Arg Ser Gly Ser Leu Ala Phe Leu Phe Thr Ala
 85 90 95

EP 2 453 012 A1

Pro Tyr Ala Asn Gly Cys Asp Ala Ala Thr Ala Ser Leu Pro Ser Phe
100 105 110

5 Ser Ala Asp Ala Ala Arg Arg Phe Ser Ala Asp His Gly Ile Ala Val
115 120 125

Arg Ser Val Ala Leu Arg Val Ala Asp Ala Ala Glu Ala Phe Arg Ala
10 130 135 140

Ser Arg Arg Arg Gly Ala Arg Pro Ala Phe Ala Pro Val Asp Leu Gly
145 150 155 160

15 Arg Gly Phe Ala Phe Ala Glu Val Glu Leu Tyr Gly Asp Val Val Leu
165 170 175

Arg Phe Val Ser His Pro Asp Gly Thr Asp Val Pro Phe Leu Pro Gly
20 180 185 190

Phe Glu Gly Val Thr Asn Pro Asp Ala Val Asp Tyr Gly Leu Thr Arg
25 195 200 205

Phe Asp His Val Val Gly Asn Val Pro Glu Leu Ala Pro Ala Ala Ala
210 215 220

30 Tyr Ile Ala Gly Phe Thr Gly Phe His Glu Phe Ala Glu Phe Thr Ala
225 230 235 240

Glu Asp Val Gly Thr Thr Glu Ser Gly Leu Asn Ser Val Val Leu Ala
35 245 250 255

Asn Asn Ser Glu Gly Val Leu Leu Pro Leu Asn Glu Pro Val His Gly
260 265 270

40 Thr Lys Arg Arg Ser Gln Ile Gln Thr Phe Leu Glu His His Gly Gly
275 280 285

Pro Gly Val Gln His Ile Ala Val Ala Ser Ser Asp Val Leu Arg Thr
45 290 295 300

Leu Arg Lys Met Arg Ala Arg Ser Ala Met Gly Gly Phe Asp Phe Leu
305 310 315 320

50 Pro Pro Pro Leu Pro Lys Tyr Tyr Glu Gly Val Arg Arg Leu Ala Gly
325 330 335

55

EP 2 453 012 A1

Asp Val Leu Ser Glu Ala Gln Ile Lys Glu Cys Gln Glu Leu Gly Val
 340 345 350

5

Leu Val Asp Arg Asp Asp Gln Gly Val Leu Leu Gln Ile Phe Thr Lys
 355 360 365

10

Pro Val Gly Asp Arg Pro Thr Leu Phe Leu Glu Met Ile Gln Arg Ile
 370 375 380

15

Gly Cys Met Glu Lys Asp Glu Arg Gly Glu Glu Tyr Gln Lys Gly Gly
 385 390 395 400

Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu Phe Lys Ser Ile
 405 410 415

20

Glu Asp Tyr Glu Lys Ser Leu Glu Ala Lys Gln Ser Ala Ala Val Gln
 420 425 430

Gly Ser

25

<210> 29

<211> 1209

<212> DNA

30

<213> Rhodococcus sp.

<400> 29

atgactaccg cgcacattcg cctgacgccc cgcgaggtgg cgcacatct ggagaccgac 60

35

gagctccggc agttggtcgg gctcgtcgaa cacgacgacg cgtcggatcc gtttcccgtg 120

gtcgcgatgg atgccgtggt gttogtgtgc ggcaacgcga cgcagagcac gcagtacttc 180

gtctccacgt ggggcatgac cctcgtcgcc tacgccgggc cggagaccgg tcagcgtcgc 240

40

cacaagtcct togtcctcga gtcggggtcg gcacggttcg tgctgcacgg cgcctcgcgat 300

ccgaagagcc cgctcgcgga ccatcaccgg gcgcacggcg acggcgtggt ggacctggcg 360

atggaagttc tcgacgtcga ccgctgcatc gcgcatgcac gctcgcaggg ggccaccatt 420

45

ctcggaggagc cgcgcgacgt cacggatcag ttcggcaccg tgcggctcgc ggcgatcgcc 480

acgtacggca gcacccggca caccatcgtc gaccgaagcc gatacgacgg cccctacctc 540

cccggattcg tcgcgcgctc cagcggtttc gcggcgcgac cgggtaaacc cccgcgattg 600

50

ttccaggcgc tcgaccacgc cgtcggcaac gtcgagatgg gccggatgga tcaactgggtc 660

cggttctaca accgcgtcat gggcttcacg aacatggccg aattcgtcgg cgacgacatc 720

55

EP 2 453 012 A1

gccacggagt actcggcgct gatgtcgaag gtcgtggcga acggcaatca ccgggtgaag 780
 ttcccgetca acgaaccegc ggtgggaaag aagaagtgc agatcgacga atatctcgag 840
 5 ttctacggtg agccgggctg ccagcatctg gccctcgcga ccggagacat cctcgcgacg 900
 gtggacgctg tgcgggcccga ggggtgtcga ttctgaaca caccgcgacg gtactacgag 960
 gaccacacagc tgcgcgcccg gatcggcagg gtgcgggtgc cgggtggagga actgcagaag 1020
 10 cgcggaatcc tcgtcgaccg cgacgaggac ggatacctcc tgcagatctt caccaaaccg 1080
 ctcggcgacc ggccgaccgt gttcttcgag gtgatcgaac ggcacggttc gctcgggttc 1140
 15 ggggcgggta acttccaggc cctgttcgaa tccatcgagc gtgagcaggc ggcgcgcggc 1200
 aatctgtga 1209

<210> 30
 <211> 402
 <212> PRT
 <213> Rhodococcus sp.

<400> 30

25 Met Thr Thr Ala Asp Ile Arg Leu Thr Pro Arg Glu Val Ala Ala His
 1 5 10 15

30 Leu Glu Thr Asp Glu Leu Arg Gln Leu Val Gly Leu Val Glu His Asp
 20 25 30

Asp Ala Ser Asp Pro Phe Pro Val Val Ala Met Asp Ala Val Val Phe
 35 40 45

35 Val Cys Gly Asn Ala Thr Gln Ser Thr Gln Tyr Phe Val Ser Thr Trp
 50 55 60

40 Gly Met Thr Leu Val Ala Tyr Ala Gly Pro Glu Thr Gly Gln Arg Ser
 65 70 75 80

His Lys Ser Phe Val Leu Glu Ser Gly Ser Ala Arg Phe Val Leu His
 85 90 95

45 Gly Ala Val Asp Pro Lys Ser Pro Leu Ala Asp His His Arg Ala His
 100 105 110

50 Gly Asp Gly Val Val Asp Leu Ala Met Glu Val Leu Asp Val Asp Arg
 115 120 125

Cys Ile Ala His Ala Arg Ser Gln Gly Ala Thr Ile Leu Glu Glu Pro

55

EP 2 453 012 A1

	130		135		140														
5	Arg	Asp	Val	Thr	Asp	Gln	Phe	Gly	Thr	Val	Arg	Leu	Ala	Ala	Ile	Ala			
	145					150					155					160			
	Thr	Tyr	Gly	Ser	Thr	Arg	His	Thr	Ile	Val	Asp	Arg	Ser	Arg	Tyr	Asp			
10					165					170					175				
	Gly	Pro	Tyr	Leu	Pro	Gly	Phe	Val	Ala	Arg	Ser	Ser	Gly	Phe	Ala	Ala			
				180					185					190					
15	Arg	Pro	Gly	Lys	Pro	Pro	Arg	Leu	Phe	Gln	Ala	Leu	Asp	His	Ala	Val			
			195					200					205						
	Gly	Asn	Val	Glu	Met	Gly	Arg	Met	Asp	His	Trp	Val	Arg	Phe	Tyr	Asn			
20		210					215					220							
	Arg	Val	Met	Gly	Phe	Thr	Asn	Met	Ala	Glu	Phe	Val	Gly	Asp	Asp	Ile			
	225					230					235					240			
25	Ala	Thr	Glu	Tyr	Ser	Ala	Leu	Met	Ser	Lys	Val	Val	Ala	Asn	Gly	Asn			
					245					250					255				
	His	Arg	Val	Lys	Phe	Pro	Leu	Asn	Glu	Pro	Ala	Val	Gly	Lys	Lys	Lys			
30				260					265					270					
	Ser	Gln	Ile	Asp	Glu	Tyr	Leu	Glu	Phe	Tyr	Gly	Glu	Pro	Gly	Cys	Gln			
			275					280					285						
35	His	Leu	Ala	Leu	Ala	Thr	Gly	Asp	Ile	Leu	Ala	Thr	Val	Asp	Ala	Leu			
	290						295					300							
	Arg	Ala	Glu	Gly	Val	Glu	Phe	Leu	Asn	Thr	Pro	Asp	Ala	Tyr	Tyr	Glu			
40	305					310					315					320			
	Asp	Pro	Gln	Leu	Arg	Ala	Arg	Ile	Gly	Arg	Val	Arg	Val	Pro	Val	Glu			
45					325					330					335				
	Glu	Leu	Gln	Lys	Arg	Gly	Ile	Leu	Val	Asp	Arg	Asp	Glu	Asp	Gly	Tyr			
				340					345					350					
50	Leu	Leu	Gln	Ile	Phe	Thr	Lys	Pro	Leu	Gly	Asp	Arg	Pro	Thr	Val	Phe			
			355					360					365						

55

EP 2 453 012 A1

Phe Glu Val Ile Glu Arg His Gly Ser Leu Gly Phe Gly Ala Gly Asn
 370 375 380

5 Phe Gln Ala Leu Phe Glu Ser Ile Glu Arg Glu Gln Ala Ala Arg Gly
 385 390 395 400

Asn Leu

10

<210> 31
 <211> 1353
 <212> DNA

15 <213> Artificial sequence

<220>
 <223> Nucleic acid sequence encoding Arabidopsis HPPD plus containing
 at the 5' end a nucleic acid encoding an Ala and 6 His amino
 acids

20

<220>
 <221> misc_feature
 <222> (4)..(6)
 <223> sequence coding for an Ala

25

<220>
 <221> misc_feature
 <222> (7)..(24)
 <223> sequence coding for an His Tag containing 6 His

30

<400> 31
 atggctcatc accatcacca tcacccaaac gccgccgttt cagagaatca aaacatgat 60
 gacggcgctg cgctcgcgcc gggattcaag ctcgtcggat tttccaagtt cgtaagaaag 120
 35 aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180
 gacgcaacca acgtcgctcg tcgcttctcc tggggctcgg ggatgagatt ctccgcaaaa 240
 tccgatcttt ccaccgaaa catggttcac gcctottacc tactcacctc cggtgacctc 300
 40 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatcccaag ttctgatcac ggctcttgtc gttccttctt ctcgtcacat 420
 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 45 agtgtagcta atggcgctat tccttcgctc cctcctatcg tcctcaatga agcagttacg 540
 atcgctgagg ttaaaactata cggcgatggt gttctccgat atgtagtta caaagcagaa 600
 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctcgtc 660
 ccattggatt atgggtatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggt 720
 ccggctttaa cttatgtagc ggggttcact ggttttcacc aattcgaga gttcacagca 780

55

EP 2 453 012 A1

gacgacgttg gaaccgccga gagcgggtta aattcagcgg tcctggctag caatgatgaa 840
 5 atggttcttc taccgattaa cgagccagtg cacggaaca agaggaagag tcagattcag 900
 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga ccttgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 10 ccttctcctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggg cgacgatatt tatagagata 1200
 15 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
 tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacгаа 1320
 aagactcttg aagccaaaca gttagtggga tga 1353

20

<210> 32
 <211> 450
 <212> PRT
 <213> Artificial sequence

25

<220>
 <223> encoded by SEQ ID No. 31

30

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala

35

<220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

<400> 32

40

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

45

Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

50

Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

55

EP 2 453 012 A1

Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
65 70 75 80

5 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
85 90 95

10 Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
100 105 110

15 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
115 120 125

20 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
130 135 140

25 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
145 150 155 160

30 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
165 170 175

35 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
180 185 190

40 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
195 200 205

45 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
210 215 220

50 Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
225 230 235 240

55 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
245 250 255

60 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
260 265 270

65 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
275 280 285

70 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
290 295 300

75

EP 2 453 012 A1

His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320
 5
 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335
 10
 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350
 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365
 15
 Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380
 20
 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
 385 390 395 400
 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
 405 410 415
 25
 Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu
 420 425 430
 30
 Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445
 35
 Val Gly
 450

<210> 33
 <211> 1353
 <212> DNA
 <213> Artificial sequence
 40
 <220>
 <223> nucleotide sequence encoding mutant HPPD polypeptide
 45
 <220>
 <221> misc_feature
 <222> (4)..(6)
 <223> sequence coding for Ala
 50
 <220>
 <221> misc_feature
 <222> (7)..(24)
 <223> sequence coding an His Tag containing 6 His
 55

EP 2 453 012 A1

<400> 33
 atggctcatc accatcacca tcacccaaac gccgcggtt cagagaatca aaaccatgat 60
 5 gacggcgctg cgtcgtcgcc gggattcaag ctcgtcggat tttccaagtt cgtaagaaag 120
 aatccaaagt ctgataaatt caaggttaag cgttccatc acatcgagtt ctggtgccgc 180
 gacgcaacca acgtcgtcgc tcgcttctcc tggggctctg ggatgagatt ctccgcaaaa 240
 10 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatcccaag tttcgatcac ggtcttctg gttccttctt ctcgtcacat 420
 15 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgtcg cctcctatcg tcctcaatga agcagttacg 540
 atcgtcgagg ttaaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600
 20 gataaccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgtcgttc 660
 ccattggatt atggtatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggg 720
 25 ccggctttaa cttatgtagc ggggttctact ggttttcacc aattcgcaga gttcacagca 780
 gacgacgttg gaaccgccga gagcggttta aatgcggcgg tcctggctag caatgatgaa 840
 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
 30 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 ctttctctc cgctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
 35 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200
 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gaggggagga 1260
 40 tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacгаа 1320
 aagactcttg aagccaaaca gttagtggga tga 1353

45 <210> 34
 <211> 450
 <212> PRT
 <213> Artificial sequence

50 <220>
 <223> encoded by SEQ ID No. 33

<220>

55

EP 2 453 012 A1

<221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala

5 <220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

10 <400> 34

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

15 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

20 Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

25 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

30 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

35 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

40 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140

45 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160

Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175

50 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190

55

EP 2 453 012 A1

Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
195 200 205

5 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
210 215 220

10 Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
225 230 235 240

Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
245 250 255

15 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ala
260 265 270

20 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
275 280 285

Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
290 295 300

25 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
305 310 315 320

30 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
325 330 335

35 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
340 345 350

Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
355 360 365

40 Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
370 375 380

45 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
385 390 395 400

Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
405 410 415

50 Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu
420 425 430

55

EP 2 453 012 A1

Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445

5

Val Gly
 450

10 <210> 35
 <211> 1353
 <212> DNA
 <213> Artificial sequence

15 <220>
 <223> nucleotide sequence encoding mutant HPPD polypeptide

<220>
 <221> misc_feature
 <222> (4)..(6)
 20 <223> sequence coding for Ala

<220>
 <221> misc_feature
 <222> (7)..(24)
 25 <223> sequence coding for an His Tag containing 6 His

<400> 35
 atggctcadc accatcacca tcacccaaac gccgcggtt cagagaatca aaaccatgat 60
 30 gacggcgctg cgtcgctgcc gggattcaag ctcgctcgat tttccaagtt cgtaagaaag 120
 aatccaaagt ctgataaatt caagggttaag cgcttccatc acatcgagtt ctggtgctggc 180
 gacgcaacca acgctgctcg tcgcttctcc tggggtctgg ggatgagatt ctccgcaaaa 240
 35 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cgggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatcccaag tttcgatcac ggctcttgtc gttccttctt ctcgtcacat 420
 40 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgctg cctcctatcg tcctcaatga agcagttacg 540
 atcgctgagg ttaaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600
 45 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctgctc 660
 ccattggatt atggatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggt 720
 ccggctttaa cttatgtagc ggggttact ggttttcacc aattcgaga gttcacagca 780
 50 gacgacgttg gaaccgcca gagcggttta aattcagcgg tcctggctag caatgatgaa 840
 atggttcttc taccgattgc cgagccagtg cacggaacaa agaggaagag tcagattcag 900

55

EP 2 453 012 A1

acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga ccoctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 5 ccttctcctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggg cgacgatatt tatagagata 1200
 10 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
 tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacgaa 1320
 aagactcttg aagccaaaca gttagtggga tga 1353
 15

<210> 36
 <211> 450
 <212> PRT
 <213> Artificial sequence
 20
 <220>
 <223> encoded by SEQ ID No. 35

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala
 25

<220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His
 30

<400> 36
 35 Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 40 20 25 30

Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

45 Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

50 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 55

EP 2 453 012 A1

				85					90					95			
5	Ser	Gly	Asp	Leu	Arg	Phe	Leu	Phe	Thr	Ala	Pro	Tyr	Ser	Pro	Ser	Leu	
				100					105				110				
	Ser	Ala	Gly	Glu	Ile	Lys	Pro	Thr	Thr	Thr	Ala	Ser	Ile	Pro	Ser	Phe	
10			115					120				125					
	Asp	His	Gly	Ser	Cys	Arg	Ser	Phe	Phe	Ser	Ser	His	Gly	Leu	Gly	Val	
	130						135					140					
15	Arg	Ala	Val	Ala	Ile	Glu	Val	Glu	Asp	Ala	Glu	Ser	Ala	Phe	Ser	Ile	
	145					150					155					160	
	Ser	Val	Ala	Asn	Gly	Ala	Ile	Pro	Ser	Ser	Pro	Pro	Ile	Val	Leu	Asn	
20					165					170					175		
	Glu	Ala	Val	Thr	Ile	Ala	Glu	Val	Lys	Leu	Tyr	Gly	Asp	Val	Val	Leu	
				180					185					190			
25	Arg	Tyr	Val	Ser	Tyr	Lys	Ala	Glu	Asp	Thr	Glu	Lys	Ser	Glu	Phe	Leu	
			195					200					205				
30	Pro	Gly	Phe	Glu	Arg	Val	Glu	Asp	Ala	Ser	Ser	Phe	Pro	Leu	Asp	Tyr	
		210					215					220					
	Gly	Ile	Arg	Arg	Leu	Asp	His	Ala	Val	Gly	Asn	Val	Pro	Glu	Leu	Gly	
35						230					235					240	
	Pro	Ala	Leu	Thr	Tyr	Val	Ala	Gly	Phe	Thr	Gly	Phe	His	Gln	Phe	Ala	
					245					250					255		
40	Glu	Phe	Thr	Ala	Asp	Asp	Val	Gly	Thr	Ala	Glu	Ser	Gly	Leu	Asn	Ser	
				260					265					270			
	Ala	Val	Leu	Ala	Ser	Asn	Asp	Glu	Met	Val	Leu	Leu	Pro	Ile	Ala	Glu	
45			275					280					285				
	Pro	Val	His	Gly	Thr	Lys	Arg	Lys	Ser	Gln	Ile	Gln	Thr	Tyr	Leu	Glu	
		290					295					300					
50	His	Asn	Glu	Gly	Ala	Gly	Leu	Gln	His	Leu	Ala	Leu	Met	Ser	Glu	Asp	
	305					310					315					320	

55

EP 2 453 012 A1

Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
325 330 335

5 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
340 345 350

10 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
355 360 365

Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
370 375 380

15 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
385 390 395 400

20 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
405 410 415

Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu
420 425 430

25 Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
435 440 445

30 Val Gly
450

<210> 37
35 <211> 1353
<212> DNA
<213> Artificial sequence

<220>
40 <223> nucleotide sequence encoding mutant HPPD polypeptide

<220>
45 <221> misc_feature
<222> (4)..(6)
<223> sequence coding for Ala

<220>
50 <221> misc_feature
<222> (7)..(24)
<223> sequence coding for an His Tag containing 6 His

<400> 37
atggctcatc accatcacca tcacaaaac gccgccgttt cagagaatca aaaccatgat 60
gacggcgctg cgtcgctgcc gggattcaag ctcgctggat tttccaagtt cgtaagaaag 120

EP 2 453 012 A1

aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180
 5 gacgcaacca acgtcgctcg tcgcttctcc tggggctctgg ggatgagatt ctccgcaaaa 240
 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctcc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 10 accacagctt ctatcccaag ttctgatcac ggctcttctc gttccttctt ctcgtcacat 420
 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgctc cctcctatcg tcctcaatga agcagttacg 540
 15 atcgctgagg ttaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600
 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctcgtc 660
 ccattggatt atgggatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggc 720
 20 ccggctttaa cttatgtagc ggggttccact ggttttcacc aattcgcac tttcacagca 780
 gacgacgttg gaaccgccga gagcggttta aatcagcgg tcctggctag caatgatgaa 840
 atggttcttc taocgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
 25 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 ccttctctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
 30 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200
 35 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
 tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacгаа 1320
 aagactcttg aagccaaaca gttagtggga tga 1353

40 <210> 38
 <211> 450
 <212> PRT
 <213> Artificial sequence
 45 <220>
 <223> encoded by SEQ ID No. 37
 50 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala
 <220>

55

EP 2 453 012 A1

<221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

5 <400> 38

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

10 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

15 Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

20 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

25 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

30 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

35 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140

Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160

40 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175

45 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190

50 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
 195 200 205

Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr

55

EP 2 453 012 A1

	210		215			220											
5	Gly 225	Ile	Arg	Arg	Leu	Asp 230	His	Ala	Val	Gly	Asn 235	Val	Pro	Glu	Leu	Gly 240	
	Pro	Ala	Leu	Thr	Tyr 245	Val	Ala	Gly	Phe	Thr 250	Gly	Phe	His	Gln	Phe	Ala 255	
10	Ser	Phe	Thr	Ala	Asp 260	Asp	Val	Gly	Thr	Ala 265	Glu	Ser	Gly	Leu	Asn	Ser 270	
15	Ala	Val	Leu	Ala	Ser	Asn	Asp	Glu 280	Met	Val	Leu	Leu	Pro 285	Ile	Asn	Glu	
	Pro	Val	His	Gly	Thr	Lys	Arg 295	Lys	Ser	Gln	Ile	Gln 300	Thr	Tyr	Leu	Glu	
20	His 305	Asn	Glu	Gly	Ala	Gly 310	Leu	Gln	His	Leu	Ala 315	Leu	Met	Ser	Glu	Asp 320	
25	Ile	Phe	Arg	Thr	Leu 325	Arg	Glu	Met	Arg	Lys 330	Arg	Ser	Ser	Ile	Gly 335	Gly	
30	Phe	Asp	Phe	Met 340	Pro	Ser	Pro	Pro	Pro	Thr 345	Tyr	Tyr	Gln	Asn 350	Leu	Lys	
	Lys	Arg	Val 355	Gly	Asp	Val	Leu	Ser 360	Asp	Asp	Gln	Ile	Lys 365	Glu	Cys	Glu	
35	Glu	Leu	Gly	Ile	Leu	Val	Asp 375	Arg	Asp	Asp	Gln	Gly 380	Thr	Leu	Leu	Gln	
40	Ile 385	Phe	Thr	Lys	Pro	Leu	Gly 390	Asp	Arg	Pro	Thr 395	Ile	Phe	Ile	Glu	Ile 400	
	Ile	Gln	Arg	Val	Gly 405	Cys	Met	Met	Lys	Asp 410	Glu	Glu	Gly	Lys	Ala	Tyr 415	
45	Gln	Ser	Gly	Gly	Cys	Gly	Gly	Phe	Gly 425	Lys	Gly	Asn	Phe	Ser 430	Glu	Leu	
50	Phe	Lys	Ser 435	Ile	Glu	Glu	Tyr	Glu 440	Lys	Thr	Leu	Glu	Ala 445	Lys	Gln	Leu	
55																	

EP 2 453 012 A1

Val Gly
450

5 <210> 39
 <211> 1353
 <212> DNA
 <213> Artificial sequence

10 <220>
 <223> nucleotide sequence encoding mutant HPPD polypeptide

<220>
 <221> misc_feature
 15 <222> (4)..(6)
 <223> sequence coding for Ala

<220>
 <221> misc_feature
 20 <222> (7)..(24)
 <223> sequence coding for an His Tag containing 6 His

<400> 39
 atggctcatc accatcacca tcacaaaaac gccgccgttt cagagaatca aaaccatgat 60

25 gacggcgtg cgctcgtgcc gggattcaag ctcgctcggat tttccaagtt cgtaagaaag 120
 aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180
 gacgcaacca acgtcgtcgc tcgcttctcc tggggctctgg ggatgagatt ctccgcaaaa 240

30 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatcccaag ttctgatcac ggcctctgtc gttccttctt ctcgtcacat 420

35 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgtcg cctctatcg tcctcaatga agcagttacg 540
 atcgctgagg ttaaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600

40 gataaccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctgctc 660
 ccattggatt atggatatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggc 720
 ccggctttaa cttatgtagc ggggttccact ggttttcacc aattcgcaga gttcacagca 780

45 gacgacgttg gaaccgcca gagcggttta aattcagcgg cgctggctag caatgatgaa 840
 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900

50 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga cctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 ccttctctc cgcctactta ctaccagaat ctcaagaaac gggctcggcga cgtgctcagc 1080

55

EP 2 453 012 A1

gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 5 acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200
 atccagagag taggatgcat gatgaaagat gaggaaggga aggcttacca gagtggagga 1260
 tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacgaa 1320
 10 aagactcttg aagccaaaca gttagtggga tga 1353

<210> 40
 <211> 450
 <212> PRT
 15 <213> Artificial sequence
 <220>
 <223> encoded by SEQ ID No. 39

20 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala

25 <220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

30 <400> 40

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

35 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

40

Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

45 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

50 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

55

EP 2 453 012 A1

5 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
115 120 125

Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
130 135 140

10 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
145 150 155 160

15 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
165 170 175

Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
180 185 190

20 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
195 200 205

25 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
210 215 220

Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
225 230 235 240

30 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
245 250 255

35 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
260 265 270

40 Ala Ala Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
275 280 285

Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
290 295 300

45 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
305 310 315 320

50 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
325 330 335

Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys

55

EP 2 453 012 A1

	340		345		350	
5	Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu	355	360	365		
10	Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln	370	375	380		
	Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile	385	390	395	400	
15	Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr	405	410	415		
20	Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu	420	425	430		
	Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu	435	440	445		
25	Val Gly	450				
30	<210> 41					
	<211> 1353					
	<212> DNA					
	<213> Artificial sequence					
35	<220>					
	<223> nucleotide sequence encoding mutant HPPD polypeptide					
40	<220>					
	<221> misc_feature					
	<222> (4)..(6)					
	<223> sequence coding for Ala					
45	<220>					
	<221> misc_feature					
	<222> (7)..(24)					
	<223> sequence coding for an His Tag containing 6 His					
	<400> 41					
	atggctcatc accatcacca tcaccaaac gccgccgttt cagagaatca aaaccatgat				60	
	gacggcgctg cgtcgtcgcc gggattcaag ctgctcggat tttccaagtt cgtaagaaag				120	
50	aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctgggtcgcc				180	
	gacgcaacca acgtcgtctg tcgcttctcc tggggtctgg ggatgagatt ctccgcaaa				240	
55						

EP 2 453 012 A1

tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
cgattccttt tcaactgctcc ttactctccg tctctctccg ccggagagat taaaccgaca 360
5 accacagctt ctatcccaag tttcgatcac ggctcttgtc gttccttctt ctcgtcacat 420
ggctctcggtg ttagagccgt tgcgattgaa gtagaagaag cagagtcagc tttctccatc 480
agtgtagcta atggcgctat tccttcgctg cctcctatcg tcctcaatga agcagttacg 540
10 atcgctgagg ttaaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600
gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctcgtc 660
ccattggatt atgggatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggc 720
15 ccggctttaa cttatgtagc ggggttcact ggttttcacc aattcgaga gttcacagca 780
gacgacgttg gaaccgccga gagcggttta aattcagcgg tcctggctag caatgatgaa 840
atggttcttc tagcgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
20 acgtatattg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
25 ccttctctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200
30 atccagagag taggatgcat gatgaaagat gaggaagga aggcttacca gagtggagga 1260
tgtggtggtt ttggcaaagg caatttctct gagctcttca agtccattga agaatacгаа 1320
aagactcttg aagccaaaca gttagtggga tga 1353

35
<210> 42
<211> 450
<212> PRT
<213> Artificial sequence

40
<220>
<223> encoded by SEQ ID No. 41

45
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Ala

50
<220>
<221> MISC_FEATURE
<222> (3)..(8)
<223> His Tag made of 6 His

<400> 42

55

EP 2 453 012 A1

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

5 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

10 Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

15 Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

20 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

25 Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

30 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140

35 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160

Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175

40 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190

45 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
 195 200 205

50 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
 210 215 220

Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
 225 230 235 240

55

EP 2 453 012 A1

5 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
 245 250 255

10 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
 260 265 270

15 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Ala Ile Asn Glu
 275 280 285

20 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
 290 295 300

25 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320

30 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335

35 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350

40 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365

45 Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380

50 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
 385 390 395 400

55 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
 405 410 415

60 Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu
 420 425 430

65 Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445

70 Val Gly
 450

<210> 43

EP 2 453 012 A1

<211> 1353
 <212> DNA
 <213> Artificial sequence

5
 <220>
 <223> nucleotide sequence encoding mutant HPPD polypeptide

10
 <220>
 <221> misc_feature
 <222> (4)..(6)
 <223> sequence coding for Ala

15
 <220>
 <221> misc_feature
 <222> (7)..(24)
 <223> sequence coding for an His Tag containing 6 His

<400> 43
 atggetcatc accatcacca tcacaaaaac gccgccgttt cagagaatca aaacatgat 60
 20 gacggcgcctg cgtcgtcgcc gggattcaag ctcgtcggat tttccaagtt cgtaagaaag 120
 aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180
 gacgcaacca acgtcgcctg tcgcttctcc tggggctctg ggatgagatt ctccgcaaaa 240
 25 tccgatcttt ccaccgaaa catgggtcac gcctettacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatccaag ttctgatcac ggctcttgtc gttccttctt ctcgtcacat 420
 30 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgctc cctcctatcg tcctcaatga agcagttacg 540
 35 atcgcctgagg ttaaactata cggcgatggt gttctccgat atgtagtta caaagcagaa 600
 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctcgtc 660
 ccattggatt atgggatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggg 720
 40 ccggctttaa cttatgtagc ggggttcaact ggttttcacc aattcgcaga gttcacagca 780
 gacgacgttg gaaccgccga gagcggttta aattcagcgg tcctggctag caatgatgaa 840
 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
 45 acgtatattg aacataacga aggcgcaggg ctacaacatc tggctctgat gaggtaagac 960
 atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 ccttctctc cgcctactta ctaccagaat ctcaagaaac gggctcggca cgtgctcagc 1080
 50 gatgatcaga tcaaggagtg tgaggaatta gggattatgg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacagggc cgacgatatt tatagagata 1200

55

EP 2 453 012 A1

atccagagag taggatgcat gatgaaagat gaggaaggggaggcttacca gagtggagga 1260
 tgtgggtggtt ttggcaaagg caattttctct gagctcttca agtccattga agaatacgaa 1320
 5 aagactcttg aagccaaaca gttagtggga tga 1353

<210> 44
 <211> 450
 10 <212> PRT
 <213> Artificial sequence
 <220>
 <223> encoded by SEQ ID No. 43

15 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala

20 <220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

25 <400> 44
 Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

30 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 35 40 45

Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

40 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

45 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

50 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

55

EP 2 453 012 A1

Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140
 5
 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160
 10 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175
 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190
 15 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
 195 200 205
 20 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
 210 215 220
 25 Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
 225 230 235 240
 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
 245 250 255
 30 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
 260 265 270
 35 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
 275 280 285
 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
 290 295 300
 40 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320
 45 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335
 Phe Asp Phe Met Pro Ser Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350
 50 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365
 55

EP 2 453 012 A1

5 Glu Leu Gly Ile Met Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380

Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
 385 390 395 400

10 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
 405 410 415

15 Gln Ser Gly Gly Cys Gly Gly Phe Gly Lys Gly Asn Phe Ser Glu Leu
 420 425 430

Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445

20 Val Gly
 450

25 <210> 45
 <211> 1353
 <212> DNA
 <213> Artificial sequence

30 <220>
 <223> nucleotide sequence encoding mutant HPPD polypeptide

<220>
 <221> misc_feature
 <222> (4)..(6)
 35 <223> sequence coding for Ala

<220>
 <221> misc_feature
 <222> (7)..(24)
 40 <223> sequence coding for an His Tag containing 6 His

<400> 45
 atggctcatc accatcacca tcacaaaaac gccgccgttt cagagaatca aaaccatgat 60
 gacggcgctg cgtcgctgcc gggattcaag ctcgctggat tttccaagtt cgtaagaaag 120
 45 aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180
 gacgcaacca acgtcgctcg tcgcttctcc tggggctctgg ggatgagatt ctccgcaaaa 240
 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360
 accacagctt ctatcccaag ttctgatcac ggctcttgtc gttccttctt ctcgtcacat 420

55

EP 2 453 012 A1

5 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgtcg cctcctatcg tcctcaatga agcagttacg 540
 atcgcctgagg ttaaactata cggcgatggt gttctccgat atgttagtta caaagcagaa 600
 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctcgttc 660
 10 ccattggatt atggtatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttggt 720
 ccggctttaa cttatgtagc ggggttccact ggttttcacc aattcgcaga gttcacagca 780
 gacgacgttg gaaccgccga gagcggttta aattcagcgg tcctggctag caatgatgaa 840
 15 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga cctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 20 ccttctcctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200
 25 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
 tgtggtggtt ttggcattgg caatttctct gagctcttca agtccattga agaatacgaa 1320
 30 aagactcttg aagcceaaca gttagtggga tga 1353

35 <210> 46
 <211> 450
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> encoded by SEQ ID No. 45

40 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala

45 <220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His

<400> 46
 50 Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

55

EP 2 453 012 A1

Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

5 Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

10 Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60

15 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

20 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

25 Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110

30 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

35 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140

40 Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160

45 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175

50 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190

55 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
 195 200 205

60 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
 210 215 220

65 Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
 225 230 235 240

70 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
 245 250 255

EP 2 453 012 A1

Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
 260 265 270
 5
 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
 275 280 285
 10
 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
 290 295 300
 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320
 15
 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335
 20
 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350
 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365
 25
 Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380
 30
 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
 385 390 395 400
 35
 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
 405 410 415
 Gln Ser Gly Gly Cys Gly Gly Phe Gly Ile Gly Asn Phe Ser Glu Leu
 420 425 430
 40
 Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445
 45
 Val Gly
 450
 <210> 47
 <211> 1353
 <212> DNA
 <213> Artificial sequence
 <220>

55

EP 2 453 012 A1

<223> nucleotide sequence encoding mutant HPPD polypeptide

5 <220>
 <221> misc_feature
 <222> (4)..(6)
 <223> sequence coding for Ala

10 <220>
 <221> misc_feature
 <222> (7)..(24)
 <223> sequence coding for an His Tag containing 6 His

<400> 47

15 atggctcatc accatcacca tcacaaaaac gccgccgttt cagagaatca aaaccatgat 60
 gacggcgtg cgtcgtcgcc gggattcaag ctcgtcggat tttccaagtt cgtaagaaag 120
 aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180

20 gacgcaacca acgtcgctcg tcgcttctcc tggggtctgg ggatgagatt ctccgcaaaa 240
 tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300
 cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360

25 accacagctt ctatcccaag ttctgatcac ggctcttgtc gttccttctt ctcgtcacat 420
 ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480
 agtgtagcta atggcgctat tccttcgtcg cctcctatcg tcctcaatga agcagttacg 540

30 atcgctgagg ttaaaactata cggcgatggt gttctccgat atgtagtta caaagcagaa 600
 gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgtcgttc 660
 ccattggatt atggtatccg gcggcttgac cacgcogtgg gaaacgttcc tgagcttggg 720

35 ccggctttaa cttatgtagc ggggttccact ggttttcacc aattcgcaga gttcacagca 780
 gacgacgttg gaaccgcca gagcggttta aattcagcgg tcctggctag caatgatgaa 840
 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900

40 acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
 atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
 ccttctctc cgctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080

45 gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
 acgttgcttc aaatcttcac aaaaccacta ggtgacaggc cgacgatatt tatagagata 1200

50 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
 tgtggtggtt ttggccaggg caatttctct gagctcttca agtccattga agaatacgaa 1320
 aagactcttg aagccaaca gttagtggga tga 1353

55

EP 2 453 012 A1

5 <210> 48
 <211> 450
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> encoded by SEQ ID No. 47
 10

 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Ala
 15

 <220>
 <221> MISC_FEATURE
 <222> (3)..(8)
 <223> His Tag made of 6 His
 20

 <400> 48

 Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
 1 5 10 15

 25 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
 20 25 30

 30 Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys
 35 40 45

 Val Lys Arg Phe His His Ile Glu Phe Trp Cys Gly Asp Ala Thr Asn
 50 55 60
 35
 Val Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Arg Phe Ser Ala Lys
 65 70 75 80

 40 Ser Asp Leu Ser Thr Gly Asn Met Val His Ala Ser Tyr Leu Leu Thr
 85 90 95

 Ser Gly Asp Leu Arg Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Leu
 100 105 110
 45

 Ser Ala Gly Glu Ile Lys Pro Thr Thr Thr Ala Ser Ile Pro Ser Phe
 115 120 125

 50 Asp His Gly Ser Cys Arg Ser Phe Phe Ser Ser His Gly Leu Gly Val
 130 135 140

 55

EP 2 453 012 A1

Arg Ala Val Ala Ile Glu Val Glu Asp Ala Glu Ser Ala Phe Ser Ile
 145 150 155 160

5 Ser Val Ala Asn Gly Ala Ile Pro Ser Ser Pro Pro Ile Val Leu Asn
 165 170 175

10 Glu Ala Val Thr Ile Ala Glu Val Lys Leu Tyr Gly Asp Val Val Leu
 180 185 190

15 Arg Tyr Val Ser Tyr Lys Ala Glu Asp Thr Glu Lys Ser Glu Phe Leu
 195 200 205

20 Pro Gly Phe Glu Arg Val Glu Asp Ala Ser Ser Phe Pro Leu Asp Tyr
 210 215 220

25 Gly Ile Arg Arg Leu Asp His Ala Val Gly Asn Val Pro Glu Leu Gly
 225 230 235 240

30 Pro Ala Leu Thr Tyr Val Ala Gly Phe Thr Gly Phe His Gln Phe Ala
 245 250 255

35 Glu Phe Thr Ala Asp Asp Val Gly Thr Ala Glu Ser Gly Leu Asn Ser
 260 265 270

40 Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
 275 280 285

45 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
 290 295 300

50 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320

55 Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335

60 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350

65 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365

70 Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380

75

EP 2 453 012 A1

Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
385 390 395 400

5

Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
405 410 415

10

Gln Ser Gly Gly Cys Gly Gly Phe Gly Gln Gly Asn Phe Ser Glu Leu
420 425 430

15

Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
435 440 445

Val Gly
450

20

<210> 49
<211> 1353
<212> DNA
<213> Artificial sequence

25

<220>
<223> nucleotide sequence encoding mutant HPPD polypeptide

30

<220>
<221> misc_feature
<222> (4)..(6)
<223> sequence coding for Ala

35

<220>
<221> misc_feature
<222> (7)..(24)
<223> sequence coding for an His Tag containing 6 His

<400> 49
atggctcacc accatcacca tcacccaaac gccgccgttt cagagaatca aaaccatgat 60

40

gacggcgctg cgtcgctgcc gggattcaag ctcgctggat tttccaagtt cgtaagaaag 120

aatccaaagt ctgataaatt caaggttaag cgcttccatc acatcgagtt ctggtgcggc 180

gacgcaacca acgctgctcg tcgcttctcc tggggctctg ggatgagatt ctccgcaaaa 240

45

tccgatcttt ccaccgaaa catggttcac gcctcttacc tactcacctc cggtgacctc 300

cgattccttt tcaactgctc ttactctccg tctctctccg ccggagagat taaaccgaca 360

accacagctt ctatcccaag tttcgatcac ggctcttgtc gttccttctt ctcgtcacat 420

50

ggtctcggtg ttagagccgt tgcgattgaa gtagaagacg cagagtcagc tttctccatc 480

agtgtagcta atggcgctat tccttcgctc cctcctatcg tcctcaatga agcagttacg 540

55

EP 2 453 012 A1

atcgctgagg ttaaactata cggcgatggt gttctccgat atgtagtta caaagcagaa 600
gataccgaaa aatccgaatt cttgccaggg ttcgagcgtg tagaggatgc gtcgctgctc 660
5 ccattggatt atggtatccg gcggcttgac cacgccgtgg gaaacgttcc tgagcttgg 720
ccggctttaa cttatgtagc ggggttact ggttttcaacc aattcgcaga gttcacagca 780
gacgacgttg gaaccgccga gagcggttta aattcagcgg tcctggctag caatgatgaa 840
10 atggttcttc taccgattaa cgagccagtg cacggaacaa agaggaagag tcagattcag 900
acgtatttgg aacataacga aggcgcaggg ctacaacatc tggctctgat gagtgaagac 960
atattcagga ccctgagaga gatgaggaag aggagcagta ttggaggatt cgacttcatg 1020
15 ccttctctc cgcctactta ctaccagaat ctcaagaaac gggtcggcga cgtgctcagc 1080
gatgatcaga tcaaggagtg tgaggaatta gggattcttg tagacagaga tgatcaaggg 1140
acgttgcttc aaatcttcac aaaaccacta ggtgacaggg cgacgatatt tatagagata 1200
20 atccagagag taggatgcat gatgaaagat gaggaagggg aggcttacca gagtggagga 1260
tgtggtggtt ttggcgtggg caatttctct gagctcttca agtccattga agaatacгаа 1320
25 aagactcttg aagccaaaca gttagtggga tga 1353

<210> 50
<211> 450
<212> PRT
30 <213> Artificial sequence
<220>
<223> encoded by SEQ ID No. 49

35 <220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Ala

40 <220>
<221> MISC_FEATURE
<222> (3)..(8)
<223> His Tag made of 6 His

45 <400> 50

Met Ala His His His His His His Gln Asn Ala Ala Val Ser Glu Asn
1 5 10 15

50 Gln Asn His Asp Asp Gly Ala Ala Ser Ser Pro Gly Phe Lys Leu Val
20 25 30

Gly Phe Ser Lys Phe Val Arg Lys Asn Pro Lys Ser Asp Lys Phe Lys

55

EP 2 453 012 A1

		35				40						45				
5	Val	Lys	Arg	Phe	His	His	Ile	Glu	Phe	Trp	Cys	Gly	Asp	Ala	Thr	Asn
		50					55					60				
	Val	Ala	Arg	Arg	Phe	Ser	Trp	Gly	Leu	Gly	Met	Arg	Phe	Ser	Ala	Lys
10		65				70					75					80
	Ser	Asp	Leu	Ser	Thr	Gly	Asn	Met	Val	His	Ala	Ser	Tyr	Leu	Leu	Thr
					85					90					95	
15	Ser	Gly	Asp	Leu	Arg	Phe	Leu	Phe	Thr	Ala	Pro	Tyr	Ser	Pro	Ser	Leu
				100					105					110		
	Ser	Ala	Gly	Glu	Ile	Lys	Pro	Thr	Thr	Thr	Ala	Ser	Ile	Pro	Ser	Phe
20			115					120					125			
	Asp	His	Gly	Ser	Cys	Arg	Ser	Phe	Phe	Ser	Ser	His	Gly	Leu	Gly	Val
		130					135					140				
25	Arg	Ala	Val	Ala	Ile	Glu	Val	Glu	Asp	Ala	Glu	Ser	Ala	Phe	Ser	Ile
		145				150					155					160
	Ser	Val	Ala	Asn	Gly	Ala	Ile	Pro	Ser	Ser	Pro	Pro	Ile	Val	Leu	Asn
30					165					170					175	
	Glu	Ala	Val	Thr	Ile	Ala	Glu	Val	Lys	Leu	Tyr	Gly	Asp	Val	Val	Leu
				180					185					190		
35	Arg	Tyr	Val	Ser	Tyr	Lys	Ala	Glu	Asp	Thr	Glu	Lys	Ser	Glu	Phe	Leu
			195					200					205			
40	Pro	Gly	Phe	Glu	Arg	Val	Glu	Asp	Ala	Ser	Ser	Phe	Pro	Leu	Asp	Tyr
		210					215					220				
	Gly	Ile	Arg	Arg	Leu	Asp	His	Ala	Val	Gly	Asn	Val	Pro	Glu	Leu	Gly
45		225				230					235					240
	Pro	Ala	Leu	Thr	Tyr	Val	Ala	Gly	Phe	Thr	Gly	Phe	His	Gln	Phe	Ala
					245					250					255	
50	Glu	Phe	Thr	Ala	Asp	Asp	Val	Gly	Thr	Ala	Glu	Ser	Gly	Leu	Asn	Ser
				260					265					270		
55																

EP 2 453 012 A1

Ala Val Leu Ala Ser Asn Asp Glu Met Val Leu Leu Pro Ile Asn Glu
 275 280 285

5 Pro Val His Gly Thr Lys Arg Lys Ser Gln Ile Gln Thr Tyr Leu Glu
 290 300

10 His Asn Glu Gly Ala Gly Leu Gln His Leu Ala Leu Met Ser Glu Asp
 305 310 315 320

Ile Phe Arg Thr Leu Arg Glu Met Arg Lys Arg Ser Ser Ile Gly Gly
 325 330 335

15 Phe Asp Phe Met Pro Ser Pro Pro Pro Thr Tyr Tyr Gln Asn Leu Lys
 340 345 350

20 Lys Arg Val Gly Asp Val Leu Ser Asp Asp Gln Ile Lys Glu Cys Glu
 355 360 365

Glu Leu Gly Ile Leu Val Asp Arg Asp Asp Gln Gly Thr Leu Leu Gln
 370 375 380

25 Ile Phe Thr Lys Pro Leu Gly Asp Arg Pro Thr Ile Phe Ile Glu Ile
 385 390 395 400

30 Ile Gln Arg Val Gly Cys Met Met Lys Asp Glu Glu Gly Lys Ala Tyr
 405 410 415

Gln Ser Gly Gly Cys Gly Gly Phe Gly Val Gly Asn Phe Ser Glu Leu
 420 425 430

35 Phe Lys Ser Ile Glu Glu Tyr Glu Lys Thr Leu Glu Ala Lys Gln Leu
 435 440 445

40 Val Gly
 450

45

Claims

- 50 1. An isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein,
 wherein said mutated HPPD protein has HPPD activity, and
 wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid
 sequence comprises at least one amino acid selected from:
- 55 a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at a position in an HPPD protein, said position
 corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
 b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at a position in an HPPD protein, said position corresponding
 to position 251 of the amino acid sequence of SEQ ID No. 2;

EP 2 453 012 A1

- c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;
- d) Ala, Phe, His, Gln, Val or Trp at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;
- 5 e) Leu or Val at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;
- f) Leu, Gln, Arg, Val or Tyr at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID No. 2;
- 10 g) Ala, Thr or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;
- h) Ala, Ile, Asn, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- i) Leu, Gln or Val at a position in an HPPD protein, said position corresponding to position 293 of the amino acid sequence of SEQ ID No. 2;
- 15 j) Ile or Met at a position in an HPPD protein, said position corresponding to position 294 of the amino acid sequence of SEQ ID No. 2;
- k) Gln at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;
- l) Ile, Met or Asn at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- 20 m) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- n) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 381 of the amino acid sequence of SEQ ID No. 2;
- 25 o) Phe or Ser at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;
- p) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 419 of the amino acid sequence of SEQ ID No. 2;
- 30 q) Asp, Lys or Asn at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- r) Ala, Gly, Met, Pro or Thr at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- s) Ala, Phe, Ile or Val at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 2;
- 35 t) Ile, Pro, Arg or Ser at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2;
- u) Glu, Phe, Thr or Val at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;
- v) Ile, Met, Gln or Val at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2; and
- 40 w) at least one amino acid deletion or replacement at any one of positions 228, 248, 270, 271, 379 and/or 427.

2. The isolated nucleic acid of claim 1, wherein said at least one amino acid is selected from

- 45 a) Ala, Asp, Glu, Phe, Thr, Val or Tyr at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
- b) Ala, Asp, Glu, Ile, Lys, Leu, Pro or Arg at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 2;
- 50 c) Glu, Thr, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;
- d) Ala, Phe, Val or Trp at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;
- e) Leu or Val at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;
- 55 f) Leu, Gln, Arg, Val or Tyr at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID NO: 2;
- g) Ala or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;

- h) Ala, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- i) Gln at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;
- 5 j) Ile or Met at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- k) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- 10 l) Phe at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;
- m) Asp, Lys, or Asn at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- n) Ala or Gly at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- 15 o) Ile, Arg or Ser at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2;
- p) Glu, Phe or Val at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;
- 20 q) Ile, Met, Gln or Val at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2;
- r) Ala, Cys, Thr, Val or Gly at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- s) Ala, Glu, His, Lys, Gln, Arg, Thr, Gly, Leu, Asn, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;
- 25 t) Ala, Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- u) Ala, Glu, Lys, Arg, Ser, Thr, His, Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;
- v) His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2; and
- 30 w) Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

3. The nucleic acid of claim 1 or 2, wherein said at least one amino acid is selected from

- 35 a) Glu, Thr, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;
- b) Ala or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;
- 40 c) Ala, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- d) Ile or Met at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- 45 e) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- f) Asp, Asn or Lys at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- g) Ala or Gly at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- 50 h) Ala, Cys, Thr or Val at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- i) Ala, Glu, His, Lys, Gln, Arg, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;
- 55 j) Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- k) Ala, Glu, Lys, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;
- l) His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid

EP 2 453 012 A1

sequence of SEQ ID No. 2; and

m) Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.

- 5 4. The isolated nucleic acid of any one of claims 1 to 3, wherein said HPPD protein is derived from *Streptomyces avermitilis* (Genebank SAV11864), *Daucus carota* (Genebank DCU 87257), *Arabidopsis thaliana* (Genebank AF047834), *Mycosphaerella graminicola* (Genebank AF038152), *oryza sativa* / rice [BAD26248], *Zea mays* / corn [ACN36372], *avena sativa* [ABZ23427], *Pseudomonas fluorescens* [ABF50055], *Synechococcus* sp. [YP_473959], *Blepharisma japonicum* [BAF91881], *Rhodococcus RHA1* sp. ro0240 [YP_702005], *Rhodococcus RHA1* sp. ro0341 [YP_703002], *Picrophilus torridus* [YP_024147], *Kordia algicida* [ZP_02161490], *Sorghum bicolor* [XP_002453359], *Triticum aestivum* / wheat [AAZ67144], or *Hordeum vulgare* / barley [O48604].
- 10
- 15 5. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 4 and wherein the resulting amino acid sequence comprises at least one amino acid selected from
- 20 a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr, at position 247 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 250 of SEQ ID No. 2);
- 25 b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser, at position 248 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 251 of SEQ ID No. 2);
- 30 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 249 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 252 of SEQ ID No. 2);
- 35 d) Ala, His, Gln, Trp or Val, at position 250 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 253 of SEQ ID No. 2);
- 40 e) Val at position 262 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 265 of SEQ ID No. 2);
- 45 f) Leu, Gln, Arg or Tyr, at position 265 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 268 of SEQ ID No. 2);
- 50 g) Ala or Thr at position 266 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 269 of SEQ ID No. 2);
- 55 h) Ala, Ile, Asn, Thr or Val at position 277 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu or Val, at position 290 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 293 of SEQ ID No. 2);
- j) Met at position 291 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile, Met or Asn at position 332 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 335 of SEQ ID No. 2);
- l) Tyr at position 378 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 381 of SEQ ID No. 2);
- m) Ser at position 389 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 416 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 419 of SEQ ID No. 2);
- o) Asp or Asn, at position 418 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 421 of SEQ ID No. 2);
- p) Ala, Met, Pro or Thr at position 419 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 421 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 424 of SEQ ID No. 2);
- r) Ile, Pro or Arg, at position 422 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 425 of SEQ ID No. 2);
- s) Phe, Thr or Val, at position 423 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 426 of SEQ ID No. 2);
- t) Met, Gln or Val at position 428 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Thr at position 225 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 245 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 248 of SEQ ID No. 2);
- w) Ala, Ile, Met or Val at position 267 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 270 of SEQ ID No. 2);

EP 2 453 012 A1

- x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 268 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 271 of SEQ ID No. 2);
y) His at position 376 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 379 of SEQ ID No. 2); and
z) Arg at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 4 (corresponding to position 427 of SEQ ID No. 2).

6. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 6 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 224 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 250 of SEQ ID No. 2);
b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 225 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 251 of SEQ ID No. 2);
c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 226 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 252 of SEQ ID No. 2);
d) Ala, His, Gln, Val or Trp at position 227 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 253 of SEQ ID No. 2);
e) Val at position 239 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 265 of SEQ ID No. 2);
f) Leu, Gln, Arg, Val or Tyr at position 242 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 268 of SEQ ID No. 2);
g) Ala or Thr at position 243 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 269 of SEQ ID No. 2);
h) Ala, Ile, Asn, Thr or Val at position 254 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 280 of SEQ ID No. 2);
i) Leu or Val at position 267 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 293 of SEQ ID No. 2);
j) Met at position 268 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 294 of SEQ ID No. 2);
k) Ile or Asn at position 309 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 335 of SEQ ID No. 2);
l) Tyr at position 355 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 381 of SEQ ID No. 2);
m) Ser at position 366 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 392 of SEQ ID No. 2);
n) Tyr at position 393 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 419 of SEQ ID No. 2);
o) Asp or Asn at position 395 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 421 of SEQ ID No. 2);
p) Ala, Met, Pro or Thr at position 396 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 422 of SEQ ID No. 2);
q) Ala, Ile or Val at position 398 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 424 of SEQ ID No. 2);
r) Ile, Pro or Arg at position 399 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 425 of SEQ ID No. 2);
s) Glu, Phe, Thr or Val at position 400 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 426 of SEQ ID No. 2);
t) Met, Gln or Val at position 405 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 431 of SEQ ID No. 2);
u) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 202 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 228 of SEQ ID No. 2);
v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 222 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 248 of SEQ ID No. 2);
w) Ala, Ile, Met or Val at position 244 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 270 of SEQ ID No. 2);
x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 245 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 271 of SEQ ID No. 2);
y) Gln at position 353 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 379 of SEQ ID No. 2); and
z) Arg at position 401 of the amino acid sequence of SEQ ID No. 6 (corresponding to position 427 of SEQ ID No. 2).

7. The isolated nucleic acid of any one of claims 1 to 4, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 8 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 241 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 250 of SEQ ID No. 2), preferably Ala ;
- b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 242 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;
- c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 243 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;
- d) Ala, His, Gln, Val or Trp at position 244 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- e) Val at position 256 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg or Tyr at position 259 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 260 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu or Val at position 284 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 293 of SEQ ID No. 2);
- j) Met at position 285 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile at position 326 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 335 of SEQ ID No. 2);
- l) Tyr at position 372 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 381 of SEQ ID No. 2);
- m) Ser at position 383 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 410 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 419 of SEQ ID No. 2);
- o) Asp or Asn at position 412 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
- p) Ala, Met, Pro or Thr at position 413 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 415 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 424 of SEQ ID No. 2);
- r) Ile, Pro or Arg at position 416 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 425 of SEQ ID No. 2);
- s) Phe, Thr or Val at position 417 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 426 of SEQ ID No. 2);
- v) Met, Gln, or Val at position 422 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 431 of SEQ ID No. 2).
- w) Ala, Cys, Gly or Thr at position 219 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 228 of SEQ ID No. 2);
- x) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 239 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 248 of SEQ ID No. 2);
- y) Ala, Ile, Met or Val at position 261 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 270 of SEQ ID No. 2);
- z) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 271 of SEQ ID No. 2);
- aa) His at position 370 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 379 of SEQ ID No. 2); and
- bb) Arg at position 418 of the amino acid sequence of SEQ ID No. 8 (corresponding to position 427 of SEQ ID No. 2).

8. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 10 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Phe, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 188 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 250 of SEQ ID No. 2);
- b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro or Ser at position 189 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 251 of SEQ ID No. 2), preferably Ala or Lys;

EP 2 453 012 A1

- c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Glu at position 190 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 252 of SEQ ID No. 2), preferably Ser;
- d) Ala, His, Gln, Val or Trp at position 191 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 253 of SEQ ID No. 2), preferably Phe or Val;
- 5 e) Val at position 200 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg, Val or Tyr at position 203 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 268 of SEQ ID No. 2);
- 10 g) Thr or Val at position 204 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 269 of SEQ ID No. 2), preferably Val;
- h) Ala, Ile, Asn, Thr or Val at position 215 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu or Val at position 226 of the amino acid sequence of SEQ ID NO:SEQ ID No. 10 (corresponding to position 293 of SEQ ID No. 2);
- 15 j) Met at position 227 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile or Asn at position 264 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 335 of SEQ ID No. 2);
- l) Tyr at position 312 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 381 of SEQ ID No. 2);
- 20 m) Ser at position 321 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 333 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 419 of SEQ ID No. 2);
- o) Asp, Lys or Asn at position 335 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
- 25 p) Ala, Met, Pro or Thr at position 336 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 338 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 424 of SEQ ID No. 2);
- 30 r) Ile or Pro at position 339 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 425 of SEQ ID No. 2);
- s) Phe, Thr or Val at position 340 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 426 of SEQ ID No. 2);
- 35 t) Met, Gln or Val at position 345 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Val at position 164 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Ser, Thr or Tyr at position 186 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 248 of SEQ ID No. 2);
- 40 w) Ala, Ile, Leu or Val at position 205 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 270 of SEQ ID No. 2);
- x) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at position 206 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 271 of SEQ ID No. 2);
- 45 y) His at position 310 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 379 of SEQ ID No. 2); and
- z) Arg at position 341 of the amino acid sequence of SEQ ID No. 10 (corresponding to position 427 of SEQ ID No. 2).

9. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 14 and wherein the resulting amino acid sequence comprises at least one amino acid selected from
- 50

- a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 169 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 250 of SEQ ID No. 2), preferably Ala or Phe;
- 55 b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 170 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;
- c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Ser, Val or Tyr at position 171 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 252 of SEQ ID No. 2), preferably Glu, Ser or Tyr;
- d) Ala, Phe, His, Gln or Val at position 172 of the amino acid sequence of SEQ ID No. 14 (corresponding to

EP 2 453 012 A1

position 253 of SEQ ID No. 2), preferably Phe or Val;

e) Val at position 181 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg or Tyr at position 184 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 185 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 269 of SEQ ID No. 2), preferably Ala ;

h) Ile, Asn, Pro, Thr or Val at position 196 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 280 of SEQ ID No. 2), preferably Pro;

i) Leu or Val at position 206 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 293 of SEQ ID No. 2);

j) Met at position 207 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 294 of SEQ ID No. 2);

k) Ile, Met or Asn at position 244 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

l) Phe or Tyr at position 301 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 381 of SEQ ID No. 2);

m) Ser at position 312 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 392 of SEQ ID No. 2);

n) Tyr at position 325 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 419 of SEQ ID No. 2);

o) Asp, Lys or Asn at position 327 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

p) Gly, Met, Pro or Thr at position 328 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 422 of SEQ ID No. 2);

q) Ala, Ile or Val at position 330 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 424 of SEQ ID No. 2);

r) Ile, Pro, Arg or Ser at position 331 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 425 of SEQ ID No. 2);

s) Glu, Phe, Thr or Val at position 332 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

t) Ile, Met, Gln or Val at position 337 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 431 of SEQ ID No. 2);

u) Ala, Cys, Gly or Thr at position 145 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 228 of SEQ ID No. 2);

v) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Ser, Thr or Tyr at position 167 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 248 of SEQ ID No. 2);

w) Ala, Ile, Leu or Met at position 186 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 270 of SEQ ID No. 2);

x) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 187 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 271 of SEQ ID No. 2);

y) His at a position at position 299 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 379 of SEQ ID No. 2); and

z) Arg at a position at position 333 of the amino acid sequence of SEQ ID No. 14 (corresponding to position 427 of SEQ ID No. 2).

10. The isolated nucleic acid of claims 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 16 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr or Val at position 209 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 250 of SEQ ID No. 2), preferably Ala or Phe;

b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 210 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg, Lys;

c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val or Tyr at position 211 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;

d) Phe, His, Gln, Val or Trp at position 212 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 253 of SEQ ID No. 2), preferably Phe or Val;

e) Val at position 224 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 265 of SEQ ID

No. 2);

f) Leu, Gln, Arg or Tyr at position 227 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 228 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 239 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 280 of SEQ ID No. 2);

i) Leu or Val at position 251 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 293 of SEQ ID No. 2);

j) Met at position 252 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 294 of SEQ ID No. 2);

k) Ile, Met or Asn at position 289 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

l) Tyr at position 336 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 381 of SEQ ID No. 2);

m) Ser at position 347 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 392 of SEQ ID No. 2);

n) Tyr at position 359 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 419 of SEQ ID No. 2);

o) Asp, Lys or Asn at position 361 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

p) Ala, Met, Pro or Thr at position 362 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 422 of SEQ ID No. 2);

q) Ala, Ile or Val at position 364 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 424 of SEQ ID No. 2);

r) Ile, Pro, Arg or Ser at position 365 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 425 of SEQ ID No. 2);

s) Glu, Phe, Thr or Val at position 366 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

t) Ile, Met, Gln or Val at position 371 of the amino acid sequence of SEQ ID No. 16 (corresponding to position 431 of SEQ ID No. 2);

u) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 185 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 228 of SEQ ID No. 2);

v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 207 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 248 of SEQ ID No. 2);

w) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 229 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 270 of SEQ ID No. 2);

x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 230 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 271 of SEQ ID No. 2);

y) His at a position in an HPPD protein, said position corresponding to position 334 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 379 of SEQ ID No. 2); and

z) Arg at a position in an HPPD protein, said position corresponding to position 367 of the amino acid sequence of SEQ ID No. 2 (corresponding to position 427 of SEQ ID No. 2).

11. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 18 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 231 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;

b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 232 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 233 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 252 of SEQ ID No. 2), preferably Ser or Tyr;

d) Ala, His, Gln, Val or Trp at position 234 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

e) Val at position 246 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val or Tyr at position 249 of the amino acid sequence of SEQ ID No. 18 (corresponding to

- position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 250 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 261 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu or Val at position 273 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 293 of SEQ ID No. 2);
- j) Met at position 274 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile, Met or Asn at position 311 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
- l) Tyr at position 356 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 381 of SEQ ID No. 2);
- m) Ser at position 367 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 379 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 419 of SEQ ID No. 2);
- o) Asp, Lys or Asn at position 381 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
- p) Ala, Met, Pro or Thr at position 382 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 384 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 424 of SEQ ID No. 2);
- r) Ile, Pro, Arg or Ser at position 385 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 425 of SEQ ID No. 2);
- s) Glu, Phe, Thr or Val at position 386 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;
- t) Met, Gln or Val at position 391 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 207 of the amino acid sequence of SEQ ID No. 1 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 229 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 248 of SEQ ID No. 2);
- w) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 270 of SEQ ID No. 2);
- x) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 271 of SEQ ID No. 2);
- y) His at a position in an HPPD protein, said position corresponding to position 354 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 379 of SEQ ID No. 2); and
- z) Arg at a position in an HPPD protein, said position corresponding to position 387 of the amino acid sequence of SEQ ID No. 18 (corresponding to position 427 of SEQ ID No. 2).

12. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 30 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 232 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;
- b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 233 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;
- c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 234 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 252 of SEQ ID No. 2), preferably Ser or Tyr;
- d) Ala, His, Gln, Val or Trp at position 235 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- e) Val at position 247 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg, Val or Tyr at position 250 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 251 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 269 of

- SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 280 of SEQ ID No. 2);
- 5 i) Leu or Val at position 274 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 293 of SEQ ID No. 2);
- j) Met at position 275 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile, Met or Asn at position 312 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
- 10 l) Tyr at position 357 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 381 of SEQ ID No. 2);
- m) Ser at position 368 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 380 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 419 of SEQ ID No. 2);
- 15 o) Asp, Lys or Asn at position 382 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;
- p) Ala, Met, Pro or Thr at position 383 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 385 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 424 of SEQ ID No. 2);
- 20 r) Ile, Pro, Arg or Ser at position 386 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 425 of SEQ ID No. 2);
- s) Glu, Phe, Thr or Val at position 387 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;
- 25 t) Met, Gln or Val at position 392 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 208 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser or Tyr at a position in an HPPD protein, said position corresponding to position 230 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 248 of SEQ ID No. 2);
- 30 w) Ala, Ile, Leu or Met at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 270 of SEQ ID No. 2);
- x) Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 271 of SEQ ID No. 2);
- 35 y) His at a position in an HPPD protein, said position corresponding to position 355 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 379 of SEQ ID No. 2); and
- z) Arg at a position in an HPPD protein, said position corresponding to position 388 of the amino acid sequence of SEQ ID No. 30 (corresponding to position 427 of SEQ ID No. 2).

40 **13.** The isolated nucleic acid of claims 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 20 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- 45 a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 201 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;
- b) Ala, Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser at position 202 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;
- c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 203 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 252 of SEQ ID No. 2), preferably Glu, Ser or Tyr;
- 50 d) Ala, His, Gln, Val or Trp at position 204 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- e) Val at position 216 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg, Val or Tyr at position 219 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 268 of SEQ ID No. 2);
- 55 g) Ala or Thr at position 220 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 230 of the amino acid sequence of SEQ ID No. 20 (corresponding to

EP 2 453 012 A1

position 280 of SEQ ID No. 2);

i) Leu or Val at position 242 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 293 of SEQ ID No. 2);

5 j) Met at position 243 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 294 of SEQ ID No. 2);

k) Ile, Met or Asn at position 280 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

l) Phe or Tyr at position 323 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 381 of SEQ ID No. 2);

10 m) Ser at position 334 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 392 of SEQ ID No. 2);

n) Tyr at position 346 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 419 of SEQ ID No. 2);

o) Asp or Lys at position 348 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

p) Ala, Met, Pro or Thr at position 349 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 422 of SEQ ID No. 2);

q) Ala, Ile or Val at position 351 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 424 of SEQ ID No. 2);

20 r) Ile, Pro, Arg or Ser at position 352 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 425 of SEQ ID No. 2);

s) Glu, Phe, Thr or Val at position 353 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

25 t) Met, Gln, Phe or Val at position 358 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 431 of SEQ ID No. 2);

u) Ala, Cys, Gly or Thr at position 177 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 228 of SEQ ID No. 2);

v) Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 199 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 248 of SEQ ID No. 2);

30 w) Ala, Ile, Leu or Met at a position at position 221 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 270 of SEQ ID No. 2);

x) Ala, Glu, His, Ile, Leu, Met, Arg, Ser, Thr or Val at position 222 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 271 of SEQ ID No. 2);

35 y) His at position 321 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 379 of SEQ ID No. 2); and

z) Arg at position 354 of the amino acid sequence of SEQ ID No. 20 (corresponding to position 427 of SEQ ID No. 2).

40 **14.** The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 22 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 219 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 250 of SEQ ID No. 2), preferably Phe or Ala;

45 b) Ala, Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser at position 220 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 251 of SEQ ID No. 2), preferably Ala, Arg or Lys;

c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val or Tyr at position 221 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 252 of SEQ ID No. 2), preferably Glu or Tyr;

d) Ala, His, Gln, Val or Trp at position 222 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

50 e) Val at position 234 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val or Tyr at position 237 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 268 of SEQ ID No. 2);

55 g) Ala or Thr at position 238 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 249 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 280 of SEQ ID No. 2);

i) Leu or Val at position 261 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 293 of

SEQ ID No. 2);

j) Met at position 262 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 294 of SEQ ID No. 2);

k) Ile, Met or Asn at position 299 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 335 of SEQ ID No. 2), preferably Met;

l) Tyr at position 342 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 381 of SEQ ID No. 2);

m) Ser at position 353 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 392 of SEQ ID No. 2);

n) Tyr at position 365 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 419 of SEQ ID No. 2);

o) Asp, Lys or Asn at position 367 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 421 of SEQ ID No. 2), preferably Lys;

p) Ala, Met, Pro or Thr at position 368 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 422 of SEQ ID No. 2);

q) Ala, Ile or Val at position 370 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 424 of SEQ ID No. 2);

r) Ile, Pro, Arg or Ser at position 371 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 425 of SEQ ID No. 2);

s) Glu, Phe, Thr or Val at position 372 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 426 of SEQ ID No. 2), preferably Glu;

t) Met, Gln or Val at position 377 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 431 of SEQ ID No. 2);

u) Ala, Cys, Gly or Thr at position 195 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 228 of SEQ ID No. 2);

v) Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 217 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 248 of SEQ ID No. 2);

w) Ala, Ile, Leu or Val at position 239 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 270 of SEQ ID No. 2);

x) Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Thr or Val at position 240 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 271 of SEQ ID No. 2);

y) His at a position at position 340 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 379 of SEQ ID No. 2); and

z) Arg at a position at position 373 of the amino acid sequence of SEQ ID No. 22 (corresponding to position 427 of SEQ ID No. 2).

15. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 24 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 241 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 250 of SEQ ID No. 2), preferably Ala;

b) Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser at position 242 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;

c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val, or Tyr at position 243 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;

d) Ala, His, Gln, Val or Trp at position 244 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 253 of SEQ ID No. 2), preferably Val;

e) Val at position 256 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 265 of SEQ ID No. 2);

f) Leu, Gln, Arg, Val or Tyr at position 259 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 268 of SEQ ID No. 2);

g) Ala or Thr at position 260 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;

h) Ala, Ile, Asn, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 280 of SEQ ID No. 2);

i) Leu or Val at position 284 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 293 of SEQ ID No. 2);

j) Met at position 285 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 294 of SEQ ID No. 2);

EP 2 453 012 A1

- k) Ile or Asn at position 326 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 335 of SEQ ID No. 2);
- l) Tyr at position 372 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 381 of SEQ ID No. 2);
- m) Ser at position 383 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 410 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 419 of SEQ ID No. 2);
- o) Asp or Asn at position 412 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 421 of SEQ ID No. 2);
- p) Ala, Met, Pro or Thr at position 413 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 422 of SEQ ID No. 2);
- q) Ala, Ile or Val at position 415 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 424 of SEQ ID No. 2);
- r) Ile, Pro or Arg at position 416 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 425 of SEQ ID No. 2);
- s) Phe, Thr or Val at position 417 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 426 of SEQ ID No. 2);
- t) Met, Gln or Val at position 422 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Thr at position 219 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 239 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 248 of SEQ ID No. 2);
- w) Ala, Ile, Met or Val at position 261 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 270 of SEQ ID No. 2);
- x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 262 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 271 of SEQ ID No. 2);
- y) His at position 370 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 379 of SEQ ID No. 2); and
- z) Arg at position 418 of the amino acid sequence of SEQ ID No. 24 (corresponding to position 427 of SEQ ID No. 2).

16. The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 26 and wherein the resulting amino acid sequence comprises at least one amino acid selected from

- a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 237 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 250 of SEQ ID No. 2), preferably Ala;
- b) Asp, Glu, Lys, Leu, Asn, Pro, Arg or Ser at position 238 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 251 of SEQ ID No. 2), preferably Arg or Lys;
- c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Val or Tyr at position 239 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 252 of SEQ ID No. 2), preferably Tyr;
- d) Ala, His, Gln, Val or Trp at position 240 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 253 of SEQ ID No. 2), preferably Val;
- e) Val at position 252 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 265 of SEQ ID No. 2);
- f) Leu, Gln, Arg, Val or Tyr at position 255 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 268 of SEQ ID No. 2);
- g) Ala or Thr at position 256 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 269 of SEQ ID No. 2), preferably Ala;
- h) Ala, Ile, Asn, Thr or Val at position 267 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 280 of SEQ ID No. 2);
- i) Leu or Val at position 280 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 293 of SEQ ID No. 2);
- j) Met at position 281 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 294 of SEQ ID No. 2);
- k) Ile, Met or Asn at position 322 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 335 of SEQ ID No. 2), preferably Met;
- l) Tyr at position 368 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 381 of SEQ ID No. 2);

EP 2 453 012 A1

- m) Ser at position 379 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 392 of SEQ ID No. 2);
- n) Tyr at position 406 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 419 of SEQ ID No. 2);
- 5 o) Asp or Asn at position 408 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 421 of SEQ ID No. 2);
- p) Ala, Met, Pro or Thr at position 409 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 422 of SEQ ID No. 2);
- 10 q) Ala, Ile or Val at position 411 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 424 of SEQ ID No. 2);
- r) Ile, Pro, Arg at position 412 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 425 of SEQ ID No. 2);
- s) Phe, Thr or Val at position 413 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 426 of SEQ ID No. 2);
- 15 t) Met or Gln or Val at position 418 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 431 of SEQ ID No. 2);
- u) Ala, Cys, Gly or Thr at a position in an HPPD protein, said position corresponding to position 215 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 228 of SEQ ID No. 2);
- v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 235 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 248 of SEQ ID No. 2);
- 20 w) Ala, Ile, Met or Val at position 257 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 270 of SEQ ID No. 2);
- x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 258 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 271 of SEQ ID No. 2);
- 25 y) His at a position at position 366 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 379 of SEQ ID No. 2); and
- z) Arg at position 414 of the amino acid sequence of SEQ ID No. 26 (corresponding to position 427 of SEQ ID No. 2).
- 30 **17.** The isolated nucleic acid of claim 1, wherein said HPPD protein comprises the amino acid sequence of SEQ ID No. 2 and wherein the resulting amino acid sequence comprises at least one amino acid selected from
- a) Ala, Asp, Glu, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at position 250 of the amino acid sequence of SEQ ID No. 2;
- b) Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at position 251 of the amino acid sequence of SEQ ID No. 2;
- 35 c) Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at position 252 of the amino acid sequence of SEQ ID No. 2;
- d) Ala, His, Gln, Val or Trp at position 253 of the amino acid sequence of SEQ ID No. 2;
- e) Val at a position at position 265 of the amino acid sequence of SEQ ID No. 2;
- f) Leu, Gln, Arg, Val or Tyr at position 268 of the amino acid sequence of SEQ ID No. 2;
- 40 g) Ala or Thr at position 269 of the amino acid sequence of SEQ ID No. 2;
- h) Ala, Ile, Asn, Thr or Val at position 280 of the amino acid sequence of SEQ ID No. 2;
- i) Leu or Val at position 293 of the amino acid sequence of SEQ ID No. 2;
- j) Met at position 294 of the amino acid sequence of SEQ ID No. 2;
- k) Ile or Asn at position 335 of the amino acid sequence of SEQ ID No. 2;
- 45 l) Tyr at position 381 of the amino acid sequence of SEQ ID No. 2;
- m) Ser at position 392 of the amino acid sequence of SEQ ID No. 2;
- n) Tyr at position 419 of the amino acid sequence of SEQ ID No. 2;
- o) Asp or Asn at position 421 of the amino acid sequence of SEQ ID No. 2;
- p) Ala, Met, Pro or Thr at position 422 of the amino acid sequence of SEQ ID No. 2;
- 50 q) Ala, Ile or Val at position 424 of the amino acid sequence of SEQ ID No. 2;
- r) Ile, Pro or Arg at position 425 of the amino acid sequence of SEQ ID No. 2;
- s) Phe, Thr or Val at position 426 of the amino acid sequence of SEQ ID No. 2;
- t) Met, Gln or Val position 431 of the amino acid sequence of SEQ ID No. 2;
- u) Ala, Cys, Gly or Thr at position 228 of the amino acid sequence of SEQ ID No. 2;
- 55 v) Ala, Glu, Gly, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at position 248 of the amino acid sequence of SEQ ID No. 2;
- w) Ala, Ile, Met or Val at position 270 of the amino acid sequence of SEQ ID No. 2;
- x) Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at position 271 of the amino acid sequence of SEQ ID No. 2;
- y) His at position 379 of the amino acid sequence of SEQ ID No. 2; and

z) Arg at position 427 of the amino acid sequence of SEQ ID No. 2.

- 5 18. The nucleic acid of any one of claims 1 to 17, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises (positions corresponding to SEQ ID No. 2) (a) Glu, Ser or Tyr at position 252; (b) Val or Ala at position 269; (c) Pro, Val or Ala at position 280; (d) Asp, Lys or Asn at position 421; and (e) Gly or Ala at position 422.
- 10 19. The nucleic acid of any one of claims 1 to 18, wherein in said mutated HPPD protein at least two amino acids have been replaced so that the resulting amino acid sequence comprises at least two amino acids selected from the amino acids at the positions listed in any one of claims 1 to 18.
- 15 20. An isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, and wherein in said mutated HPPD protein at least one amino acid at position 228, 248, 270, 271, 379 and/or 427 (according to the numbering of SEQ ID No. 2) has been replaced by another amino acid.
- 20 21. The isolated nucleic acid of claim 20, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from
- 25 a. Ala, Cys, Gly, Thr or Val at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- b. Ala, Glu, Gly, His, Lys, Leu, Asn, Gln, Arg, Ser, Thr or Tyr at a position in an HPPD protein, said position corresponding to position 248 of the amino acid sequence of SEQ ID No. 2;
- 30 c. Ala, Ile, Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- d. Ala, Glu, His, Ile, Lys, Leu, Met, Arg, Ser, Thr or Val at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2;
- e. His or Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2; and
- 35 f. Leu or Arg at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.
- 40 22. The isolated nucleic acid of claim 21 or 22, wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from
- 45 a) Val or Thr at a position in an HPPD protein, said position corresponding to position 228 of the amino acid sequence of SEQ ID No. 2;
- b) Leu, Met or Val at a position in an HPPD protein, said position corresponding to position 270 of the amino acid sequence of SEQ ID No. 2;
- c) Ala or Ser at a position in an HPPD protein, said position corresponding to position 271 of the amino acid sequence of SEQ ID No. 2,
- d) Gln at a position in an HPPD protein, said position corresponding to position 379 of the amino acid sequence of SEQ ID No. 2; and
- e) Leu at a position in an HPPD protein, said position corresponding to position 427 of the amino acid sequence of SEQ ID No. 2.
- 50 23. The nucleic acid of any one of claims 1 to 22, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one herbicide acting on HPPD.
- 55 24. A protein encoded by the isolated nucleic acid of any one of claims 1 to 23.
25. A chimeric gene comprising a coding sequence comprising the nucleic acid of any one of claims 1 to 23 operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region.
26. A method of obtaining a mutated HPPD protein capable of modulating the tolerance of a plant to at least one herbicide acting on HPPD, wherein said mutated HPPD protein has HPPD activity, the method comprising
- i) providing an HPPD protein;

ii) replacing at least one amino acid in said HPPD protein so that the resulting amino acid sequence comprises at least one selected from

- a) Ala, Asp, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID No. 2;
- b) Ala, Asp, Glu, Ile, Lys, Leu, Asn, Pro, Arg or Ser at a position in an HPPD protein, said position corresponding to position 251 of the amino acid sequence of SEQ ID No. 2;
- c) Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Val or Tyr at a position in an HPPD protein, said position corresponding to position 252 of the amino acid sequence of SEQ ID No. 2;
- d) Ala, Phe, His, Gln, Val or Trp at a position in an HPPD protein, said position corresponding to position 253 of the amino acid sequence of SEQ ID No. 2;
- e) Leu or Val at a position in an HPPD protein, said position corresponding to position 265 of the amino acid sequence of SEQ ID No. 2;
- f) Leu, Gln, Arg, Val or Tyr at a position in an HPPD protein, said position corresponding to position 268 of the amino acid sequence of SEQ ID No. 2;
- g) Ala, Thr or Val at a position in an HPPD protein, said position corresponding to position 269 of the amino acid sequence of SEQ ID No. 2;
- h) Ala, Ile, Asn, Pro, Thr or Val at a position in an HPPD protein, said position corresponding to position 280 of the amino acid sequence of SEQ ID No. 2;
- i) Leu, Gln or Val at a position in an HPPD protein, said position corresponding to position 293 of the amino acid sequence of SEQ ID No. 2;
- j) Ile or Met at a position in an HPPD protein, said position corresponding to position 294 of the amino acid sequence of SEQ ID No. 2;
- k) Gln at a position in an HPPD protein, said position corresponding to position 307 of the amino acid sequence of SEQ ID No. 2;
- l) Ile, Met or Asn at a position in an HPPD protein, said position corresponding to position 335 of the amino acid sequence of SEQ ID No. 2;
- m) Leu at a position in an HPPD protein, said position corresponding to position 368 of the amino acid sequence of SEQ ID No. 2;
- n) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 381 of the amino acid sequence of SEQ ID No. 2;
- o) Phe or Ser at a position in an HPPD protein, said position corresponding to position 392 of the amino acid sequence of SEQ ID No. 2;
- p) Phe or Tyr at a position in an HPPD protein, said position corresponding to position 419 of the amino acid sequence of SEQ ID No. 2;
- q) Asp, Phe, Lys, Asn at a position in an HPPD protein, said position corresponding to position 421 of the amino acid sequence of SEQ ID No. 2;
- r) Ala, Gly, Met, Pro or Thr at a position in an HPPD protein, said position corresponding to position 422 of the amino acid sequence of SEQ ID No. 2;
- s) Ala, Phe, Ile or Val at a position in an HPPD protein, said position corresponding to position 424 of the amino acid sequence of SEQ ID No. 2;
- t) Ile, Pro, Arg or Ser at a position in an HPPD protein, said position corresponding to position 425 of the amino acid sequence of SEQ ID No. 2;
- u) Glu, Phe, Thr or Val at a position in an HPPD protein, said position corresponding to position 426 of the amino acid sequence of SEQ ID No. 2;
- v) Ile, Met, Gln or Val at a position in an HPPD protein, said position corresponding to position 431 of the amino acid sequence of SEQ ID No. 2; and
- w) an amino acid deletion or replacement at at least one position in an HPPD protein, said position corresponding to at least one of positions 228, 248, 270, 271, 379 and 427 of the amino acid sequence of SEQ ID No. 2;

iii) determining the inhibition of the resulting HPPD protein by at least one herbicide acting on HPPD, wherein an inhibition of the resulting protein of less or more than that observed with a reference HPPD protein is indicative that the resulting protein is capable of modulating the tolerance of a plant to said herbicide.

27. The method of claim 26, wherein said mutated HPPD protein is capable of increasing the tolerance of a plant to at least one HPPD inhibitor herbicide.

28. The nucleic acid of claim 23 or the method of claim 27, wherein the herbicide acting on HPPD is tembotrione.
29. A method of producing a transgenic plant comprising introducing into a said plant the nucleic acid of any one of claims 1 to 23 or a nucleic acid encoding the HPPD enzyme identified by the method of any one of claims 26 to 28, both operably linked to a plant expressible promoter or the chimeric gene of claim 25, and obtaining progeny thereof comprising said operably linked nucleic acid or said chimeric gene.
30. The method of claim 29, wherein the nucleic acid of claim 23 or a nucleic acid identified by the method of claim 27 or 28, both operably linked to a plant expressible promoter, or the chimeric gene of claim 25 comprising the nucleic acid of claim 23 is introduced into said plant.
31. The nucleic acid of any one of claims 1 to 23 or the method of any one of claims 26 to 30, wherein said HPPD protein comprises
- a) a His at a position in an HPPD protein, said position corresponding to position 226 of the amino acid sequence of SEQ ID No. 2;
 - b) a Ser at a position in an HPPD protein, said position corresponding to position 267 of the amino acid sequence of SEQ ID No. 2;
 - c) an Asn at a position in an HPPD protein, said position corresponding to position 282 of the amino acid sequence of SEQ ID No. 2;
 - d) a His at a position in an HPPD protein, said position corresponding to position 308 of the amino acid sequence of SEQ ID No. 2;
 - e) a Tyr at a position in an HPPD protein, said position corresponding to position 342 of the amino acid sequence of SEQ ID No. 2;
 - f) a Glu at a position in an HPPD protein, said position corresponding to position 394 of the amino acid sequence of SEQ ID No. 2;
 - g) a Gly at a position in an HPPD protein, said position corresponding to position 420 of the amino acid sequence of SEQ ID No. 2; and
 - h) an Asn at a position in an HPPD protein, said position corresponding to position 423 of the amino acid sequence of SEQ ID No. 2
32. A plant cell comprising the isolated nucleic acid of any one of claims 1 to 23 or the chimeric gene of claim 25 in its genetic information.
33. A plant, part thereof or plant tissue consisting essentially of the plant cells of claim 32.
34. A plant obtainable from the method of any one of claims 29 or 30.
35. The plant of claim 33 or 34 which is selected from wheat, cotton, canola, rice, corn, soy bean, sorghum
36. A seed of the plant of any one of claims 33 to 35.
37. Progeny of the plant of any one of claims 33 to 35 or the seed of claim 36.
38. A method of modulating a plant's tolerance to at least one herbicide acting on HPPD or of obtaining a plant tolerant to an HPPD inhibitor herbicide comprising introducing the isolated nucleic acid of any one of claims 1 to 23 operably linked to a plant expressible promoter or the chimeric gene of claim 25 into a plant's genome.
39. A method for controlling weeds comprising spraying at least one HPPD inhibitor herbicide on or around a crop plant, wherein said crop plant contains the nucleic acid according to claim 23 operably linked to a plant expressible promoter or the chimeric gene of claim 25 comprising the nucleic acid of claim 23.
40. Use of a chimeric gene of claim 25 or the nucleic acid of any one of claims 1 to 23 operably linked to a plant expressible promoter for modulating the tolerance of a plant to at least one HPPD inhibitor herbicide applied for controlling weeds.
41. The method of claim 30, 38 or 39 or the use of claim 40, wherein the tolerance of a plant to at least one HPPD inhibitor herbicide is increased.

Figure 1a: Superposition of the x-ray structure of HPPD from *Arabidopsis thaliana* (dark grey) and *Pseudomonas fluorescens* (light grey). The structure is shown as ribbon plot.




Figure 1b: Superposition of the x-ray structure of HPPD from *Arabidopsis thaliana* (dark grey) and *Streptomyces avermitilis* (light grey). The structure is shown as ribbon plot.



Figure 1c: Superposition of the x-ray structure of HPPD from *Arabidopsis thaliana* (dark grey) and *Homo sapiens* (light grey). The structure is shown as ribbon plot.




Figure 1d: Superposition of the x-ray structure of HPPD from *Arabidopsis thaliana* (dark grey) and *Rattus norvegicus* (light grey). The structure is shown as ribbon plot.




Figure 2a: Amino acids forming the binding site of *Arabidopsis thaliana* (represented by bold lines). The core of the HPPD protein from *Arabidopsis thaliana* is shown as C_{alpha} trace and the iron is marked.



Figure 2b: Amino acids forming the binding site of *Pseudomonas fluorescens* (represented by bold lines). The core of the HPPD protein from *Pseudomonas fluorescens* is shown as C_{alpha} trace and the iron is marked.




Figure 2c: Amino acids forming the binding site of *Streptomyces avermitilis* (represented by bold lines). The core of the HPPD protein from *Streptomyces avermitilis* is shown as C_{alpha} trace and the iron is marked.




Figure 2d: Amino acids forming the binding site of *Homo sapiens* (represented by bold lines). The core of the HPPD protein from *Homo sapiens* is shown as C_{α} trace and the iron is marked.



Figure 2e: Amino acids forming the binding site of *Rattus norvegicus* (represented by bold lines). The core of the HPPD protein from *Rattus norvegicus* is shown as C_{α} trace and the iron is marked.



FIGURE 3: Brown test color.



A: WT, B: N282A, C: S267A



EUROPEAN SEARCH REPORT

Application Number
EP 10 19 0629

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 2009/144079 A1 (BAYER BIOSCIENCE NV [BE]; BAYER CROPSCIENCE AG [DE]; BUSCH MARCO [DE];) 3 December 2009 (2009-12-03) * page 5, paragraph 2 - page 6, paragraph 1; example 3 *	1,2, 4-17,19, 23-41	INV. C12N9/02 C12N15/82
A	----- WO 2010/085705 A2 (SYNGENTA PARTICIPATIONS AG [CH]; HAWKES TIMOTHY ROBERT [GB]; LANGFORD) 29 July 2010 (2010-07-29) -----	1,2, 4-17,19, 23-41	
A	WO 99/24585 A1 (RHONE POULENC AGROCHIMIE [FR]) 20 May 1999 (1999-05-20) * examples 3-8 *	1,2, 4-17,19, 23-41	
A	----- WO 02/46387 A2 (SYNGENTA LTD [GB]; WARNER SIMON ANTHONY JAMES [GB]; HAWKES TIMOTHY ROB) 13 June 2002 (2002-06-13) -----	1,2, 4-17,19, 23-41	
A	KAKIDANI HITOSHI ET AL: "Three-dimensional modeling of plant 4-hydroxyphenylpyruvate dioxygenase, a molecular target of triketone-type herbicides", JOURNAL OF PESTICIDE SCIENCE - NIPPON NOYAKU GAKKAISHI, NIPPON NOYAKU GAKKAI, TOKYO, JP, vol. 28, no. 4, 1 January 2003 (2003-01-01), pages 409-415, XP008100740, ISSN: 0385-1559 ----- -/--	1,2, 4-17,19, 23-41	TECHNICAL FIELDS SEARCHED (IPC) C12N
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 19 April 2011	Examiner Kania, Thomas
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

2
EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 10 19 0629

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	FRITZE IRIS M ET AL: "The crystal structures of Zea mays and Arabidopsis 4-hydroxyphenylpyruvate dioxygenase", PLANT PHYSIOLOGY (ROCKVILLE), vol. 134, no. 4, April 2004 (2004-04), pages 1388-1400, XP002631689, ISSN: 0032-0889 -----	2,4-17, 19,23-41	
A	YANG CHENG ET AL: "Structural basis for herbicidal inhibitor selectivity revealed by comparison of crystal structures of plant and mammalian 4-hydroxyphenylpyruvate dioxygenases", BIOCHEMISTRY, vol. 43, no. 32, 17 August 2004 (2004-08-17), pages 10414-10423, XP002631690, ISSN: 0006-2960 -----	1,2, 4-17,19, 23-41	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 19 April 2011	Examiner Kania, Thomas
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

2
EPO FORM 1503 03.02 (P04C01)



Application Number

EP 10 19 0629

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing claims for which payment was due.

- Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due and for those claims for which claims fees have been paid, namely claim(s):
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:
see additional sheet(s)
- The present supplementary European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims (Rule 164 (1) EPC).



**LACK OF UNITY OF INVENTION
SHEET B**

Application Number

EP 10 19 0629

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1, 2, 4-17, 19, 23-41(all partially)

An isolated nucleic acid comprising a nucleotide sequence encoding a mutated HPPD protein, wherein said mutated HPPD protein has HPPD activity, and wherein in said mutated HPPD protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from Ala, Glu, Phe, Gly, Lys, Gln, Arg, Ser, Thr, Val or Tyr at a position in an HPPD protein, said position corresponding to position 250 of the amino acid sequence of SEQ ID NO:2, as well as related subject-matter as claimed.

2. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 251

3. claims: 1-19, 23-41(all partially)

idem for position 252

4. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 253

5. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 265

6. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 268

7. claims: 1-19, 23-41(all partially)

idem for position 269

8. claims: 1-19, 23-41(all partially)

idem for position 280

9. claims: 1, 4-17, 19, 23-41(all partially)



**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 10 19 0629

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

idem for position 293

10. claims: 1, 4-17, 19, 23-41(all partially)

idem for position 294

11. claims: 1, 2, 4, 19, 23-41(all partially)

idem for position 307

12. claims: 1-19, 23-41(all partially)

idem for position 335

13. claims: 1-4, 19, 23-41(all partially)

idem for position 368

14. claims: 1, 4-19, 23-41(all partially)

idem for position 381

15. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 392

16. claims: 1, 4-17, 19, 23-41(all partially)

idem for position 419

17. claims: 1-19, 23-41(all partially)

idem for position 421

18. claims: 1-19, 23-41(all partially)

idem for position 422

19. claims: 1, 4-17, 19, 23-41(all partially)

idem for position 424



**LACK OF UNITY OF INVENTION
SHEET B**

Application Number

EP 10 19 0629

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

20. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 425

21. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 426

22. claims: 1, 2, 4-17, 19, 23-41(all partially)

idem for position 431

23. claims: 1, 2, 4-17, 19-41(all partially)

idem for position 228

24. claims: 1, 2, 4-17, 19-21, 23-41(all partially)

idem for position 248

25. claims: 1, 2, 4-17, 19-41(all partially)

idem for position 270

26. claims: 1, 2, 4-17, 19-41(all partially)

idem for position 271

27. claims: 1, 2, 4-17, 19-41(all partially)

idem for position 379

28. claims: 1, 2, 4-17, 19-41(all partially)

idem for position 427

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 10 19 0629

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-04-2011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009144079 A1	03-12-2009	AR 071316 A1	09-06-2010
		CA 2724670 A1	03-12-2009
		CN 101998993 A	30-03-2011
		EP 2268815 A1	05-01-2011
		US 2011039706 A1	17-02-2011
		US 2011132602 A1	09-06-2011
WO 2010085705 A2	29-07-2010	AR 075151 A1	09-03-2011
		CA 2749524 A1	29-07-2010
		US 2010197503 A1	05-08-2010
WO 9924585 A1	20-05-1999	AT 397071 T	15-06-2008
		AT 430201 T	15-05-2009
		AU 749323 B2	20-06-2002
		AU 1160399 A	31-05-1999
		AU 738279 B2	13-09-2001
		AU 1161499 A	31-05-1999
		BR 9815291 A2	07-04-2009
		CA 2309318 A1	20-05-1999
		CA 2309322 A1	20-05-1999
		CN 1285875 A	28-02-2001
		CO 4890885 A1	28-02-2000
		DK 1029059 T3	06-10-2008
		EP 1029059 A1	23-08-2000
		EP 1029060 A1	23-08-2000
		ES 2308820 T3	01-12-2008
		FR 2770854 A1	14-05-1999
		WO 9924586 A1	20-05-1999
		ID 21426 A	10-06-1999
		JP 2001522608 A	20-11-2001
		MA 24814 A1	31-12-1999
PT 1029059 E	17-07-2008		
TW 591108 B	11-06-2004		
ZA 9810076 A	07-05-1999		
WO 0246387 A2	13-06-2002	AU 1415802 A	18-06-2002
		BR 0116018 A	13-12-2005
		CA 2427787 A1	13-06-2002
		EP 1341903 A2	10-09-2003
		EP 2287292 A2	23-02-2011
		JP 2004528821 A	24-09-2004
		US 2004058427 A1	25-03-2004
		US 2009031442 A1	29-01-2009
		US 2009055976 A1	26-02-2009
		US 2009172831 A1	02-07-2009
		US 2008076178 A1	27-03-2008

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9638567 A [0004] [0009] [0114]
- WO 02046387 A [0004]
- WO 06132270 A [0004]
- ES 2275365 [0004]
- US 6812010 B [0009]
- WO 04024928 A [0010]
- EP 496630 A [0012]
- WO 9924585 A [0012]
- WO 2009144079 A [0014] [0026] [0129] [0131] [0134] [0141]
- WO 2002046387 A [0015]
- WO 2008150473 A [0016]
- US 20100197503 A [0017]
- US 6768044 B [0028] [0116]
- WO 9749816 A [0043]
- EP 0507698 A1 [0074]
- US 5641876 A [0074]
- US 5510474 A [0074]
- AU 689311 [0074]
- US 7053205 B [0074]
- EP 255378 A1 [0075]
- WO 9217580 A [0075]
- WO 9845460 A [0075]
- WO 9845461 A [0075]
- US 9806978 W [0075]
- US 5670349 A [0076]
- WO 9845445 A [0076]
- WO 8707644 A [0077]
- EP 0633317 A1 [0078]
- WO 2005012515 A [0095]
- WO 9102071 A [0097]
- WO 9506128 A [0097]
- WO 2009152359 A [0098]
- US 4535060 A [0098]
- US 4769061 A [0098]
- US 5094945 A [0098]
- US 4940835 A [0098]
- US 5188642 A [0098]
- US 4971908 A [0098]
- US 5145783 A [0098]
- US 5310667 A [0098]
- US 5312910 A [0098]
- US 5627061 A [0098]
- US 5633435 A [0098] [0099]
- US 5463175 A [0098]
- WO 2004074443 A [0099]
- US 6566587 B [0099]
- WO 2008100353 A [0100]
- US 5510471 A [0101]
- US 5633448 A [0101]
- WO 2007024782 A [0102]
- US 6855533 B [0102]
- US 6153401 A [0103]
- US 20080119361 A [0104]
- US 20080120739 A [0104]
- WO 9717432 A [0106]
- WO 9808932 A [0106] [0107]
- US 6326169 B [0107]
- US 6281016 B [0107]
- US 6218188 B [0107]
- US 5880275 A [0107]
- EP 451878 A [0107]
- WO 02057664 A [0107]
- WO 2007140256 A [0107]
- WO 2007142840 A [0107]
- WO 2005054479 A [0107]
- WO 2005054480 A [0107]
- WO 0147952 A [0107]
- US 6291156 B [0107]
- WO 9850427 A [0107]
- EP 09015984 A [0114]
- EP 09015985 A [0114]
- EP 09015986 A [0114]
- EP 09015987 A [0114]
- EP 09015988 A [0114]

Non-patent literature cited in the description

- **CROUCH N.P. et al.** *Tetrahedron*, 1997, vol. 53 (20), 6993-7010 [0003]
- **FRITZE et al.** *Plant Physiology*, 2004, vol. 134, 1388-1400 [0003]
- **RÜETSCHI et al.** *Eur. J. Biochem.*, 1992, vol. 205, 459-466 [0004]
- **ABOU-ZEID et al.** *Applied Env Microb*, vol. 41, 1298-1302 [0005]
- **BONNER et al.** *Plant Cells Physiol.*, 1995, vol. 36, 1013-1022 [0005]
- **BYNG et al.** *Phytochemistry*, 1981, vol. 6, 1289-1292 [0005]

EP 2 453 012 A1

- **CONNELY ; CONN.** *Z. Naturforsch*, 1986, vol. 41 c, 69-78 [0005]
- **GAINES et al.** *Plants*, 1982, vol. 156, 233-240 [0005]
- **LINGENS et al.** *European J. Biochem*, 1967, vol. 1, 363-374 [0005]
- **SAMPATHKUMAR ; MORRISSON.** *Bioch Biophys Acta*, 1982, vol. 701, 204-211 [0005]
- **NORRIS et al.** *Plant Cell*, 1995, vol. 7, 2139-2149 [0006]
- **SCHULZ et al.** *FEBS letters*, 1993, vol. 318, 162-166 [0008]
- **MITCHELL et al.** *Pest Management Science*, 2001, vol. 57, 120-128 [0008]
- **GARCIA et al.** *Biochem.*, 2000, vol. 39, 7501-7507 [0008]
- **PALLET et al.** *Pest Management Science*, 2001, vol. 57, 133-142 [0008]
- **MATRINGE et al.** *Pest Management Science*, 2005, vol. 61, 269-276 [0009]
- **DUFOURMANTEL et al.** *Plant Biotechnol J.*, 2007, vol. 5 (1), 118-33 [0013]
- **MYERS ; MILLER.** *CABIOS*, 1988, vol. 4, 11-17 [0037]
- **SMITH ; WATERMAN.** *Adv. Appl. Math.*, 1981, vol. 2, 482-489 [0037]
- **NEEDLEMAN ; WUNSCH.** *J. Mol. Biol.*, 1970, vol. 48, 443-453 [0037]
- **ALTSCHUL.** *Proc. Natl. Acad. Sci USA*, 1990, 872264 [0037]
- **BRUTLAG et al.** *Comp. App. Biosci.*, 1990, vol. 6, 237-245 [0037]
- **BRUTLAG.** *Comp. App. Biosci.*, 1990, vol. 6, 237-245 [0040]
- **YANG et al.** *Biochemistry*, 2004, vol. 43, 10414-10423 [0042]
- **SERRE et al.** *Structure Fold Des.*, 1999, vol. 7, 977-988 [0042]
- **BROWNLEE et al.** *Biochemistry*, 2004, vol. 43, 6370-6377 [0042]
- **SANDERS et al.** *Nucleic Acids Res.*, 1987, vol. 15 (4), 1543-58 [0074]
- **DATLA, R. et al.** *Biotechnology Ann. Rev.*, 1997, vol. 3, 269-296 [0075]
- **CARRINGTON ; FREED.** *J. Virol.*, 1990, vol. 64, 1590-1597 [0077]
- **TRANEL ; WRIGHT.** *Weed Science*, 2002, vol. 50, 700-712 [0095]
- **OWEN ; ZELAYA.** *Pest Manag. Sci.*, 2005, vol. 61, 301-311 [0095]
- **ESTRUCH et al.** *Proc Natl Acad Sci U S A*. 28, 1996, vol. 93 (11), 5389-94 [0107]
- **WATERFIELD et al.** *Appl Environ Microbiol.*, 2001, vol. 67 (11), 5017-24 [0107]
- **FFRENCH-CONSTANT ; BOWEN.** *Cell Mol Life Sci.*, 2000, vol. 57 (5), 828-33 [0107]
- **BRADFORD.** *Anal Biochem*, 1976, vol. 72, 248-254 [0127]
- **CHA, S.** Tight-binding inhibitors - I. Kinetic behaviour. *Biochemical Pharmacology*, 1975, vol. 24, 2177-2185 [0135]
- **GARCIA et al.** *Biochemistry*, 2000, vol. 39, 7501-7507 [0138]